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1. EXECUTIVE SUMMARY
Purpose of report
This document has been commissioned by the
British Society of Gastroenterology. It is intended
to draw together the evidence needed to fill the
void created by the absence of a national frame-
work or guidance for service provision for the
management of patients with gastrointestinal and
hepatic disorders. It sets out the service, economic
and personal burden of such disorders in the UK,
describes current service provision, and draws
conclusions about the effectiveness of current
models, based on available evidence. It does not
seek to replicate existing guidance, which has been
produced for upper and lower gastrointestinal
cancers, hepatobiliary and pancreatic disorders,
and many chronic disorders of the gut. It does,
however, draw on evidence contained in these
documents. It is intended to be of value to patient
groups, clinicians, managers, civil servants, and
politicians, particularly those responsible for devel-
oping or delivering services for patients with
gastrointestinal disorders.
Methods used
A systematic review of the literature was under-
taken to document the burden of disease and to
identify new methods of service delivery in
gastroenterology. This systematic review was
supplemented by additional papers, identified
when the literature on incidence, mortality,
morbidity, and costs was assessed.
Routine data sources were interrogated to obtain
additional data on burden of disease, the activity
of the NHS, and costs, in relation to gastrointest-
inal disorders.
The views of users of the service were sought,
through discussions with the voluntary sector and
through a workshop held at the Royal College of
Physicians in December 2004.
The views of professionals were obtained by
wide dissemination of the document in a draft
form, seeking feedback on the content and
additional material.
Main findings
The burden of gastrointestinal and liver disease is
heavy for patients, the NHS, and the economy,
with gastrointestinal disease the third most com-
mon cause of death, the leading cause of cancer
death, and the most common cause of hospital
admission. There have been increases in the
incidence of most gastrointestinal diseases which
have major implications for future healthcare
needs. These diseases include hepatitis C infec-
tions, acute and chronic pancreatitis, alcoholic
liver disease, gallstone disease, upper gastrointest-
inal haemorrhage, diverticular disease, Barrett’s
oesophagus, and oesophageal and colorectal can-
cers. Socioeconomic deprivation is linked to a
number of gastrointestinal diseases, such as gastric
and oesophageal cancers, hepatitis B and C
infections, peptic ulcer, upper gastrointestinal
haemorrhage, as well as poorer prognosis for
colorectal, gastric, and oesophageal cancers.
The burden on patients’ health related quality of
life has been found to be substantial for symptoms,
activities of daily living, and employment, with
conditions with a high level of disruption to
sufferers’ lives found to include: gastro-oesopha-
geal reflux disease, dyspepsia, irritable bowel
syndrome, anorectal disorders, gastrointestinal
cancers, and chronic liver disease. However,
impact on patients is neither fully nor accurately
reflected in routine mortality and activity statistics
and although overall, the burden of gastrointest-
inal disease on health related quality of life in the
general population appears to be high, the burden
is neither systematically nor comprehensively
described.
An overwhelming finding concerning evidence
related to service delivery is the lack of high quality
health technology assessment and evaluation. In
particular, evidence of cost effectiveness from
multicentre studies is lacking, with more research
needed to establish a robust evidence base for
models of service delivery.
Waiting times form the bulk of patients’ con-
cerns, with great difficulty in meeting government
standards for referral and treatment. An extensive
and systematic study of the problem of access for
the delivery of gastrointestinal services has yet to
be carried out and significant publications report-
ing inequalities in the delivery of gastrointestinal
services are lacking. There is also a need to increase
awareness and the implementation of initiatives
aimed at improving the information flow between
patients and practitioners.
Strong evidence exists, however, for a shift in
care towards greater patient self management for
chronic disease. The development of general
practitioners with a special interest in gastroenter-
ology is supported in primary care, but their
clinical and cost effectiveness need to be
researched. Indeed, emphasis needs to be given
to developing interventions to increase preventa-
tive activities in primary care, and more research is
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required to determine their effectiveness and cost effectiveness.
Despite strong support for the development and use of
widespread screening programmes for a wide variety of
gastrointestinal diseases, there is a lack of evidence about
how they are managed, their effectiveness, and their cost
effectiveness. In contrast, a strong body of evidence exists on
diagnostic services, and the need to develop and implement
appropriate training and stringent assessment to ensure patient
safety. There is also a substantial amount of work detailing
guidelines for care.
In hospital, patients with gastrointestinal disorders should be
looked after by those with specialist training, and more
diagnostic endoscopies could be undertaken by trained nurses.
Importantly, for service reconfiguration, there is currently
insufficient evidence to support greater concentration of
specialists in tertiary centres. More research is needed especially
on the impact on secondary services before further changes are
implemented.
Consultant gastroenterologist numbers need to increase to
meet a rising burden of gastrointestinal disease.
Gastroenterology teams should be led by consultants, but
include appropriate non-consultant career grade staff, specialist
nurses, and other staff with integrated specialist training,
where appropriate.
More research is needed into the delivery and organisation of
services for patients with gastrointestinal and liver disorders, in
particular to assess the clinical and cost effectiveness of general
practitioners with a special interest in gastroenterology and
endoscopy; the clinical and cost effectiveness of undertaking
endoscopy or minor gastrointestinal surgery in diagnosis and
treatment centres; and the reconfiguration of specialist services
and the potential impact on secondary and primary care and on
patients.
2. INTRODUCTION
2.0 Background including policy drivers
This document has been commissioned by the British Society of
Gastroenterology. It is intended to draw together the evidence
needed to fill the void created by the absence of a national
framework or guidance for service provision for the manage-
ment of patients with gastrointestinal (GI) and hepatic
disorders. It sets out the service, economic and personal burden
of such disorders in the UK, describes current service provision,
and draws conclusions about the effectiveness of current
models, based on the presently available evidence. It does not
seek to replicate existing guidance, which has been produced
for upper and lower gastrointestinal cancers, hepatobiliary and
pancreatic disorders, and many chronic disorders of the gut. It
does, however, draw on evidence contained in these docu-
ments.
The document takes into account recent strategies for the
NHS in the UK, and recommendations for quality and service
improvement, new information strategies in England and
Wales. In particular, it builds on the recommendations of three
reports from Derek Wanless, which have significantly influ-
enced the strategic direction of the NHS.
In July 2000 the Government published the NHS plan which
set out the core principles for the NHS and a framework for
delivering these principles over the next decade. Following on
from this the Chancellor of the Exchequer commissioned the
first Wanless Report1 to examine future health trends and
resources required over the next two decades. The report
welcomed the Government’s intention to extend the National
Service Framework (NSF) approach to other disease areas and
recommended that the NSFs and their equivalents in the
developed administrations are rolled out in a similar way to the
diseases already covered. It also recommended that a more
effective partnership between health professionals and the
public should be facilitated in a number of ways. These include
setting standards for the service to help give people a clearer
understanding of what the health service will and will not
provide for them. Other factors include improving health
information, reducing key health risk factors, and reinforcing
patient involvement in NHS activities.
These recommendations were repeated and reinforced in a
report on the NHS in Wales advised by Sir Derek Wanless.2 The
report re-emphasised the need for sustainable change: a shift in
delivery from secondary care towards greater care in the
community and more self management by patients; and
significant investment in improving information and informa-
tion technology. The report also emphasised the importance of
change based on evidence. The third Wanless report3 empha-
sised the need for improvements in public health and the need
for greater investment in prevention and risk reduction.
2.1 Aims and objectives
This review aims at describing how best to provide services for
patients with gastrointestinal disorders from a professional and
patient perspective, based on available evidence on disease
burden and service provision.
Its objectives are to:
1. Review and synthesise published research evidence and
routine data concerning the burden of GI diseases on
– Patients—their mortality, morbidity, and quality of life
– The NHS—its volume and cost
– The economy of the UK.
2. Systematically review and synthesise research findings
concerning the effectiveness of models of service provision
for GI diseases and the cost effectiveness of GI services.
3. Describe the patients perspective on emerging issues of
service delivery highlighted through the literature review
as undergoing change.
4. Draw conclusions about optimal service provision based
on evidence of burden and effectiveness, patients’ view
and in the current policy and service context.
The report covers the broad spectrum of GI and liver
conditions. It does not examine disorders of nutrition, both
malnutrition and obesity, as these have been dealt with in
detail elsewhere.4–6
2.2 Overview of methods
Four methods were used in the generation of this document:
N A systematic review of the literature was undertaken to
identify research papers concerning the effectiveness of
methods of service delivery in gastroenterology. This
systematic review was supplemented by additional papers
identified when the publications on incidence, mortality,
morbidity, service activity, and costs were assessed. Some
further papers were identified and included from consulta-
tion feedback.
N Routine data sources were interrogated to identify additional
data on burden of disease and the activity of the NHS in
relation to GI disorders.
N The views of users of the service were sought, through
discussions with the voluntary sector and through a work-
shop held at the Royal College of Physicians in December
2004.
N The views of professionals were obtained by wide dissemi-
nation of the document in a draft form, seeking feedback on
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the content and additional material. The full draft report was
presented at the BSG annual conference in March 2005,
alongside a strategy document outlined by the BSG
president, based on the review findings. After this meeting,
comments were invited, and the online report was made
available to the BSG membership through a web link. In
addition, patient representative groups and other GI
specialist organisations were contacted to gain feedback.
Comments were received over a 6 month period after release
of the first draft, and these were incorporated where they
were supported by evidence from well designed and reported
research studies. Table A.13 summarises and appraises these
papers.
More detail of the methods used is given in the appropriate
sections of the document.
3. BURDEN OF GASTROINTESTINAL AND LIVER
DISEASE IN THE UK
3.0 Methods and data limitations
Gastrointestinal and liver disorders affect people of all ages.
Some disorders are acute and life threatening, others are more
chronic, less dangerous to life, but severely debilitating.
Gastrointestinal cancers are common—some are curable, others
are almost invariably fatal. Bowel problems cause considerable
distress in the elderly. The care and management of such
diverse problems requires contributions from a wide variety of
professions.
The main methods used in this chapter involved extensive
and comprehensive searches of the literature on incidence,
prevalence, mortality, and patients’ quality of life for the
various gastrointestinal diseases in the UK and, for comparative
purposes, for those in other European or Western countries.
Part of the literature had been already compiled through
reviews undertaken during the course of previous studies of the
incidence and mortality of gastrointestinal diseases such as
inflammatory bowel disease, liver cirrhosis, and acute pancrea-
titis.
The literature searches were primarily undertaken on the
Medline and Embase databases with ‘‘incidence’’, ‘‘preva-
lence’’, ‘‘case fatality’’, ‘‘mortality’’, ‘‘quality of life’’, ‘‘death
rate’’, ‘‘hospital’’, ‘‘admission’’, ‘‘gastrointestinal’’, ‘‘review’’,
‘‘epidemiology’’, ‘‘aetiology’’, ‘‘trend’’, ‘‘population’’, ‘‘rate’’,
‘‘100 000’’, ‘‘10 000’’, ‘‘million’’, ‘‘UK’’, ‘‘England’’, ‘‘Scotland’’,
‘‘Wales’’, other countries, and the various gastrointestinal
diseases as the main search terms.
The literature reviews were supplemented with extensive
searches of routine data sources in the UK to provide additional
information on the burden of gastrointestinal disease in the
UK. The main routine data sources used in this chapter were:
firstly, the cancer surveillance and registry units in England,
Wales, Scotland, and northern Ireland for publications and data
on the incidence, mortality, survival, and socioeconomic aspects
of gastrointestinal cancers. Secondly, data and reports pub-
lished by the Office of National Statistics (ONS) and its
predecessor, the Office of Population Censuses and Surveys
(OPCS), were obtained for information on the causes of
gastrointestinal and other mortality in England and Wales.
Thirdly, information on hepatitis B and C infections was
obtained from publications involving communicable disease
surveillance units in the UK.
The main categories of gastrointestinal disease with corre-
sponding ICD-9 and ICD-10 codes used are as follows: diseases
of the digestive system (ICD-9 = 520–579; ICD-10 = K00-
K93), malignant neoplasms of the digestive system (150–159;
K15-K26), benign and other neoplasms of the digestive system
(210, 211, 230, 235.2–235.5; D00, D01, D12, D13, D37),
intestinal infectious diseases (001–009; A00-A09), and viral
hepatitis (070; B15-B19).
Some of the main limitations of available data in the UK for
investigating the burden of gastrointestinal diseases are: firstly,
that incidence and prevalence data are routinely compiled for
gastrointestinal cancers and communicable diseases only.
Fairly complete incidence data for a few acute gastrointestinal
disorders such as acute pancreatitis and acute appendicitis can
be traced from hospital admissions, although there have been
major concerns about the accuracy of routine hospital data.8–11
Secondly, different criteria for measuring incidence, case mix
variation, and different methods used for age standardising
population based incidence and mortality rates can also affect
comparability across studies; while case fatality from follow-up
studies is affected by factors such as the length of follow-up
and the inclusion of deaths after discharge with in-hospital
deaths, as well as case mix. Trends in hospital admissions for
many gastrointestinal disorders, such as gallstone operations
and liver replacements, are also strongly affected by factors
such as the availability of hospital facilities, as well as the
prevailing clinical practice at the time.
People with other gastrointestinal diseases such as functional
disorders are mainly managed in primary care; and so incidence
or prevalence data for these diseases can usually only be
determined through national primary care surveys, costly
databases compiled by pharmaceutical companies, or through
intensive local or regional surveys of general practices.
For other gastrointestinal disorders, many people remain
undiagnosed. Incidence or prevalence data for some of these
diseases, such as gastro-oesophageal reflux disease, irritable
bowel syndrome, and dyspepsia, can often be obtained at a
regional level only, through diagnostic questionnaires or
interviews; while differences in diagnostic criteria often affect
comparability across studies.
For some gastrointestinal disorders, it is not possible to
distinguish functional disorders from more serious diseases
without the use of special investigation or tests. The growing
sophistication of gastrointestinal diagnostic methods has
probably resulted in increased diagnosis of milder forms of
what would have been traditionally regarded as serious
digestive diseases, and caution is therefore required when
making comparisons longitudinally over time.12 In other words,
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increases in reported incidence over time may be attributable to
improvements in diagnostic methods rather than real increases.
Routine mortality data are usually available for underlying
cause of death only, while patterns of certification of the
underlying cause of death vary according to the type of disease
or condition. People who die soon after a hospital admission for
myocardial infarction, stroke or lung cancer are almost always
certified with these diseases as their underlying cause of death.
In contrast, the certified underlying causes of death for those
who die soon after admission for most gastrointestinal
disorders are typically much less likely to be these gastro-
intestinal diseases.13 Therefore, mortality statistics, based on
underlying cause of death often underreport true mortality
from gastrointestinal diseases.
In summary, for many gastrointestinal diseases, other than
cancers, burden of disease data are often patchy, collected at a
local or regional level, have variation in case ascertainment and
in comparability between studies and longitudinally over time,
and can underreport the true burden of disease. Even for
cancers that have been allocated specialist surveillance and
registration units, despite improvements over time, there are
sometimes differences between cancer registries in case
ascertainment and completeness of registrations, so that some
degree of caution is required when making comparisons
longitudinally and between registry regions.
3.1 Spectrum of gastrointestinal disorders
Gastrointestinal disorders cover disease of the alimentary canal
(from oesophagus to anus) and its associated organs (liver,
gallbladder, and pancreas). They affect a significant proportion
of the population. Of the cancers, those of the gastrointestinal
tract are among the most common, with colorectal cancer being
the second most common cancer in England and Wales as
measured by incidence and mortality when both sexes are
included.14 It includes very common conditions such as gastro-
oesophageal reflux disease, non-ulcer dyspepsia, and functional
bowel disease, which although a significant proportion of the
population probably self treat at some stage in their life, have a
huge impact on primary and secondary care. Other common
conditions include inflammatory bowel disease, coeliac and
diverticular disease. Alcoholic liver disease remains a signifi-
cant problem but with increasing obesity and lifestyle trends
chronic liver disease due to non-alcoholic fatty liver disease and
hepatitis C is being increasingly seen. The wide spectrum of
disorders requires a range of treatment involving self care,
primary care through to secondary care, and highly specialised
tertiary referral centres.
3.2 Incidence of gastrointestinal diseases
Gastrointestinal symptoms and complaints are common among
the general population. About one in six admissions to hospital
are for a primary diagnosis of gastrointestinal disease, and
about one in six of the main surgical procedures in general
hospitals are performed on the digestive tract. The following
sections outline patterns of incidence and prevalence for some
of the main gastrointestinal disorders in anatomical sequence:
diseases of the oesophagus, followed by diseases of the stomach
and duodenum, the small bowel and colon, the liver, pancreas
and gastrointestinal cancers.
Incidence of diseases of the oesophagus
Gastro-oesophageal reflux disease
Gastro-oesophageal reflux disease (GORD or GERD when
oesophagus is spelt as esophagus) occurs when reflux of
stomach acid into the oesophagus is severe or frequent enough
to impact the patient’s life or damage the oesophagus, or both.
It is the most common disorder of the gastrointestinal tract,
resulting from failure of the gastro-oesophageal sphincter.
GORD is a chronic condition that, in most cases, returns shortly
after discontinuing treatment.
Risk factors for GORD include hiatus hernia, certain foods,
heavy alcohol use, smoking, and pregnancy. There is also a
strong genetic component in the incidence of GORD: a first
degree relative of a patient is four times more likely to be
afflicted, while a recent study estimated that 50% of the risk of
GORD is genetic.15 Other possible risk factors include con-
comitant drugs for treatment of hypertension, angina, and
arthritis,16 and obesity.17
The risk of GORD increases with age, rising sharply above the
age of 40. More than 50% of those afflicted are between the
ages of 45 and 64. Incidence varies geographically, it is slightly
higher in women than in men, and it is higher among white
people than among Asian and Afro-Caribbean ethnic
groups.18 19
In Western countries, 10–40% of the adult population
experience heartburn, which is the main symptom of GORD,
although estimates vary according to the diagnostic criteria
used.18 20 21 In the UK, a recent community based study reported
a prevalence of 28.7% for GORD symptoms.22 Subjects with
chronic GORD are at risk of developing Barrett’s oesophagus
(see below). About 10–15% of subjects who undergo endoscopy
for GORD evaluation are found to have Barrett’s oesopha-
gus,16 23 while other complications of GORD include erosive
oesophagitis, ulceration, strictures, and gastrointestinal bleed-
ing.24
Barrett’s oesophagus
Severe, longstanding gastro-oesophageal reflux disease can
damage the oesophagus and lead to a condition known as
Barrett’s oesophagus. This refers to an abnormal change or
metaplasia in the cells of the lower end of the oesophagus.
Barrett’s oesophagus, or columnar-lined oesophagus (CLO),
occurs in about one in 400 of the general population, or about
15% of patients with reflux oesophagitis. It is a rare diagnosis in
people aged under 40 years, but its prevalence increases sharply
with age and with obesity. It is much more common in white
people than in Asian and Afro-Caribbean ethnic groups,18
among men than women, and among people in higher
socioeconomic groups.25
Barrett’s oesophagus is a major risk factor,16 23 24 and the only
known precursor,26–28 for oesophageal adenocarcinoma,
although the degree of risk is not very clearly defined as many
people with Barrett’s oesophagus remain undiagnosed. The
diagnosed incidence of Barrett’s oesophagus has been increas-
ing sharply over time in the UK,29 30 indicating real increases in
its prevalence.
Oesophagitis
Oesophagitis refers to the inflammation of the lower end of the
oesophageal lining, arising mainly through the chronic reflux of
stomach acid and digestive enzymes into the oesophagus.
When the inflammation is severe, oesophageal ulcers may
develop. Around 50% of people with GORD also have
oesophagitis.31 Other, less common causes of oesophagitis
include hiatus hernia, certain fungal infections such as monila
and candida, viruses, irradiation, and caustic substances such
as lye. The prevalence of oesophagitis increases with age and
obesity, and it is also more common in men than in women,
and among white people than in Asian and black ethnic
groups.32 33
Oesophagitis is present in about 20% of patients at
endoscopy,34 although case series from endoscopy units suggest
that the diagnosis of oesophagitis is increasing over time. For
example, one recent British study reported a diagnostic rate of
32%.35 It is likely that this reflects a true increase in the
4 Williams, Roberts, Ali, et al
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prevalence of oesophagitis, but the magnitude of the increase
may not be entirely accurate owing to effective treatments for
the condition, such as the advent of proton pump inhibitors.21
Dyspepsia
Functional gastrointestinal disorders are defined by symptoms
in the absence of any structural abnormalities, and affect all
areas of the GI tract, ranging from globus (feeling of a lump in
the throat), non-cardiac chest pain, functional dyspepsia in the
upper GI tract, and irritable bowel syndrome (IBS) in the lower
GI tract. Functional gastrointestinal disorders are characterised
by poorly understood abnormalities of gut motility and sensory
perception. These and rare motility disorders occur owing to
dysfunctional interactions between the brain/central nervous
system and the gut/enteric nervous system. Biological triggers
underlying functional gastrointestinal disorders are being
identified, leading to research aimed at providing effective
treatments.
Dyspepsia describes pain or discomfort in the upper abdo-
men, rather than a defined condition, and it is a chronic,
relapsing, and remitting symptom. Causes of dyspepsia include
peptic ulcers, acid reflux disease, oesophagitis, anti-inflamma-
tory drugs, gastritis and duodenitis, hiatus hernia, gastric
motility disorder, oesophageal or gastric cancers, although in
many cases there is no underlying disease.
Dyspepsia has been defined in different ways by a number of
expert groups. For example, the 1988 Working Party classifica-
tion states that symptoms need to be referable to the upper GI
tract, and need to be present for the past four weeks. The less
inclusive Rome II criteria later stated that patients need to have
predominant pain or discomfort centred in the upper abdomen
for at least 12 weeks of the past year, and excluded patients
with heartburn or acid reflux as their only symptoms. More
recently, the BSG have defined dyspepsia as any group of
symptoms that alert doctors to consider diseases of the upper
GI tract.
Dyspepsia symptoms typically affect between 20 and 40% of
the UK population, depending on the diagnostic criteria used.21
Most recent British studies have used the BSG definition and
have typically reported dyspepsia prevalence rates of about 40%
(table 3.2.1),36–39 although lower rates of 26%,40 29%,41 and
12%,42 have also been reported. Prevalence rates in the UK have
often been higher than those reported for populations in other
Western countries (table 3.2.1).
Dyspepsia also accounts for between 1.2 and 4% of all
consultations in primary care in the UK.34 43 Half of these
consultations are for functional dyspepsia. Non-cardiac chest
pain may be of gastrointestinal origin but sufferers often persist
in the belief that they have heart disease, resulting in severe
morbidity. Fifty per cent of patients consulting their GP for
chest pain,44 and a similar proportion seen in rapid access chest
pain clinics,45 have no cardiac cause of their symptoms.
Although mortality in people with functional gastrointestinal
disorders is not raised compared with the general population,
these disorders have a significant impact on quality of life. For
example, two studies reported that 75% of people with non-
cardiac chest pain suffered persistent symptoms and impaired
quality of life over periods of 10 years or more; 30–50% never
returned to work and were unable to carry out household
tasks.44 46
Peptic ulcers have been thought to account for a quarter of all
cases of dyspepsia.47 Several British studies from the 1940s to
the 1980s reported that 18%,48 26%,41 and 31% 39 of people
referred with dyspepsia were found to have peptic ulcers,
although more recently this percentage has fallen to around 10–
15%.34 39 49 50
Incidence of diseases of the stomach and duodenum
Peptic ulcer
Peptic ulcer is the collective term that includes ulcers of the
stomach and the duodenum. About 90–95% of duodenal ulcers
and 70–80% of gastric ulcers are caused by the Helicobacter pylori
Table 3.2.1 Prevalence rates (% of population) of dyspepsia, as reported from various regional studies in the UK and in other
Western countries
Country Region Year of study* Study size
Prevalence (% of
population)` Authors and reference
UK studies:
UK Scotland 1967 1 487 men 29.0 Weir RD and Backett BM, 196841
UK Hampshire 1988 2 066 38.0 Jones RH and Lydeard SE, 198939
UK
England and Scotland - 5
centres 1989 7 428 41.0 Jones RH et al, 199038
UK 150 Centres 1994 2 112 40.3 Penston JG and Pounder RE, 199636
UK north of England 1997 3 179 25.7 Kennedy TM et al, 199840
UK Glasgow 1998 1 611 12.0 Woodward M et al, 199942
UK Leeds 1999 8 407 37.8 Moayyedi P et al, 200037
Foreign studies:
Norway 1979–1980 14 390 20 Johnsen R et al, 198851
Norway Sørreisa, 1987 1 802 27.5 Bernersen B et al, 199652
USA Olmsted County 1988–1991 835 25.8 Talley NJ et al, 199253
Denmark 1993 3 619 14–51 Kay L and Jorgensen T, 199454
Germany Essen 1993 180 24.4 Holtmann G et al, 199455
Netherlands 1994 500 17 Schlemper RJ et al, 199556
Japan 1994 231 32 Schlemper RJ et al, 199556
USA Olmsted County 1996 2 200 19.8 Locke GR et al, 199757
Australia Sydney 1997 592 13.2 Nandurkar et al, 199858
Germany Ludwigshafen 1997 4 054 20.4 Zober A et al, 199859
Spain 1998 264 23.9 Caballero-Plasencia AM et al, 199960
New Zealand Wellington 1999 817 34.2 Haque M et al, 200061
Sweden Uppsala 1999 1 422 14.5 Agreus L et al, 200062
Netherlands Utrecht 2000 500 13.8 Boekema PJ et al, 200163
Iceland 2000 2 000 17.8 Olafsdottir LB et al, 200564
Australia New South Wales 2001 2 300 11.4–36 Westbrook JJ and Talley NJ, 200265
*The year before the year of publication is given, where the study period was not specified; `ranges of prevalence refer to prevalence rates obtained using different
criteria for diagnosing dyspepsia.
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infection. Other risk factors include non-steroidal anti-inflam-
matory drugs (NSAIDs) and corticosteroids, increased gastric
acid secretion, blood group ‘‘O’’, smoking, and heavy alcohol
use.
Duodenal and gastric ulcer differ in their incidence by age
and sex. The incidence of duodenal ulcer peaks at age 45–64
years, and is twice as common in men than in women, whereas
gastric ulcer is more common in the elderly and more equally
found in men and women.
The incidence of peptic ulcer in the UK increased during the
first half of the 20th century. Since the 1950s, however, hospital
admission rates for peptic ulcer have fallen among most age
groups.66–70 Since the early 1980s, this is largely because of a
reduction in recurrent ulcer disease consequent upon the
identification and eradication of Helicobacter pylori infection in
patients presenting with peptic ulcer. For example, admission
rates for duodenal ulcer in Scotland fell by 38% from 157 to 98
per 100 000 population between 1975 and 1990,69 and the
prevalence of peptic ulcer in primary care in England and Wales
fell by 50% from 1994 to 1998.71 Hospital admissions for
perforated peptic ulcer have also fallen over time in the UK; for
example, by 26% in Oxford between 1976 and 1982,72 and by
44% in Scotland for perforated duodenal ulcer between 1975
and 1990.69
However, in contrast with this downward trend, hospital
admissions for perforated peptic ulcer increased among elderly
women in the UK during the 1970s and 1980s,69 73 74 and
perforated duodenal but not gastric ulcer, and haemorrhagic
peptic ulcers, increased among elderly people in England during
the 1990s.75 These increases have been linked to the use of
NSAIDs, which have been shown to cause both gastric and
duodenal ulceration, including ulcer perforation and haemor-
rhage.76 77 Patients taking NSAIDs have been reported to be at
4.7 times greater risk of haemorrhagic peptic ulcer, with an
increasing risk with age up to 13.2 in people aged over 60.21
Recent small reductions in the incidence of peptic ulcer among
elderly women since the mid-1980s, indicates increased
awareness of the side effects of NSAIDs, and more selective
prescribing of these drugs.12 70
Helicobacter pylori infection
Helicobacter pylori is a bacterial infection that was discovered in
1982 and is the causal agent in 90–95% of duodenal ulcers and
70–80% of gastric ulcers. It is also linked to other gastro-
intestinal diseases such as gastritis and dyspepsia,34 49 and it is
estimated to be the cause of 73% of all gastric cancers.78 79
Helicobacter pylori has been listed as a grade I carcinogen because
gastric cancer can occur after Helicobacter pylori gastritis leads to
atrophy and metaplasia.80
Risk of infection is strongly linked to social deprivation in
childhood, and it is much higher in unsanitary or overcrowded
living conditions with no fixed hot water supply.80 It is thought
that the crowded living conditions of the expanding cities at the
beginning of the industrial revolution led to a decline in
hygiene and the spread of the infection early in life.12 81
The prevalence of the Helicobacter pylori infection in the UK
has declined in recent decades, as the infection is progressively
eradicated from patients presenting with peptic ulcer and also
because of a declining incidence as conditions improved over
time. Successive birth cohorts have had a lower risk of
childhood infection: the prevalence of Helicobacter pylori in 20–
30 year olds is 10–20%, rising with age to 50–60% in 70 year
olds.
Up to half of the world’s population is infected with
Helicobacter pylori.80 Prevalence varies between about 80% for
adults in developing countries, Japan, and South America,
around 40% in the UK, and 20% in Scandinavia. Local
differences in prevalence exist where there has been substantial
immigration from countries with a higher prevalence of
infection.
About 15% of people infected with Helicobacter pylori will
develop peptic ulcer or gastric cancer as a long term
consequence of the infection. Infection in infancy is thought
to lead to pangastritis, which predisposes to gastric ulcer and
Table 3.2.2 Hospital admission rates (per 100 000 adult population) for upper gastrointestinal haemorrhage as reported from
various regional studies in the UK and in other countries
Country City/region Study period No of cases
Hospital admission rate
per 100 000 adult population Authors and reference
UK studies:
UK Oxford 1953–1967 2149 47* Schiller KF et al, 197084
UK Oxford 1981–1982 125 56* Berry AR et al, 198485
UK NE Scotland 1967–1968 817 116 Johnston SJ et al, 197386
UK Newport, Gwent 1980–1981 330 52* Madden MV and Griffith GH, 198587
UK Nottingham 1984–1986 1017 64* Katschinski BD et al, 198988
UK Bath 1986–1988 430 70* Holman RA et al, 199089
UK NE Scotland 1991–1993 1098 117 Masson J et al, 199690
UK north west Thames 1991–1993 NA 91 Rockall TA et al, 199591
UK South west Thames 1991–1993 NA 99 Rockall TA et al, 199591
UK West Midlands 1991–1993 NA 102 Rockall TA et al, 199591
UK Trent 1991–1993 NA 107 Rockall TA et al, 199591
UK West of Scotland 1992–1993 1882 172 Blatchford O et al, 199792
Foreign studies:
Sweden Varberg 1957–1961 283 121* Herner B and Lauritzen G, 196593
Sweden Sundsvall 1980–1988 978 100* Henriksson AE and Svensson JO, 199194
Spain Cordoba 1983–1988 3270 160* Mino Fugarolas G et al, 199295
Denmark Odense 1990–1992 183 88 Hallas J et al, 199596
USA San Diego 1991–1994 258 102* Longstreth GF, 199597
Saudi Arabia Abha 1991–1993 240 31 Ahmed ME et al, 199798
Finland Central province 1992–1994 298 68 Soplepmann J et al, 199799
Estonia Tartu county 1992–1994 270 99 Soplepmann J et al, 199799
Netherlands Amsterdam 1993–1994 951 45 Vreeburg EM et al, 199783
Crete Heraklion 1998–1999 353 160 Paspatis GA et al, 2000100
Italy and Spain Multicentre 1998–2001 2813 40 Laporte JR et al, 2004101
*Admission rates are expressed per 100 000 general population, instead of the usual 100 000 adult population for upper gastrointestinal haemorrhage, and therefore
underreport incidence in comparison with the other studies; admission rates are calculated from the cited number of cases and total populations served by the
hospital(s).
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gastric cancer, while infection in later childhood may lead to
antral gastritis, which predisposes to duodenal ulcers and
duodenitis.82 It has been estimated that one in 35 men and one
in 60 women in England and Wales die from a Helicobacter pylori
related disease.78 Eradication therapy for Helicobacter pylori
infection has been shown to be effective for pylori peptic ulcer
disease.49
Gastrointestinal haemorrhage
Gastrointestinal haemorrhage refers to bleeding from the bowel
wall or mucosa anywhere along the GI tract. Presentation
depends on the location and rate of haemorrhaging and
includes melaena from rapid bleeding high in the gastrointest-
inal tract, iron deficiency anaemia from chronic slow blood loss,
or red blood from the colon or ileum.
Acute upper gastrointestinal bleeding is the commonest
emergency managed by gastroenterologists. About half of all
upper gastrointestinal haemorrhages are caused by peptic
ulcers and NSAIDs, while other causes include oesophageal or
gastric varices, gastric erosions, Mallory-Weiss tear in the lining
of the oesophagus, angiodysplasia, and upper gastrointestinal
malignancies. For example, a review of nine European studies
from 1973 to 1995 reported that the main causes of
haemorrhage were duodenal ulcer (24% of all cases), gastric
ulcer (13%), varices (9%), gastritis/erosions (9%), oesophagitis
(8%), malignancies (5%), and no diagnosis (14%).83
Lower gastrointestinal haemorrhage accounts for about 20%
of all acute gastrointestinal haemorrhages. The most common
causes are diverticular disease, inflammatory bowel disease,
colonic polyps, ischaemic or infective colitis, gastroenteritis,
haemorrhoids, angiodysplasia, and colorectal neoplasms. Most
lower gastrointestinal haemorrhages occur in elderly people,
and most of these bleeds settle spontaneously and do not
require emergency surgery. It is estimated that 20–30% of all
gastrointestinal haemorrhages are related to the use of non-
steroidal anti-inflammatory drugs.
The incidence of upper gastrointestinal haemorrhage
increases very sharply with age, it is higher in men than in
women, and it tends to be highest in areas with high incidence
of peptic ulcer—for example, in Scotland and the north of
England rather than in southern regions. High hospital
admissions rates of upper gastrointestinal haemorrhage have
been reported in the west of Scotland (172 per 100 000 in 1992–
93),92 Aberdeen (117 in 1991–93),90 and the north east of
Scotland (116 in 1967–6886; table 3.2.2).
A study of four health regions in the south of England and
the Midlands reported an overall hospital admission rate of 103
per 100 000; which varied between 91 for north west Thames
and 107 for Trent.91 However, lower hospitalised incidence rates
of 45–70 per 100 000 were reported from earlier studies
particularly in relatively affluent studies such as Bath and
Oxford from the 1950s to the 1980s.84 85 88 89 With an ageing UK
population, incidence is likely to continue to rise.91
Incidence rates of upper gastrointestinal haemorrhage in the
UK are often higher than those reported in other recent studies
in Europe and elsewhere. These include studies in Central
Finland,99 the Netherlands,83 Saudi Arabia,98 Estonia,99 and a
multicentre study in Spain and Italy. None the less, high
incidence rates of 160 per 100 000 have been reported from
studies in Crete in the late 1990s,100 and Spain in the 1980s.95
Incidence of diseases of the small bowel and colon
Inflammatory bowel disease
Ulcerative colitis and Crohn’s disease are the two main
idiopathic types of inflammatory bowel disease. Ulcerative
colitis, otherwise known as idiopathic proctocolitis, causes
Table 3.2.3 Incidence and prevalence rates (per 100 000 population) for Crohn’s disease and for ulcerative colitis, as reported
from various regional studies in the UK
City/region Study period Study sources* No of cases
Incidence rate
per 100 000 population
Prevalence per 100
000 population Authors and reference
Crohn’s disease:
Cardiff 1931–90 SP, HR, Lab 86 2.3 in 1961–65
11.9 in 1981–85
8.6 in 1986–90
– Thomas GA et al, 1995121
Cardiff 1991–95 SP, HR, Lab 84 5.6 – Yapp TR et al, 2000122
Oxford 1951–60 SP, HR 24 0.8 9 in 1960 Evans JG and Acheson ED, 1965131
Derby 1951–85 HR, Lab 225 0.7 in 1951–55
6.7 in 1981–85
85 in 1985 Fellows IW et al, 1990124
Nottingham 1958–72 SP, HR, Lab 144 0.7 in 1958–60
3.6 in 1970–72
– Miller DS et al, 1974137
Clydesdale 1961–70 HR 357 1.2 in 1961–65
1.9 in 1966–70
– Smith IS et al, 1975138
Gloucester 1966–70 HR, Lab 19 1.5 – Tresadern JC et al, 1973139
North Tees 1971–77 HR, Lab 73 5.3 35 in 1977 Devlin HB et al, 1980134
NE Scotland and
N Isles of Scotland
1955–88 SP, HR, Lab 1008 1.3 in 1955–57
9.8 in 1985–87
147 in 1988 Kyle J, 1992123
Northern Ireland 1966–81 HR, Lab 440 1.3 in 1966–73
2.3 in 1974–81
– Humphreys WG et al, 1990140
Blackpool 1968–80 HR, Lab 156 3.3 in 1971–75
6.1 in 1976–80
47 in 1980 Lee FI and Costello FT, 1985125
Leicestershire 1972–89 SP, HR, Lab 582 3.2–4.7 (among Europeans)– Jayanthi V et al, 1992126
North Tees 1985–94 SP 200 8.3 145 in 1994 Rubin GP et al, 2000136
Trent 2002 SP, HR, Lab 113 – 130 in 2002 Stone MA et al, 2003141
Ulcerative colitis:
Oxford 1951–60 SP, HR 238 6.5 80 in 1960 Evans JG and Acheson ED, 1965131
NE Scotland 1967–76 SP, HR, Lab 537 11.3 – Sinclair TS et al, 1983135
Cardiff 1968–87 SP, HR, Lab 6.4 in 1968–77
6.3 in 1978–87
– Srivastava ED et al, 1992133
North Tees 1971–77 HR, Lab 146 15.1 99 in 1977 Devlin HB et al, 1980134
High Wycombe 1975–84 HR, Lab 313 7.1 84 in 1984 Jones HW et al, 1988132
North Tees 1985–94 SP 334 13.9 243 in 1994 Rubin GP et al, 2000136
Trent 2002 SP, HR, Lab 211 – 243 in 2002 Stone MA et al, 2003141
*Study sources: SP, survey of physicians; HR, review of hospital records or admission data; Lab, pathology data.
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inflammation and ulcers in the colon. Crohn’s disease differs
from ulcerative colitis because it can occur anywhere along the
GI tract and causes inflammation deeper within the intestinal
wall. Inflammatory bowel disease usually affects younger
people and has a chronic relapsing course that impacts on
educational, social, professional, and family life. Along with
gastrointestinal cancers and liver disease, inflammatory bowel
disease is one of the three most important areas for British
gastroenterologists.
A total of about 150 000 people have inflammatory bowel
disease in the UK, and a total of approximately 2.2 million
across Europe.102 Although there is substantial regional varia-
tion (table 3.2.3), the prevalence of Crohn’s disease in the UK is
currently about 55–140 per 100 000 population, and that of
ulcerative colitis is about 160–240 per 100 000, with a combined
incidence of about 13 300 new cases diagnosed each year.103
The causes of ulcerative colitis and Crohn’s disease are not fully
known. Although they are thought to be autoimmune diseases, it
is not certain whether autoimmune abnormalities are a cause or
result of the diseases. Suggested risk factors include appendect-
omy, diet, smoking, perinatal and childhood infections, and oral
contraceptives,102 while a possible link with measles vaccination
has been disputed.104 105 Inflammatory bowel disease predisposes
strongly to cancer of the colon,106–110 to venous thromboembo-
lism,111–113 and osteoporosis,114–116 and it is also associated with
coeliac disease,117 118 and primary sclerosing cholangitis.119 120
There is a peak in incidence of inflammatory bowel disease
between the ages of 10 and 19 years, and a smaller peak beyond
50 years of age. Women may be at a slightly increased risk of
Crohn’s disease than men, whereas the risk for ulcerative colitis
is the same for men and women.
Studies of Crohn’s disease in the UK, and in Europe, have
typically reported large increases in incidence over the past 50
years, while others have reported incidence rates that have
stabilised after earlier increases (table 3.2.3). There was a sharp
increase in the incidence of Crohn’s disease in Cardiff from the
early 1960s to the early 1980s, before levelling off in the late
1980s,121 and subsequently declining during 1991–95.122 Other
sharp increases in incidence of Crohn’s disease up to the 1980s
have been reported for the north east of Scotland,123 Derby,124
Blackpool,125 and among Europeans in Leicestershire.126
Incidence rates for ulcerative colitis have been more stable
over time than those for Crohn’s disease,127 although a few
recent European studies have reported increasing,128 129 or
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Figure 3.2.1 Incidence rate (per 100 000
population) for Crohn’s disease in the UK
and in other European countries. Source:
Shivananda et al, 1996.148
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population) for ulcerative colitis in the UK
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Shivananda et al, 1996.148
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decreasing rates.130 Several regional British studies have
reported incidence rates of about six or 7 per 100 000
(table 3.2.3),131–133 although substantially higher rates of 11 to
15 have been reported for northern regions such as north Tees
and the north east of Scotland.134–136
Although the incidence of inflammatory bowel disease may
have shown a tendency to plateau in recent years, large
increases in the incidence of paediatric Crohn’s disease have
continued to be reported in the UK. For example, in Scotland
there was a threefold increase in paediatric incidence from 1968
to 1983,142 a further 50% increase from 1981–83 to 1990–92,143
and a 100% increase in north east Scotland from 1980–89 to
1990–99.144 In south Glamorgan there was a 140% increase in
the incidence of paediatric disease from 1983–88 to 1989–93,145
although it is now thought to have reached a plateau.146 A
recent comparison of two national British birth cohorts
indicates that the prevalence of Crohn’s disease has increased
in younger people, although the prevalence of ulcerative colitis
has remained stable.147
A comparison of incidence rates for Crohn’s disease and
ulcerative colitis in the UK, with those reported for various
other European countries in 1991–93, is shown in figs 3.2.1 and
3.2.2.148 There is substantial international variation in the
incidence of both types of inflammatory bowel disease. For
Crohn’s disease, incidence tends to be much higher in northern
European countries, particularly in Scandinavia and the
Netherlands.
The incidence of ulcerative colitis among the UK white
population (10.0 per 100 000) is similar to the average of all
European countries reported here (9.4), but UK immigrants
have a substantially higher rate (figs 3.2.1 and 3.2.2). The
incidence of Crohn’s disease in the UK white population (3.8) is
lower than the European average (5.5), but UK immigrants
have similar incidence (5.6).
Irritable bowel syndrome
Irritable bowel syndrome (IBS) refers to longstanding symp-
toms of abdominal pain, bloating, flatulence, diarrhoea, and/or
Table 3.2.4 Prevalence rates (expressed as percentages) of irritable bowel syndrome (IBS) reported from various studies in the UK
and in other Western countries
Country City/region Year of study* Study size
Prevalence (% of
population) Authors and reference
UK studies:
UK Avon 1979 301 13.6 Thompson WG and Heaton KW, 1980157
UK Hampshire 1991 1 620 22.0 Jones RH and Lydeard SE, 199243
UK Bristol 1991 1 896 9.5 Heaton KW et al, 1992155
UK Teeside 1997 3 179 16.7 Kennedy TM and Jones RH, 2000154
UK Bristol 1995–7 3 111 2.5 Thompson WG et al, 2000156
UK Birmingham 2003 4 807 10.5 Wilson S et al, 2004158
Other Western countries:
USA 1981 789 17.1 Drossman DA et al, 1982159
USA 1983 566 15.0 Sandler RS et al, 1984160
Italy Umbria 1988 533 8.5 Gaburri M et al, 1989161
Japan 1988–89 231 25.0 Schlemper RJ et al, 1993162
USA 1990 5 430 9.4 Drossman DA et al, 1993163
The Netherlands 1991 500 9.0 Schlemper RJ et al, 1993162
USA Olmsted County 1992 643 8.5–20.4 Saito YA et al, 2000164
Sweden Osthammar 1988 1 290 14.0 Agreus L et al, 1995165
Denmark Glostrup 1993 4 581 6.6 Kay L et al, 1994166
Australia Penrith, Sydney 1996 3 240 4.4–13.6 Boyce PM et al, 2000167
Spain 2000 2 000 2.1–12.1 Mearin F et al, 2001168
France 2001 15 132 4.7 Dapoigny M et al, 2004169
Canada 2001 1 149 12.1–13.5 Thompson WG et al, 2002170
New Zealand Dunedin 1998–99 980 3.3–18.8 Barbezat G et al, 2002171
Iceland 2000 2 000 30.9 Olafsdottir LB et al, 200564
USA Olmsted County 2002 643 5.1–27.6 Saito YA et al, 2003172
*Year before the year of publication is given, where the year of study was not specified; ranges of prevalence refer to prevalence rates obtained using different criteria
for diagnosing IBS.
Table 3.2.5 Prevalence rates of coeliac disease as reported from various international studies
Country Screening method Study size Prevalence rate Authors and reference
The Netherlands EMA* 1 440 1 in 288 (a) Schweizer JJ et al, 2004187
Australia EMA 3 011 1 in 251 (a) Hovell CJ et al, 2001188
Sweden TGA EMA 1 850 1 in 205 (a) Lagerqvist C et al, 2001189
The Netherlands EMA 6 127 1 in 198 (c) Csizmadia CG et al, 1999190
Brazil EMA 2 371 1 in 183 (a) Pratesi R et al, 2003191
Argentina AGA EMA 2 000 1 in 167 (a) Gomez JC et al, 2001192
USA AGA EMA 4 126 1 in 133 (a) Fasano A et al, 2003193
Finland EMA 1 070 1 in 130 (c) Kolho KL et al, 1998194
Northern Ireland AGA EMA 1 823 1 in 122 (a) Johnston SD et al, 1997195
Finland EMA 3 654 1 in 99 (c) Maki M et al, 2003196
England EMA* 7 550 1 in 87 (a) West J et al, 2003186
Europe (Finland, Germany, Italy,
Northern Ireland)
TGA EMA 29 268 1 in 50–1 in 220 (a)
1 in 88–1 in 123 (c)
Mustalahti K et al, 2004197
Determination in serum of IgA antibodies against gliadin (AGA), endomysium (EMA), and tissue transglutaminase (TGA).
*Diagnosis not confirmed by small bowel biopsy; a, adults; c, children.
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constipation. It is the most common functional gastrointestinal
disorder seen by GPs, and it is the most common disease
diagnosed by gastroenterologists. Although not life threatening,
IBS may severely impair quality of life, and it usually persists
for several years. Like dyspepsia, IBS has been defined in a
number of different ways according to different diagnostic
criteria, which affects prevalence estimates.
IBS typically affects 10 to 25% of the general UK population.
About half of people with IBS consult their GP, and of these
about 20% are referred to a consultant.149 Consultation
behaviour is often influenced by life events or psychological
factors, as well as severity of symptoms. IBS constitutes about
20 to 50% of the outpatient gastroenterology workload.150–152
IBS can occur at any age, although it most commonly starts
in late teenage years or early adulthood, and it is up to three
times more common in women than in men. Although there is
no consistent effect of age and ethnicity on symptoms,149 they
vary according to which parts of the gut are affected.
Recent community based studies in the UK have reported an
IBS prevalence of 10.5% in Birmingham,158 16.7% in Teeside,154
9.5% and 2.5% in Bristol,155 156 and 22% in Hampshire.43 In each
of these studies, the prevalence in women was two to four times
higher than in men. Prevalence also appears to be increasing in
the UK. For example, a comparison of two British national birth
cohorts revealed a prevalence rate that had risen from 2.9% in
1988 to 8.3% in 2000 among people aged 30 years.147
The prevalence of IBS ranges in all countries of the world
from about 3% to 25%. Although differing diagnostic criteria
affect comparability across studies, reported prevalence rates in
the UK appear to be comparable with, or perhaps slightly
higher than those reported in most other Western countries
(table 3.2.4).
Coeliac disease
Coeliac disease is an inflammatory condition of the small
intestine resulting from sensitivity to gluten, a protein in wheat
flour, and similar proteins in barley and rye. It develops in
genetically predisposed people but can be diagnosed at any age
from early childhood to old age. It appears that a ‘‘trigger
factor’’ may be required to initiate that response. The trigger
might be a viral infection but is usually not known. Removal of
wheat gluten (as well as barley and rye) from the diet permits
the intestinal mucosa to recover.
Coeliac disease is highly prevalent throughout the world,
particularly in countries where wheat forms part of the staple
diet, and it is one of the most important conditions managed by
gastroenterologists. It is more prevalent in the families of those
who are affected: it is estimated that as many as 10% of first
degree relatives of patients are also affected.173 Previous
underdiagnosis of coeliac disease in primary care reflects an
evolving awareness of the diversity in the presentation of
coeliac disease.174 Coeliac disease is often associated with other
diseases such as ulcerative colitis, biliary cirrhosis, primary
sclerosing cholangitis, osteoporosis, malignant lymphomas, and
thyroid disorders,175–183 as well as being linked to increased risks
of gastrointestinal cancer.182 184 185
The prevalence of coeliac disease is thought to be about 1% in
the UK,186 which appears to be comparable with other countries,
globally (table 3.2.5). The prevalence of coeliac disease has
increased sharply in the UK in the last couple of decades;
largely because of improved diagnosis rates as a result of the
introduction of screening tools which can be used in primary
care. In the diagnosis of coeliac disease, IgA antibodies to tissue
transglutaminase and endomysium show good sensitivity and
specificity for coeliac disease; however, it is recommended that
the diagnosis is confirmed by small bowel biopsy. Cases of
coeliac disease have been described in patients with normal
biopsy and positive serology and visa versa. In patients with
coeliac disease and IgA deficiency the serology will be negative,
in such patients IgG transglutaminase and endomysial anti-
body should be determined.
Diverticular disease
Diverticular of the intestine is a major cause of mortality and
morbidity in the UK, mainly among elderly people. It refers to
diverticula, or small sacs or pouches that form in the wall of the
colon. The most common complication is acute diverticulitis,
which occurs when the diverticular become infected, and is
sometimes associated with perforation, intestinal obstruction,
fistula or abscess formation. Diverticular disease is very
common in elderly people, but it is rare in younger age groups
and in developing countries. It is thought to be caused mainly
by longstanding constipation.198
Risk factors for diverticular disease include low fibre diets
and low levels of physical activity, while vegetarians have a
lower incidence of diverticular disease.199 200 Increased risks of
perforated diverticula have been identified for NSAIDs,201–204
corticosteroids,205 and opiate analgesics,206 whereas calcium
antagonists are thought to have a protective effect.203
Diverticular disease is much more common in the west than
in less developed countries.203 For example, a study from the
1960s reported a hospital admission rate of 12.9 per 100 000 in
Scotland that was over 60 times higher than those in Fiji,
Nigeria, and Singapore.207 Westerners residing in those coun-
tries were also substantially more affected than the native
populations. In Singapore, for instance, the admission rate
among Europeans (5.4 per 100 000) was over 40 times that in
the indigenous population.207
In the UK, diverticular disease is much more common among
white people than among Asian ethnic groups,208 while
incidence increases sharply with age. About 5% of people are
affected when in their 40s, and about 50% of people when aged
over 80.209 Diverticular disease is more common in men than in
women among younger age groups, but it is more common in
women among older age groups.203
Because uncomplicated disease is not associated with any
particular symptoms, it is often not discovered until post-
mortem examination, while few studies have examined the
progression from uncomplicated to complicated diverticular
disease. Lower gastrointestinal haemorrhaging, which occurs in
about 15–20% of cases, and infection resulting in peritonitis or
abscesses are the most common complications, and are the
causes of most admissions to hospital.210 For details of mortality
associated with complicated and uncomplicated diverticular
disease, see section 3.3.
With an ageing UK population, the incidence of diverticular
disease is increasing.211 212 For example, hospital admissions for
diverticular disease increased by 16% in men from 20 to 23 per
100 000, and by 12% in women from 29 to 32 per 100 000 in
England during the 1990s,212 while emergency surgical admis-
sions for diverticular disease increased significantly in the
south west of England from 1974 to 1998.213
Incidence of diseases of the liver
Chronic liver disease and cirrhosis
Chronic liver disease and cirrhosis, traditionally referred to as
liver cirrhosis, encompasses a wide range of acute and chronic
liver conditions that are caused by a number of different agents.
These conditions may lead to cirrhosis, resulting in scarring,
injury, and dysfunction of the liver. They include heavy alcohol
consumption, hepatitis B or C viral infections, prolonged
exposure to certain drugs and toxins, inherited diseases such
as haemochromatosis and Wilson’s disease, autoimmune liver
disease, and chronic liver diseases such as alcoholic fatty liver
disease, primary biliary cirrhosis and other chronic diseases of
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the bile ducts. Around 25% of liver disease is alcohol related,
and a similar amount is caused by hepatitis C.214
Alcoholic l iver disease
Alcoholic liver disease refers to a handful of liver diseases that
are attributed to the effects of alcohol. These include alcoholic
cirrhosis, alcoholic fatty liver disease, alcoholic hepatitis, and
alcoholic hepatic failure. Because of diagnostic difficulties,
there is negligible reporting of population based incidence rates
for the different aetiologies; while in most cases routine
hospital data fail to distinguish between them. For example,
in Scotland in 1999–2000, 71% of hospital discharges for
alcoholic liver disease were diagnosed as ‘‘unspecified alcoholic
liver disease’’.215 Since only 15–30% of heavy consumers of
alcohol develop advanced alcoholic liver disease,216 genetic and
other environmental factors also have an important role.
Earlier, regional British studies reported incidence rates for
alcoholic liver disease of 6.5, 14.6, and 2.8 per 100 000
population in respectively, west Birmingham in 1971–76,217
Tayside in 1975–79, and the Scottish Islands of Lewis and
Harris in 1977–82.218 The study of west Birmingham also
reported an increase in alcoholic liver disease from 2.3 to 9.5 per
100 000 from 1959–61 to 1974–76.217
More recent figures show a 160% rise in hospital admissions
for alcoholic liver disease in Scotland between 1996 and 2000,219
while an earlier Scottish study also reported a 160% increase in
admissions for liver cirrhosis from 1983 to 1995.220 The large
increase in alcoholic liver disease in the UK in recent years has
become a major public health concern and has led to the
publication of a national alcohol reduction strategy.221
Incidence rates for alcoholic liver disease in the UK are still
relatively low compared with those in many other Western
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Figure 3.2.3 Prevalence rates (% of
population) for reported hepatitis C
infections in England, Scotland, Wales,
Northern Ireland, and other European
countries. Notes: Rates in England, Scotland,
Wales, and Northern Ireland are based on
reported laboratory diagnoses.229 The data
source for reported rates in the other
European countries is Burroughs and
McNamara.227
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countries. For example, a rate of 32 per 100 000 was recently
reported for Los Angeles, which varied between 8 per 100 000
for Asian ethnic groups and 61 for Hispanics,216 while the
incidence rate in Stockholm County increased from 8 to 24 per
100 000 during the 1970s before falling to 12 per 100 000 by the
late 1980s.222
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD), largely unheard of
before the 1980s, is another liver disease on the increase,
coinciding with the epidemic of obesity in the UK and in other
Western countries. NAFLD is the term used to describe a
number of liver conditions, including simple steatosis (fat
accumulation in liver cells), steatosis with non-specific inflam-
mation, steatohepatitis (fat accumulation and liver cell injury),
and hepatocellular cancer.223 It has also been suggested that
cryptogenic cirrhosis may often actually be ‘‘burned out’’ non-
alcoholic steatohepatitis.224
NAFLD is commonly seen in conjunction with type 2
diabetes, obesity, hypertension, and dyslipidaemia, and is
regarded as the liver’s response to the metabolic syndrome.
Although not the only risk factor, obesity is the most prevalent
risk factor for NAFLD and is present in 65–90% of cases.
Additional risk factors include advanced age and type 2
diabetes, while men and women are equally affected.
Although many people with NAFLD remain undiagnosed, it is
thought to affect about 20% of the general population in the
UK,225 while the obesity epidemic is expected to result in
increases in the prevalence of NAFLD in the future.
Non-alcoholic steatohepatit is
Non-alcoholic steatohepatitis (NASH) is a major cause of non-
alcoholic liver disease which closely resembles alcoholic liver
disease, but occurs in people who consume little or no alcohol.
As with alcoholic liver disease, an excess of fat is deposited in
the liver, which leads to NASH, inflammation, and scarring,
and can progress to cirrhosis. NASH is thought to progress to
advanced liver disease in about 15–20% of cases. Most cases are
asymptomatic and are diagnosed when abnormal liver blood
results are discovered during routine investigations.226
Until relatively recently NASH was thought to be confined
largely to middle aged obese women with diabetes. However, it
has become increasingly recognised that NASH also occurs in
people who are neither obese nor diabetic, and that it may be
one of the most common liver diseases in the Western world.226
Unfortunately, figures on the incidence or prevalence of NASH
in the UK are conspicuous by their absence.
Hepatit is C
The hepatitis C infection is caused by a virus, which is mainly
passed through blood and blood products. Most new cases in
western Europe are related to intravenous drug abuse, through
using infected needles, and to the increased prevalence of
hepatitis C infection in Eastern European immigrants.227 Other
less common routes of infection in the UK include unprotected
sex, through contaminated skin piercing and tattooing equip-
ment, or from mother to baby.228 As symptoms from acute
hepatitis C infection are uncommon, infection is often
discovered by chance on routine screening or on testing after
the patient’s liver function tests have been found to be
abnormal.
An estimated 0.5% of the general UK population, or about
300 000 people, are infected with hepatitis C. Since about one
fifth of those infected appear to get rid of the virus naturally
without treatment,228 the estimated prevalence of hepatitis C
infection is about 0.4% or 240 000 people, which is about four
times higher than the total number of 60 294 reported hepatitis
C diagnoses in the UK up to the end of 2003.229
Prevalence rates, based on the total number of reported
laboratory diagnoses in the UK, at the end of 2003 were 0.08%
for the general population in England, 0.36% in Scotland, 0.11%
in Wales, and 0.04% in Northern Ireland.229 These are typically
lower than prevalence rates reported for other European
countries (fig 3.2.3). There are an estimated five million
hepatitis C carriers in western Europe,227 and 170 million in
the world.230 Prevalence rates in the UK, and in Europe (1.0% of
the population) are lower than in other parts of the world, such
as Africa (5.3%), the Eastern Mediterranean (4.6%), and South
East Asia (2.2%).230
Greatly increased risks of hepatitis C infection are found
among high risk subgroups of the UK population, such as
injecting drug users. In Scotland, for example, reported
prevalence rates for hepatitis C antibodies among injecting
drug users varied between 23% in the Forth Valley and 62% in
Greater Glasgow in 1999–2000,229 while a prevalence rate of
44% was reported for injecting drug users in London in 2001.231
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Figure 3.2.5 Incidence rates (per 100 000
population) and prevalence rates (% of
population) for hepatitis B infection in the UK
and in other European countries. (A)
Incidence rate; (B) prevalence rate. Source:
World Health Organisation.230
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Another document reported the highest prevalence in 2001–02
of about 45–50% in London and the north west of England, the
lowest prevalence of about 15% in the north east, and a
prevalence of 20–35% in other English regions.232
Reported incidence rates for hepatitis C increased alarmingly
in the UK during the 1990s, particularly in Scotland (fig 3.2.4A).
Based on reported diagnoses, the incidence is currently about
40 per 100 000 in Scotland, 10–15 per 100 000 in England,
Wales, and in the UK overall, and around 5 per 100 000 in
Northern Ireland.229 In Tayside, prevalence increased from
0.01% to 1.03% of the population from 1988 to 1998.233 The
rise of hepatitis C infections has led to the recent publication of
national English strategy and action plan documents.228 232
About 40% of people with an acute hepatitis C infection have
lifelong chronic infection, which often causes liver cirrhosis or
cancer many years after the initial infection. Infected people
who consume alcohol have accelerated liver damage, and
increased incidence of liver cirrhosis and hepatocellular
cancer.234 235 Hepatitis C infection invariably causes chronic
illness, resulting in a major financial burden on healthcare
resources. In western Europe, hepatitis C accounts for 70% of
all cases of chronic hepatitis, 40% of all liver cirrhosis, and 60%
of all hepatocellular cancer.227 Because of the increasing
incidence of hepatitis C, it is estimated that the future burden
of hepatitis C health care related to new incidence of cirrhosis
will increase by 60% by 2008, and that there will be a fivefold
increased need for liver transplantation.214
Hepatit is B
Hepatitis B is also caused by a virus; which, in Europe and
North America, is mainly passed from person to person by
unprotected sex. In the rest of the world it is mainly passed
from infected mothers to their children or from child to child.226
Both hepatitis B and chronic hepatitis C are premalignant
diseases leading to hepatocellular cancer. However, unlike
hepatitis C, vaccination for hepatitis B has proved to be
successful in reducing infection rates.227
The prevalence of hepatitis B in the UK is thought to be 0.1%
of the general population or approximately 60 000 people,226
which compares with a total of about 13 000 reported diagnoses
up to the end of 2003.229 In districts of the UK where there are
high levels of immigration, prevalence can be much higher; as
high as 2% of the population. In Europe, an estimated one
million people are infected each year, although the infection is
more common in South East Asia, the Middle and Far East,
Africa, and southern Europe.
Compared with hepatitis C, there is a less discernible trend in
the incidence of reported hepatitis B diagnoses in the UK in
recent years (fig 3.2.4B), although there appears to have been
quite sharp increases in Scotland during the late 1990s and in
Northern Ireland during the past few years. Reported incidence
rates for hepatitis B are about one fifth of those for hepatitis C.
Recent World Health Organisation figures also indicate that the
incidence and prevalence of hepatitis B in the UK is relatively
low compared with many European countries; particularly
south European countries such as Turkey and Greece
(figs 3.2.5A and 3.2.5B).
Primary bil iary cirrhosis
Primary biliary cirrhosis is a disease characterised by inflam-
matory destruction of the small bile ducts within the liver that
eventually leads to cirrhosis of the liver. The cause of primary
biliary cirrhosis is unknown, but because of the presence of
autoantibodies, it is generally thought to be an autoimmune
disease. However, other aetiologies such as infectious agents
have not been completely excluded.
About 90% of primary biliary cirrhosis occurs in women, and
most commonly between the ages of 40 and 60 years. Incidence
appears to be increasing sharply in the UK (table 3.2.6).236 For
example, the prevalence of primary biliary cirrhosis in northern
Table 3.2.6 Incidence and prevalence rates (per 100 000 population) for primary biliary cirrhosis as reported from various studies
in the UK, and in other countries
Country Region Study period Study sources* No of cases
Incidence per 100
000 population
Prevalence per 100
000 population Authors and reference
UK studies:
UK Sheffield 1976–79 SP, Lab 34 0.6 5.4 Triger DR, 1980239
UK Northern England1976–87 SP, Lab, HR 347 1.9 1.8 in 1976
12.9 in 1987
Myszor M and James OF, 1990237
UK Dundee 1975–79 LHD 29 1.1 4.0 Hislop WS et al, 1982240
UK NE England 1972–79 SP 117 1.0 3.7 (rural)
14.4 (urban)
Hamlyn AN et al, 1983241
UK Glasgow 1965–80 Lab, LHD 373 1.1–1.5 7.0–9.3 Goudie BM et al, 1987242
UK Northern England1987–94 SP, Lab, HR,
LHD, ND
770 2.3 in 1987
3.2 in 1994
20.2 in 1987
34.5 in 1994
James OF et al, 1999238
UK Newcastle 1987–94 SP, Lab, HR,
LHD, ND
160 2.2 18.0 in 1987 Metcalf JV et al, 1997243
24.0 in 1994
UK Swansea 1995–96 Lab, HR, LHD 67 – 20.0 Kingham JG and Parker DR, 1998244
Foreign studies:
Sweden Umea 1972–83 SP, Lab, HR 86 1.3 15.1 Danielsson A et al, 1990245
Sweden Malmo 1973–82 Lab, HR, ND 33 1.4 9.2 in 1982 Eriksson S and Lindgren S, 1984246
Sweden Orebro 1976–83 Lab 36 1.4 12.8 in 1983 Lofgren J et al, 1985247
Europe 10 centres 1981 SP 569 – 2.3 (0.5–7.5) Triger DR et al, 1984248
Canada Ontario 1986 SP 206 0.3 2.2 Witt-Sullivan H et al, 1990249
Spain Granada 1976–89 SP, HR 25 4.1 3.6 in 1976 Caballero Plasencia AM et al, 1991250
6.2 in 1989
Australia Victoria 1991 SP, HR 84 – 1.9 Watson RG et al, 1995251
Norway Oslo 1986–95 HR 25 1.6 14.6 in 1995 Boberg KM et al, 1998252
Estonia 1973–92 SP, Lab 69 0.2 2.7 Remmel T et al, 1995253
USA Olmsted County 1976–2000 Lab, HR 22 1.3 in men
0.5 in women
6.3 in women Bambha K et al, 2003254
Alaska 1984–2000 Lab, HR 18 – 16 (natives) Hurlburt KJ et al, 2002255
Australia Victoria 1990–2002 SP, Lab, HR 249 – 5.1 Sood S et al, 2004256
*Study sources: SP, survey of physicians; Lab, laboratory data on subjects with AMA; HR, review of hospital records or admission data; LHD, liver history data; ND,
notification of deaths.
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England rose sevenfold between 1976 and 1987,237 and by 70%
from 1987 to 1994.238
There are large geographical and secular variations in the
prevalence of primary biliary cirrhosis world wide (table 3.2.6).
The disease appears to be most common in north west Europe,
particularly in northern Britain and Scandinavia: some of the
highest reported prevalence rates are for northern England
(34.5 per 100 000 population)243 and for northern Sweden
(15.2).245 These compare with much lower prevalence rates of
1.9 in Victoria, Australia,251 2.2 in Ontario, Canada,249 and 2.7 in
Estonia,253 while primary biliary cirrhosis is rarely found in
Africa or Asia.
Primary sclerosing cholangitis
Primary sclerosing cholangitis is a chronic inflammatory condition
that occurs when the bile ducts inside and outside the liver
become inflamed and scarred. As the scarring increases, blockage
of the ducts leads to damage to the liver. Although the exact cause
of primary sclerosing cholangitis is unknown, it is thought that
the tissue damage is mediated by the immune system.257
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Figure 3.2.6 Prevalence rates (expressed
as percentages) of gallstones among men
and women in regional ultrasound surveys in
the UK and in other European countries.
Source: Aerts and Penninckx, 2003.266
Notes: The year before publication is stated
where the study period was not specified.
Study regions, overall study sizes and
references for the different studies from left to
right are: Norway—Schwedt, n = 1371272;
East Germany—Neuruppin, 3226273;
Sweden—Stockholm, 556274; France—
Viduaban, 831275; Italy—multicentre study,
29 379276; Poland—national study, 10
133277; Italy—Sirmione, 1911278;
Romania—Timisoara, 1323277; Spain—
Guadalajara, 536279; Italy—Rome, 2320280;
Denmark— Copenhagen, 3608281;
England—Bristol, 1896267; Germany—
Romerstein, 2498.282
Table 3.2.7 Aetiology (expressed as percentages) of acute pancreatitis, as reported from various regional studies in the UK, and in
other European or Western countries
Country City/region Study period No of cases
Aetiology
Authors and referenceGallstones (%) Alcoholic (%)
Other and unknown
(%)
UK studies:
UK Bristol 1950–69 590 58 5 37 Trapnell JE and Duncan EH,
1975284
UK Bristol 1968–79 737 50 8 42 Corfield AP et al, 1985285
UK Nottingham 1969–76 214 46 8 45 Bourke JB et al, 1979286
UK NE Scotland 1983–85 378 41 15 44 Thomson SR et al, 1987287
UK Wessex region 1994–95 186 33 20 47 Toh SK et al, 2000288
UK Glasgow 1991–93 279 42 35 24 De Beaux AC et al, 1995289
UK Somerset 1991–95 263 56 12 32 Norton SA et al, 2001290
Other European or Western countries:
Finland Tampere 1967–68 97 53 16 31 Mero M, 1982291
Sweden Gothenburg 1974–75 204 26 66 8 Svensson JO et al, 1979292
Finland Tampere 1977–78 163 23 58 19 Mero M, 1982291
Norway Buskerud 1992 93 51 15 34 Halvorsen FA and Ritland S,
1996293
France Nice 1986–94 57 51 25 24 Benchimol D et al, 1996294
Spain Alicante 1991 473 52 20 28 Minguez M et al, 1995295
Italy Bologna 1990–94 204 60 13 27 Gullo L et al, 2002296
Greece Thessaloniki 1990–94 84 71 6 23 Gullo L et al, 2002296
Hungary Gyor, Szeged 1990–94 483 24 61 13 Gullo L et al, 2002296
France Paris 1990–94 65 35 39 26 Gullo L et al, 2002296
Germany Ulm, Luneberg 1990–94 232 35 38 27 Gullo L et al, 2002296
Portugal Coimbra 1994 91 59 24 17 Milheiro A et al, 1995297
Norway Bergen 1986–95 978 49 25 26 Gislason H et al, 2004298
Sweden Malmo 1985–99 929 42 25 33 Lindqvist B et al, 2004299
France Nice 1994–95 121 43 31 26 Maes B et al, 1999300
Iceland Reykavic 1998–99 50 42 32 26 Birgisson H et al, 2002301
New Zealand Auckland 1998–2001 112 42 29 29 Flint R et al, 2004302
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Primary sclerosing cholangitis usually begins between the
ages of 30 and 60 and is about twice as common in men as in
women.120 Primary sclerosing cholangitis is closely associated
with inflammatory bowel disease, particularly ulcerative
colitis,257 258 and coeliac disease.177 Around 75–80% of northern
European people with primary sclerosing cholangitis have
underlying inflammatory bowel disease.120
Primary sclerosing cholangitis usually progresses to biliary
cirrhosis, persistent jaundice, and liver failure. For patients
with end stage primary sclerosing cholangitis, liver transplan-
tation remains the only effective treatment. Primary sclerosing
cholangitis also predisposes to cholangiocarcinoma in up to
30% of cases,120 259 and has been associated with increased risks
of cancer of the colon, pancreas, gallbladder, and liver.260 It has
also been shown to potentiate the risks of cancer of the colon in
people with ulcerative colitis.261–263
Although the disease is becoming increasingly common,
there is relatively little reported information on incidence or
prevalence. Prevalence rates of 12.7 per 100 000 have been
reported in south Wales in 2003,264 8.5,252 and 5.6265 per 100 000
population have been reported from Norwegian studies in the
mid-1990s, and 20.9 per 100 000 for Minnesota, USA in 2000.254
Gallstone disease
Gallstones or cholelithiasis occur when bile stored in the
gallbladder hardens into pieces of stone-like material. The two
types of gallstones are cholesterol stones that are made
primarily of hardened cholesterol, and account for about 80%
of gallstones, and pigment stones that are darker and made of
bilirubin. It is thought that cholesterol stones form when bile
contains too much cholesterol, too much bilirubin, or not
enough bile salts, or when the gallbladder does not empty for
some other reason. However, the cause of pigment stones is
uncertain, although they tend to occur in people who have
cirrhosis, biliary tract infections, and hereditary blood dis-
orders, such as sickle cell anaemia, in which too much bilirubin
is formed.
Gallstone disease is the most common abdominal condition
for which patients are admitted to hospital in developed
countries.266 The incidence of gallstones increases with age
and obesity, and it is higher in women than in men. Other risk
factors include diabetes, Crohn’s disease, cholesterol lowering
drugs, gastric bypass surgery, hormone replacement therapy,
fasting, and rapid weight loss. Gallstones are very common in
the UK among older age groups, with reported prevalence rates
of 12% among men, and 22% among women, who were aged
over 60 years in an ultrasound survey in Bristol.267
Gallstones can block the normal flow of bile if they lodge in
any of the ducts that carry bile from the liver to the small
intestine. Complications of gallstones include chronic inflam-
mation or infection of the gallbladder (cholecystitis), abscess
formation, acute pancreatitis, and biliary obstruction.266
Gallstones have been shown to be the dominant aetiological
agent in 30–60% of cases of acute pancreatitis in the UK, and in
25–75% of cases in other European or Western countries
(table 3.2.7).
Hospital admission rates and operations for gallstones have
mainly increased in the UK in recent decades,213 268–271 although
admissions reflect the availability of hospital facilities and the
prevalent medical practice, as well as the level of incidence.271 In
England, for example, admissions increased by 30% in men, and
by 64% in women, in England from 1989–90 to 1999–2000.271
Figure 3.2.6 shows prevalence rates for gallstones, as
measured through cross-sectional ultrasound surveys, in
regional studies in England and in other European countries.
The rates varied between 5 and 24%, they were typically 1.5 to
two times higher in women than in men, and the highest rates
were reported for Norway and for the former East Germany.
The rates reported from the English study of Bristol are lower
than those in most of the other European countries.
Haemochromatosis
Haemochromatosis is an inherited condition that is charac-
terised by the deposition of excessive iron in tissue and organs
throughout the body, resulting in progressive damage and
organ failure. Apart from liver disease, other conditions
associated with iron overload include diabetes, joint damage,
heart disease, and impotence. Excessive iron overload is
associated with increased risks of mortality; mainly from liver
cirrhosis, liver failure, liver cancer, and diabetes. Many patients
with haemochromatosis remain undiagnosed for several years
during the early stages of this condition.227 Although reliable
prevalence data for haemochromatosis are not available for the
UK, the disease is common in northern Europe. Prevalence
rates of 1% and 0.93% have been reported for Germany and
Ireland, with lower rates reported for France (0.5%), Sweden
(0.5%), Denmark (0.38%), Iceland (0.37%), and Norway
(0.34%).227
Table 3.2.8 Incidence rates (per 100 000 population) for acute pancreatitis, as reported from various national and regional
studies in the UK
Region Study period Study sources*
Incidence rate per 100 000
population Authors and reference
Bristol 1950–69 HR, Lab, DR 5.4 in 1961–67 Trapnell JE and Duncan EH, 1975284
Bristol 1968–79 HR, Lab, DR 5.4–7.3 from 1968 to 79 Corfield AP et al, 1985285
Nottingham 1969–76 HR, Lab, DR 5.7 Bourke JB et al, 1979286
Four counties of SE England 1963–98 HR 4.9 in 1963–74
9.8 in 1987–98
Goldacre MJ and Roberts SE, 2004303
Wessex region, south of
England 1994–95 HR, Lab 15.2 Toh SK et al, 2000288
England 1989/90–1999/2000 HR 14.5 in 1989–90
20.7 in 1999–2000
Tinto A et al, 2002304
Scotland 1961–85 HR, Lab 6.9 (men) in 1961
75.0 (men) in 1985
11.2 (women) in 1961
48.4 (women) in 1985
Wilson C and Imrie CW, 1990305
NE Scotland 1983–85 HR, Lab 24.2 Thomson SR et al, 1987287
Scotland 1984–95 HR 25.8 in 1985 McKay CJ et al, 1999306
41.9 in 1995
*Study sources: HR, review of hospital records or admission data; Lab, pathology records; DR, deaths records.
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Incidence of diseases of the pancreas
Acute pancreatit is
Like liver disease, acute pancreatitis is also becoming increas-
ingly common in the general population of the UK. It refers to a
sudden inflammation of the pancreas that is activated by
destructive pancreatic enzymes. Acute pancreatitis often lasts
for a short period of time and, in many cases, it resolves. Severe
cases of pancreatitis, however, particularly when necrotising
pancreatitis occurs, usually lead to prolonged stays in hospital
of three to six months, often with many weeks spent in
intensive care and with a high mortality rate.
As there is no specific treatment for acute pancreatitis,
surgery and manipulative endoscopy may be required for
common duct stones or pancreatic necrosis, and especially for
infected necrosis, which occurs in about 5–10% of cases of acute
pancreatitis. However, surgery can carry a high mortality,
particularly in the short term. Traditional open surgery for
infected pancreatic necrosis carries a mortality rate of up to
50%, although a number of less invasive techniques, such as
radiological drainage and a minimal access retroperitoneal
approach, have been developed.283
The two main causes of acute pancreatitis are blockage of the
pancreatic duct by gallstones and heavy alcohol consumption,
although other causes can include abdominal trauma, surgery,
hyperlipidaemia (types IV, V or VI), hyperparathyroidism,
infections such as mumps, and some drugs such as corticoster-
oids, oral contraceptives, and thiazide diuretics. Because almost
all people with an attack of acute pancreatitis are admitted to
hospital, acute pancreatitis is one of few gastrointestinal
diseases for which hospitalised incidence provides a good
measure of true incidence.
Several British studies have shown sharp increases over time
in the incidence of acute pancreatitis in recent decades
(tables 3.2.7 and 3.2.8), although variation in the definition
of incidence to some extent affects comparability across studies.
One study of four counties in south east England reported a
twofold increase in the incidence of acute pancreatitis from 4.9
to 9.8 per 100 000 population from 1963–74 to 1987–98.303 A
recent national English study reported a 43% increase in
incidence from 1989–90 to 2000–01,304 and an earlier study of
Bristol reported a 35% increase in incidence from 1968 to
1979.285
A study of Scotland reported an even greater, 10-fold increase
in incidence of acute pancreatitis among men, and a fourfold
increase among women, from 1961 to 1985 (table 3.2.8),305
although a more recent Scottish study reported a more modest
(62%) increase from 1985 to 1995.306 Increases in the incidence
of acute pancreatitis have been attributed to a rise in alcoholic
pancreatitis, linked to the increased use of alcohol in the
community in the UK,284 303 and in Finland,291 although
elsewhere in western Europe increases in incidence have been
linked to gallstones.299 Table 3.2.7 shows trends in aetiology
across studies, most notably a rise in alcoholic pancreatitis, and
a fall in gallstones pancreatitis, across most British studies since
the 1950s.
Despite differences in the measurement of incidence across
studies, recently reported rates for acute pancreatitis are
substantially higher in Scotland (about 25–65 per 100
000),287 305 306 than in England (about 8–25 per 100
000).285 288 303 304 Incidence rates in Scotland are typically
comparable with the high rates reported in the Scandinavian
countries,293 298 307 308 Iceland,301 and Germany,309 while rates in
England are comparable with those in the Netherlands.310 311
Chronic pancreatit is
Chronic pancreatitis occurs when digestive enzymes attack and
destroy the pancreas and nearby tissues, causing scarring and
pain. It is not usually the result of recurrent attacks of acute
pancreatitis but seems to develop separately. The pancreatic
gland becomes fibrosed and possibly calcified. Chronic pan-
creatitis is a disease that is characterised by horrific pain, it
severely impairs quality of life and shortens life expectancy,
although the exact prognosis is difficult to quantify and it is
poorly documented.
The most common cause of chronic pancreatitis is long term,
heavy alcohol use. Alcohol has been shown to be the dominant
aetiological agent in about 70–80% cases of chronic pancreatitis
in recent European studies.312–314 However, chronic pancreatitis
may be caused by blockage or narrowing of the pancreatic duct
by gallstones. In other cases it is genetically linked, or it may be
triggered by only one acute attack, especially if the pancreatic
ducts are damaged, or it can be caused by the effects of
malnutrition when calcification is present, and in other cases
the cause cannot be determined. Some patients with chronic
pancreatitis develop pancreatic cancer.
Chronic pancreatitis is more common in men than in women,
and it often develops between the ages of 30 and 50. The
prevalence of chronic pancreatitis in the UK is currently about
40–75 per 100 000 population,315 with an incidence of about
eight new cases per 100 000. The tropical form of pancreatitis is
a major health problem in southern Africa and Asia, with, for
example, high prevalence rates of 114–200 and 25–50 per 100
000 reported for southern India,316 and Japan,317 318 respectively.
Although less common than acute pancreatitis, the incidence
of chronic pancreatitis is also increasing,319 particularly with
large increases in alcohol use in the UK population over the past
30 years.320 321 Between 1989–90 and 1999–2000 the hospital
admission rate for chronic pancreatitis doubled in England.304
There is a large geographical variation in the reported
incidence of chronic pancreatitis in Europe, partly reflecting
differences in alcohol consumption. High rates of 26, 23, and 14
per 100 000 have been reported for France,322 Finland,314 and
Stockholm County, Sweden,222 moderate rates of 5–8 per 100
000 in Luneberg County, Germany,309 Warsaw, Poland,323 and
the Czech Republic,314 and a low rate of 1.3 in Switzerland.314
Incidence of gastrointestinal cancer
Gastrointestinal cancer is the most common type of cancer in
Europe. Out of 2.1 million new cancers in Europe in 2000,
gastrointestinal cancers accounted for 579 542 or 28.3% of the
total.324 In the UK, there are about 60 000 new cases of
gastrointestinal cancer each year.
Of all cancers in men in England and Wales in 1997,
colorectal cancer was the third most common (incidence of 14
900, 13.7% of all new cases), while cancers of the stomach
(5800, 5.3%), oesophagus (3600, 3.3%), and pancreas (2700,
2.5%) were ranked 5th, 7th, and 10th, respectively.14
Among women, colorectal cancer was the second most
incident cancer (14 000, 12.4% of all new cancers), and cancers
of the stomach (3300, 2.9%), pancreas (3000, 2.7%), and
oesophagus (2500, 2.2%) were ranked 8th, 9th, and 12th,
respectively. Together, gastrointestinal cancers represent
around a quarter of all cancers in men (the most common
Table 3.2.9 Familial association in the lifetime risk of
developing colorectal cancer
Familial association Lifetime risk
More than two first degree relatives affected 1:3
Two first degree relatives affected 1:6
One first degree relative aged ,45 years affected 1:10
One first degree and one second degree relative affected 1:12
One first degree relative aged .45 years affected 1:17
General population 1:50
Source: Keighley, 2003.324
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cancer grouping by some margin), and one fifth of cancers in
women, behind only breast cancer.14 103
Colorectal cancer
Colorectal cancer is the most common type of gastrointestinal
cancer in the UK, with about 30 000 new cases a year, and an
incidence rate of about 50 per 100 000 population. It accounts
for just over half of all gastrointestinal cancers in the UK, and
mainly affects people aged between 50 and 80.324 Of all cancers,
when both sexes are included, colorectal cancer is the second
most common cancer in England and Wales.14
Risk factors for colorectal cancers include a family history of
bowel cancer, long term inflammatory bowel disease, high fat
diets with low consumption of fibre, smoking, and lack of
exercise. Table 3.2.9 illustrates the strong familial association
with colorectal cancer. The predisposition to colorectal cancer
among people with ulcerative colitis is well established,106 107 325
with relative risks as high as 21 cited.108 109 The link between
Crohn’s disease and colorectal cancer is less well documented,
although in recent studies it has been reported as comparable to
that for ulcerative colitis.108 326 327
From 1971 to 1997 in England and Wales, age standardised
incidence of colorectal cancer increased by about 10% in men
from about 45 to 50 per 100 000 population, and also increased
slightly in women from about 30 to 35 per 100 000.14
Gastric cancer
Gastric cancer is twice as common in men as in women, and
mainly affects older people: 80% of cases are diagnosed in
people aged between 60 and 80. There are currently about 10
000 new cases a year in the UK, representing about 15% of all
gastrointestinal cancers, with an incidence rate of approxi-
mately 17 per 100 000 population. In the past 30 years there has
been a change in the distribution of gastric cancers, with an
increase in the incidence of proximal tumours near the gastro-
oesophageal junction, but a larger decline in the incidence of
antral cancers that used to dominate.324
Risk factors include longstanding infection with Helicobacter
pylori, family history of gastric cancer, a history of gastric
polyps, and other disorders such as atrophic gastritis and
pernicious anaemia, poor hygiene and socioeconomic condi-
tions, malnutrition, heavy alcohol consumption, smoking, and
certain food products and preservatives, including salt and
pickled foods. Diets high in fresh fruit and vegetables seem to
protect against gastric cancers as they contain high levels of
antioxidant vitamins that are thought to protect the stomach
lining.
From 1971 to 1997 in England and Wales, the age
standardised incidence of gastric cancer fell by about 50% in
men from about 30 to 20 per 100 000, and almost halved in
women from about 15 to 8 per 100 000.14
Oesophageal cancer
There are about 7000 new cases of oesophageal cancer a year in
the UK, with an incidence rate of about 11 per 100 000
population. This represents about 11% of all gastrointestinal
cancers in the UK, which is higher than the 5.9% in Europe as a
whole. Oesophageal cancers mainly occur in people between
the ages of 60 and 80, and are three times more common in
men than in women.324
The most important risk factor is smoking, although others
include severe acid reflux from the stomach, heavy alcohol
consumption, obesity, a rare muscular disorder known as
achalasia, diet, and chewing of betel nuts. Although the
incidence of adenocarcinoma of the oesophagus is increasing
in several European countries, squamous cell carcinoma
remains the predominant histological type. In Europe, it is
estimated that 63% of all squamous cell carcinomas in men and
33% in women are attributable to smoking.328
It is unclear why oesophageal adenocarcinoma is on the
increase, although it is thought to be linked to the rise of
gastro-oesophageal reflux disease.21 329 From 1971 to 1997 in
England and Wales, age standardised incidence of oesophageal
cancer increased by about 50%, from 8 to 12 per 100 000
population in men, and from 4 to 6 per 100 000 in women.14
Pancreatic cancer
In the UK, there are about 6000 new cases of pancreatic cancer
a year (about 8% of all gastrointestinal cancers), with an overall
incidence rate of about 11 per 100 000 population. Cancers of
the pancreas are more common in men than in women, and are
predominantly diagnosed in the 50–70 year age group.324
Risk factors include pre-existing chronic pancreatitis, liver
cirrhosis, diabetes and a history of surgery to the upper
digestive tract, smoking, family history, and environmental
exposure to certain insecticides or chemicals such as gasoline.
Chronic pancreatitis is an especially important risk factor for
pancreatic cancer, with relative risks as high as 27 having been
reported.330
From 1971 to 1997 in England and Wales, age standardised
incidence of pancreatic cancer fell by approximately one sixth
in men from about 12 to 10 per 100 000 population, but
remained stable at about 7 per 100 000 in women.14
Liver cancer
Most liver cancers (about 95%) are metastatic: primary cancer
sites in order of frequency are colon and rectum, pancreas,
oesophagus, stomach, breast, lung, and kidney.324 There are
about 2300 new cases of primary liver cancer a year, with an
overall incidence of approximately 4 per 100 000 population.
Primary liver cancer accounts for about 3% of all gastrointest-
inal cancers in the UK, and is more common in men than in
women.
Risk factors for primary liver cancer include liver cirrhosis,
either of alcoholic aetiology, through hepatitis B or C infection,
or through inherited conditions such as haemochromatosis and
a1 antitrypsin deficiency, exposure to certain chemicals such as
vinyl chloride, smoking, and long term use of anabolic steroids.
Incidence of other gastrointestinal diseases and
related conditions
Appendicit is
Appendicitis refers to the inflammation of the appendix when it
becomes blocked. The blockage is thought to be caused by a
build up of thick mucus within the appendix, or by a stool that
enters the appendix from the caecum, or by swollen lymphatic
tissue within the appendix. The most common complication of
appendicitis is perforation, which is usually caused by a delay in
treatment, and which can lead to a periappendiceal abscess or
diffuse peritonitis.
Appendicitis can occur at any age, although it is rare in
children under 2 years of age. Incidence peaks in late teens and
early twenties, it declines with increasing age, and it is higher
in men than in women. Appendicitis has also been linked to
low fibre and refined carbohydrate diets, amoebiasis, bacterial
gastroenteritis, and mumps.
About 10% of the UK population will develop acute
appendicitis at some stage, and about 70 000 appendicectomies
are performed each year. The incidence of acute appendicitis
declined in the UK and in most other Western countries
between the 1930s and the early 1990s, and there was a further
reduction in hospital admissions for acute appendicitis, of 13%
among men and 19% among women in England during the
1990s.331
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Obesity
Obesity is not a gastrointestinal disorder but plays a significant
part in many diseases of the liver and gut. A recent report by the
Royal College of Physicians dealt with the growing epidemic of
obesity in the UK and outlined its impact on a number of
diseases, including heart disease, diabetes, and gastrointestinal
disorders such as gallstones, liver disease, and gastrointestinal
cancers.6 Other studies have also documented obesity as a risk
factor for a wide range of gastrointestinal diseases, such as
colorectal cancer,332–334 oesophageal cancer,334–336 gastric can-
cer,337 338 hepatocellular cancer,339 340 gallstone disease,328 333
alcoholic liver disease,341–343 non-alcoholic fatty liver dis-
ease,333 339 342 344–346 gastro-oesophageal reflux disease,17 Barrett’s
oesophagus,347 348 hiatus hernia,349 surgical complications,350 351
and prognosis for acute pancreatitis.352 353
The Royal College of Physicians recommend prevention
strategies targeted towards improvements in nutritional
labelling of foods, public education, and social marketing and
retailing, promotion of leisure-time sports and activities, NHS
priorities and planning, promoting healthy schools, ‘‘active
transport’’, further research and development, and promotion
of local level programmes.6
Alcohol related morbidity
Several of the gastrointestinal disorders covered in the previous
sections of this report, such as alcoholic liver diseases, upper
gastrointestinal haemorrhage from oesophageal varices, acute
and chronic pancreatitis, gastric, oesophageal and liver cancer,
and gastro-oesophageal reflux disease are linked to alcohol
consumption in varying proportions of cases. Alcohol has often
been associated with a wide range of other non-gastrointestinal
diseases and conditions such as injury from traffic accidents,
other trauma, violence, suicide, breast cancer, and haemor-
rhagic stroke, as well as being the direct cause of other
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Figure 3.2.7. Estimates of age
standardised population based incidence
rates (per 100 000 population) for the main
types of gastrointestinal cancer among men
and women in the UK, eastern Europe,
northern Europe, southern Europe, western
Europe, and in Europe in 1995. (A) For
colorectal cancer; (B) for oesophageal
cancer; (C) for gastric cancer; (D) for
pancreatic cancer. Notes: Western Europe
includes Austria, Belgium, France, Germany,
Luxembourg, Switzerland, and The
Netherlands. Eastern Europe includes
Belarus, Bulgaria, Czech Republic, Hungary,
Poland, Republic of Moldova, Russia,
Slovakia, and the Ukraine. Northern Europe
includes Denmark, Estonia, Finland, Iceland,
Ireland, Latvia, Lithuania, Norway, Sweden,
and the UK. Southern Europe includes
Albania, Croatia, Greece, Italy, Macedonia,
Malta, Portugal, and Spain. Europe refers to
all countries listed above for these four
regions. Source: Bray et al, 2002.328
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disorders such as alcoholic psychoses and alcoholic dependence
syndrome.354 In the UK in recent years, there have been reports
of increasing numbers of people admitted to general hospitals
with alcohol related illnesses, particularly in Scotland.220 355 356
For example, a recent study in Glasgow reported that during
one month, 51% of all gastroenterology inpatients had been
admitted owing to alcohol related conditions,357 and 65% of
these were caused by alcoholic liver disease.
Infectious intestinal diseases and food poisoning
Food poisoning and infectious intestinal disease (IID) are
important diseases in the UK. Food poisoning notifications and
laboratory reports of pathogens responsible for IID have been
falling in the past four years. However, in 2001, there were over
85 000 food poisoning notifications; and 1 in 60 people
consulted a GP for IID in England and Wales.358
Defaecation problems
Faecal incontinence, the involuntary loss of rectal contents at a
socially inappropriate time or place, is an underappreciated
condition, which affects at least 2% of adults in the community.
The prevalence in elderly people is up to 15%, and higher still
among those living in residential or nursing homes. However,
compared with urinary incontinence, the condition is
neglected.359 Neurological related bowel problems present a
heavy burden on nursing resources,360 361 with diseases or
conditions such as multiple sclerosis,362–364 Parkinson’s
disease,365 spina bifida,366 stroke,367 and spinal cord injuries,368–
370 associated with faecal incontinence or constipation, or both
in 50% or more cases.371 The management of constipation alone
can account for up to 10% of district nursing time.372
Biliary atresia
Biliary atresia is a disease of unknown cause in which all, or
part of, the extrahepatic bile ducts are obliterated, leading to
complete biliary obstruction. Biliary atresia is, however, a rare
condition with fewer than 50 cases annually in the UK and
Ireland.373
Short bowel syndrome (HPN)
Patients with a short small intestine as a result of disease or
surgery may need additional feeding. Home parenteral nutri-
tion (HPN) is a complex technology involving the intravenous
infusion of all nutrients required for life directly into a central
vein. These nutrients include carbohydrates, fat, amino acids,
electrolytes, trace elements, and water. The patient, or carer, is
taught to manage the complicated routine, enabling transfer of
care to the home. Patient referral patterns for HPN treatment
are inconsistent, with some regions in the UK having very few
patients receiving HPN. However, there are several large centres
in the UK where HPN is considered as an essential, life-saving
treatment. The point prevalence of patients receiving HPN in
the UK in 2003 was 8.8 per million. Prevalence was higher in
Scotland (12.9 per million) than in England (8.6), Wales (4.5),
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Figure 3.2.8 Standardised population
based incidence rates (per 100 000
population) for colorectal cancer in 27
different European countries, 2000. Source:
Keighley, 2003.324
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and Northern Ireland (9.6). There is considerable regional
variation in period prevalence of patients receiving HPN in the
UK: across strategic health authorities in the UK, prevalence
varied between 1 and 21 per million population, with higher
prevalence reflecting that HPN is more common in areas that
are close to major referral centres.374
Iron deficiency anaemia
Iron deficiency anaemia (IDA) resulting from gastrointestinal
bleeding is a common feature of many gastrointestinal
disorders, including colorectal and gastric cancers. Patients
investigated for IDA have been found to have gastrointestinal
cancers in about 5–20% of cases,375–377 while IDA is also one of
the most common presenting symptoms of coeliac disease.378
International comparisons of the incidence of
gastrointestinal cancers
Figure 3.2.7 shows estimates of population based incidence
rates for the main types of gastrointestinal cancer in the UK
and in other regions of Europe in 1995.328 Among men, the UK
had the third highest, age standardised incidence of oesopha-
geal cancer in Europe (12.9 per 100 000), after France (17.0)
and Hungary (14.9), with an overall rate of 9.9 for the whole of
Europe. Among women, the UK had the second highest
incidence of oesophageal cancer (5.9 per 100 000) after
Ireland (6.6), with an overall rate of 1.9 for Europe.328
Incidence rates for gastric cancer among men and women in
the UK were similar to those in western Europe and in northern
Europe, but lower than in eastern Europe, southern Europe and
Europe overall. Incidence of gastric cancer was highest in
eastern Europe, and probably reflects the relatively low levels of
affluence in these countries, and the resulting poor diet of their
inhabitants. For both colorectal and pancreatic cancers,
incidence in the UK among both men and women was very
similar to those in Europe overall.328
Figure 3.2.8 shows incidence rates of colorectal cancers in the
UK and in 26 other European countries in 2000. Incidence rates
vary greatly across countries among men, although the highest
rates were in eastern European states such as the Czech
Republic (60.3 per 100 000), Hungary (59.8), and Slovakia
(50.6). The rate for the UK (35.4) is similar to the average of
these 27 countries (35.9). Among women, there is considerably
less variation in national rates, with the UK incidence rate
(25.3) similar to the European average of 24.2. The UK ranked
as 13th of 27 for highest incidence of colorectal cancer in men,
and 11th for women.
3.3 Mortality from gastrointestinal diseases
Of 533 329 deaths in England and Wales in 2000, 59 959
(11.2%) had a gastrointestinal disease as the certified under-
lying cause of death. These include diseases of the digestive
system (37% of all deaths from gastrointestinal disease),
malignant neoplasms of the digestive system (62%), benign
and other neoplasms of the digestive system (0.1%), intestinal
infectious diseases (0.9%), and viral hepatitis (0.3%; tables 3.3.1
and 3.3.2).
Diseases of the digestive system, which exclude gastrointest-
inal neoplasms and infectious diseases, ranked as the fourth
ICD chapter that accounted for most deaths in England and
Wales in 2000, after diseases of the circulatory system (207 228
deaths), neoplasms (134 793), and diseases of the respiratory
system (92 461).
Table 3.3.1 Population based mortality rates for the different ICD-9 chapters in England and Wales, 1990 and 2000
Underlying cause of death ICD-9 chapter ICD-9 code
2000 1990
No of deaths
Mortality rate per
100 000 population No of deaths
Mortality rate per
100 000 population
Infectious and parasitic diseases: I 001–139 3 767 7.1 3 046 6.0
Intestinal infectious diseases 001–009 547 1.0 187 0.4
Viral hepatitis 070 200 0.4 112 0.2
All other infectious diseases 010–069, 071–139 3 020 5.7 2 749 5.4
Neoplasms: II 140–239 134 793 254.6 144 577 285.1
Malignant neoplasms of the digestive system 150–159 37 004 69.9 40 965 80.8
Benign and other neoplasms of the digestive
system
210, 211, 230, 235.2–
235.5
74 0.1 66 0.1
All other neoplasms 140–149 etc, 97 715 184.6 103 646 204.2
Endocrine, nutritional and metabolic disorders,
and immunity disorders
III 240–279 7 247 13.7 10 249 20.2
Diseases of blood and blood-forming organs IV 280–289 1 791 3.4 2 427 4.8
Mental disorders V 290–319 10 866 20.5 13 395 26.4
Diseases of the nervous system and sense
organs
VI 320–289 9 632 18.2 11 644 23.0
Diseases of the circulatory system VII 390–459 207 228 391.4 259 247 511.1
Diseases of the respiratory system VIII 460–519 92 461 174.6 61 018 120.3
Diseases of the digestive system IX 520–579 22 134 41.8 18 429 36.3
Diseases of the genitourinary system X 580–629 7 270 13.7 7 317 14.4
Complications of pregnancy, childbirth and the
puerperium
XI 630–676 38 0.1 57 0.1
Diseases of the skin and subcutaneous system XII 680–709 1 266 2.4 823 1.6
Diseases of the musculoskeletal system and
connective tissue
XIII 710–739 3 407 6.4 5 286 10.4
Congenital abnormalities XIV 740–759 1 165 2.2 1 621 3.2
Certain conditions originating to the perinatal
period
XV 760–779 83 0.2 249 0.5
Symptoms, signs and ill-defined conditions XVI 790–799 13 656 25.8 4 897 9.7
Injury and poisoning XVII 800–999 16 525 31.2 17 943 35.4
Total gastrointestinal diseases 001–009,070, 150–
159,210, 211,230, 235.2–
235.5, 520–579
59 959 113.3 59 759 117.8
All causes of death I–XVII 1–999 533 329 1007.4 562 225 1108.5
Sources: ONS, 2001;379 OPCS, 1992.380
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Figure 3.3.1 shows population based mortality rates for each
major body system when deaths from cancer were allocated to
their respective body systems; for example, when gastrointest-
inal cancers were included with diseases of the digestive
system, when respiratory cancers were included with diseases
of the respiratory system, etc. Then, gastrointestinal disease
was the third body system that accounted for the most deaths
(59 000), after circulatory diseases (207 000) and respiratory
diseases (123 000). Among people aged 15–64 years, however,
the mortality rate for gastrointestinal diseases was roughly
equal to that from respiratory diseases, as the leading major
cause of death after circulatory diseases among working aged
people (fig 3.3.2).
The number of deaths from diseases of the digestive system
in 2000 increased by 20% from 18 429 in 1990. Deaths
from malignant neoplasms of the digestive system fell by
10% from 40 965 in 1990, and the small numbers of deaths
from intestinal infectious diseases and from viral hepatitis
Table 3.3.2 Population based mortality rates for different gastrointestinal diseases in England and Wales, 1990 and 2000
Underlying cause of death ICD-9 code
2000 1990
No of deaths
Mortality rate per
100 000 population No of deaths
Mortality rate per
100 000 population
Diseases of the digestive system:
Diseases of oral cavity, salivary glands and
jaws
520–529 33 0.1 18 0.0
Oesophagitis 530.1 143 0.3 110 0.2
Other diseases of oesophagus 530.2–530.9 446 0.8 456 0.9
Peptic ulcer 531–534 4 022 7.6 4 381 8.6
Gastritis and duodenitis 535 168 0.3 96 0.2
Other disorders of stomach and duodenum 536–537 103 0.2 104 0.2
Appendicitis 540–543 139 0.3 148 0.3
Hernia of abdominal cavity 550–553 721 1.4 771 1.5
Crohn’s disease 555 166 0.3 190 0.4
Ulcerative colitis 556 184 0.3 190 0.4
Vascular insufficiency of intestine 557 1 883 3.6 1 483 2.9
Other non-infective gastroenteritis and colitis558 501 0.9 341 0.7
Intestinal obstruction without mention of
hernia
560 1 396 2.6 1 217 2.4
Diverticular of intestine 562 1 826 3.4 1 466 2.9
Peritonitis 567 562 1.1 313 0.6
Other diseases of intestines and peritoneum564–566,568,569 1 134 2.1 698 1.4
Chronic liver disease and cirrhosis 571 4 770 9.0 3 063 6.0
Other disorders of liver 570,572,573 412 0.8 320 0.6
Cholelithiasis, cholecystitis and other
disorders of the gallbladder
574–575 784 1.5 673 1.3
Other disorders of biliary tract 576 324 0.6 261 0.5
Acute pancreatitis 577.0 848 1.6 793 1.6
Chronic pancreatitis 577.1 77 0.1 88 0.2
Other diseases of the pancreas 577.2–577.9 37 0.1 30 0.1
Gastrointestinal haemorrhage 578 1 429 2.7 1 167 2.3
Intestinal malabsorption 579 26 0.0 52 0.1
Total diseases of the digestive system 520–579 22 134 41.8 18 429 36.3
Benign and other neoplasms of the
digestive system
210, 211, 230, 235.2–235.5 74 0.1 66 0.1
Malignant neoplasms, digestive system:
Oesophagus 150 6 061 11.4 5 259 10.4
Stomach 151 5 779 10.9 8 712 17.2
Small intestine 152 269 0.5 210 0.4
Colon 153 9 554 18.0 11 527 22.7
Rectum, rectosigmoid junction and anus 154 4 682 8.8 5 696 11.2
Liver and intrahepatic ducts 155 2 091 3.9 1 388 2.7
Gallbladder and extrahepatic ducts 156 527 1.0 813 1.6
Pancreas 157 6 105 11.5 6 145 12.1
Retroperitoneum and peritoneum 158 186 0.4 192 0.4
Other and ill-defined sites, digestive system 159 1 750 3.3 1 023 2.0
Total malignant neoplasms, digestive system150–159 37 004 69.9 40 965 80.8
Intestinal infectious diseases:
Cholera 001 0 0.0 0 0.0
Typhoid and paratyphoid fevers 002 0 0.0 2 0.0
Other salmonella infections 003 13 0.0 68 0.1
Shigellosis 004 0 0.0 0 0.0
Other food poisoning (bacterial) 005 1 0.0 1 0.0
Amoebiasis 006 1 0.0 0 0.0
Other protozoal intestinal diseases 007 1 0.0 4 0.0
Intestinal infections due to other organisms 008 452 0.9 43 0.1
Ill-defined intestinal infections 009 79 0.1 69 0.1
Total intestinal infectious diseases 001–009 547 1.0 187 0.4
Viral hepatitis 070 200 0.4 112 0.2
Total gastrointestinal diseases 001–009,070, 150–159,210,
211,230,235.2–235.5,,520–579
59 959 113.3 59 759 117.8
Sources: ONS, 2001379; OPCS, 1992.380
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respectively, almost trebled and increased by 80% from 1990 to
2000 (table 3.3.2).
The major causes of death from diseases of the digestive
system, excluding gastrointestinal cancers, in 2000 were liver
cirrhosis (22%), peptic ulcer (18%), vascular insufficiency of the
intestine (9%), diverticular disease of the intestine (8%), and
gastrointestinal haemorrhage (6%; fig 3.3.3).
Gastrointestinal cancer is the most common cause of cancer
death of all major cancer groupings. In England and Wales in
2000, gastrointestinal cancers caused 27% of all cancer deaths,
followed by respiratory cancers (23%) and cancers of the
genitourinary system (17%; fig 3.3.4). The gastrointestinal tract
was also the most common site for all cancer deaths (fig 3.3.5).
Figure 3.3.6 shows the most common sites for all gastro-
intestinal cancer deaths. These were the colon and rectum (39%
of all gastrointestinal cancer deaths), the pancreas, the
oesophagus, and the stomach (16% each).
Table 3.3.3 shows the number of deaths and corresponding
population based mortality rates in England and Wales in 2000
among working aged people (aged 15–64 years) for some of the
most common diseases and causes of death in the general
population. The mortality rate for diseases of the digestive
system (16.3 per 100 000 population) was lower than that from
all cancers (97.6) and from ischaemic heart disease (43.4), but
was about twice as high as for stroke and for pneumonia, six
times higher than for diabetes mellitus, and 12 times higher
than for asthma. If gastrointestinal cancers are included with
diseases of the digestive system as gastrointestinal diseases, the
corresponding mortality rate (39.9) was only slightly lower
than for ischaemic heart disease, and much higher than for
stroke, pneumonia, diabetes mellitus, chronic airways obstruc-
tion, and asthma (fig 3.3.7).
Mortality statistics, based on underlying cause of death, to
some extent underreport true mortality from gastrointestinal
diseases and, importantly, this underreporting is greater for
gastrointestinal diseases than for the two other major causes of
death, circulatory and respiratory diseases. The following
sections describe mortality rates and patterns in the UK for
some of the main gastrointestinal disorders in anatomical
sequence.
Mortality from diseases of the stomach and duodenum
Peptic ulcer
Although the incidence of peptic ulcer has fallen sharply in the
UK in recent years, it was still the second largest cause of
gastrointestinal death, after liver cirrhosis, in England and
Wales in 2000, with over 4000 deaths and a mortality rate of 7.6
per 100 000 population (table 3.3.2).
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Figure 3.3.1 Population based mortality
rates for major disease groupings, in
England and Wales, 2000: people of all
ages. Source: ONS, 2001.379
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Figure 3.3.2 Population based mortality
rates for major disease groupings, in
England and Wales, 2000: people aged 15–
64 years. Source: ONS, 2001.379
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Patient deaths after hospital admission for peptic ulcer in the
UK between 1991 and 1994 was reported as 4.4%,381 with
increased risks of mortality for patients who had no previous
history of peptic ulcer (relative risk = 3), or who were under-
going surgery, were elderly or were current users of non-
steroidal anti-inflammatory drugs. Much higher case fatality
rates of 34% for perforated peptic ulcer,382 and 43% for
perforated duodenal ulcer,383 have been reported in regional
British studies.
Gastrointestinal haemorrhage
Gastrointestinal haemorrhage was the cause of almost 1500
deaths in England and Wales in the year 2000, with a
population based mortality rate that had risen by over 17%
since 1990 (table 3.3.2).
Patient deaths for upper gastrointestinal haemorrhage vary
in the UK from about 5% to 15% (table 3.3.4), although lower
rates of less than 4% have been reported.89 90 Case fatality varies
strongly according to case mix, which would explain some of
the geographical variation; while, as ever, case fatality is
affected by factors such as the length of follow-up and the
inclusion of deaths after discharge with in-hospital deaths.
Case fatality for upper gastrointestinal haemorrhage is
increased in surgical cases, and for cases of haemorrhages in
inpatients. For example, surgical mortality rates of 13–41%
have been reported from studies since the 1980s,84 85 89 while
case fatality for haemorrhages in inpatients of 18–45% have
also been reported.73 74 86 87 90 91 334 335 387 Other important risk
factors include gastrointestinal malignancies or other pre-
existing comorbidity, shock, and advanced age.92 391 398 Despite
improvements in treatment and management over time, a lack
of impact on patient deaths is probably linked to older ages at
presentation, increases in comorbidities,399 and less selective
reporting over time.400
Mortality from diseases of the small bowel and colon
Inf lammatory bowel disease
Inflammatory bowel disease is a major cause of debilitating
morbidity, particularly among young adults, rather than a
major cause of mortality. In the year 2000 in England and
Wales, there were only 166 and 184 deaths, respectively, which
were certified with Crohn’s disease and ulcerative colitis as the
underlying causes of death.
Most British population based studies have found no
increased mortality among people with inflammatory bowel
disease. For example, a study in Leicestershire reported
standardised mortality ratios (SMRs) of 0.72 (compared to a
mortality of 1.00 in the general population) for Crohn’s
disease,401 and 0.93 for ulcerative colitis,402 among European
subjects; another study of three district hospital general centres
reported SMRs of 0.94 for Crohn’s disease and 0.93 for
ulcerative colitis.403
However, some population based studies have reported
increased mortality. For example, a study of Crohn’s disease
in Cardiff from 1934 to 1976 reported a significantly increased
SMR of 2.2, that was particularly high in people aged under 20
(SMR of 11.0).404 Another study, a national UK primary care
based study during the 1990s, reported significantly increased
hazard ratios of 1.7 for Crohn’s disease and 1.4 for ulcerative
colitis. The hazard ratios were more highly increased among
younger age groups: 3.8 among people aged 20–39 years with
Crohn’s disease, and 1.8 among those aged 40–59 with
ulcerative colitis.405
Coeliac disease
Although coeliac disease is not usually recorded as an under-
lying cause of death, people with coeliac disease have been
shown to be at moderately increased risks of mortality. For
example, cohort studies in Scotland, Italy, and Sweden have
reported increased mortality of 1.9- to 3.8-fold respectively,406–409
with excess mortality often caused by malignant lymphomas or
malignancies of the gastrointestinal tract.406–410
Diverticular disease
Diverticular of the intestine is quite a common cause of death in
the UK, accounting for 1826 deaths in England and Wales in
2000. Population based mortality rates for diverticular disease
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Figure 3.3.3 Percentage causes of all deaths from diseases of the
digestive system (excluding cancers) in England and Wales, 2000. Source:
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increased greatly over the course of the 20th century, although
this probably reflects an increase in the use of barium enema
diagnostic testing and changing fashions of death certification,
as well as a true increase in the prevalence of diverticular
disease. From 1979 to 1999, age standardised population based
mortality rates remained fairly constant in England at about 1.5
per 100 000 population in men and 2.25 per 100 000 in
women.212
Mortality rates after hospital admission for diverticular
disease are fairly low. From 1989–90 to 1990–2000 in
England, age standardised in-hospital case fatality rates were
about 2.5% and 3.5% among men and women respectively,212
while a recent study in London reported case fatality of 9.5% at
one year after admission.411
Higher mortality is associated with the severe complications
such as perforated diverticular.203 For example, a recent study in
Exeter reported a case fatality rate of 5.7% for acute complica-
tions of diverticular disease, which rose to 18% for those
undergoing surgery412; a study in Birmingham reported case
fatality of 11% for acute complications of diverticular disease
from 1985–88413; and a study in Glasgow reported surgical
mortality of 26% for perforated diverticular disease from 1976
to 1983.414
Mortality from diseases of the liver
Chronic liver disease and cirrhosis
Chronic liver disease and cirrhosis is one of the major causes of
death from gastrointestinal disease in the UK. Cirrhosis
mortality increased by 50% in England and Wales from 6 to 9
per 100 000 population during the 10 year period from 1990 to
2000 (table 3.3.2). From 1957–61 to 1997–2001 it increased by
over threefold among men in England and Wales and in
Scotland, by 250% among women in England and Wales, and
by 160% among women in Scotland.415 Other studies have
reported increases of 350% in England from 1970 to 1998,416
and 112% in the West Midlands from 1993 to 2000.417
This contrasts with a fall of almost 30% in the EU average
cirrhosis mortality rate of 14 to 10 per 100 000 from 1970 to 1998.
Together with a rise in national alcohol consumption,320 321 and in
hospital admissions for alcoholic liver disease,220 the increase in
cirrhosis mortality in the UK has led to the recent publication of a
national alcohol harm reduction strategy.221
In recent years, the large increases in the number of people
infected with the hepatitis C virus, who have a rapid
progression of liver cirrhosis,234 and a poor outcome,418 have
also contributed towards the increase in cirrhosis mortality.234
Hepatitis C infection has also been the subject of national
strategy and action plan documents in England.228 232
Mortality after hospital admission with chronic liver disease
and cirrhosis is extremely high, and does not appear to have
improved in the past 40 years.217 419 Mortality varies greatly
according to aetiology: case fatality rates of 40% for alcoholic
cirrhosis and 17% chronic hepatitis were reported from an
earlier study of west Birmingham in 1959–76.217 Mortality from
chronic liver disease and cirrhosis is still relatively low
compared with that in many other European countries
(fig 3.3.8). However, while cirrhosis mortality rates have been
falling in most European countries in recent years, there has
been a sharp increase in mortality in the UK (fig 3.3.9).
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Figure 3.3.6 Percentage causes of all gastrointestinal cancer deaths,
according to the site of the cancer, in England and Wales, 2000. Source:
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Table 3.3.3 Population based mortality rates for selected causes of death among people
aged 15–64 years in England and Wales, 2000
Cause of death ICD-9 code No of deaths
Mortality rate per
100 000 population
Diseases of the digestive system 520–579 5 488 16.3
Diabetes mellitus 250 864 2.6
Ischaemic heart disease 410–444 14 567 43.4
Stroke 431–434, 436 2 375 7.1
Pneumonia 480–486 2 879 8.6
Asthma 493 437 1.3
Chronic airways obstruction 496 1 700 5.1
Neoplasms 140–239 32 795 97.6
Source: ONS, 2001.379
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Figure 3.3.7 Population based mortality rates (per 100 000 population)
for selected causes of death among people aged 15–64 years in England
and Wales, 2000. *Gastrointestinal diseases include diseases of the
digestive system, malignant neoplasms of the digestive system, benign and
other neoplasms of the digestive system, intestinal infectious diseases, and
viral hepatitis. Source: ONS, 2001.379
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Gallstone disease
Cholelithiasis, cholecystitis, and other diseases of the gallblad-
der were the cause of almost 800 deaths in England and Wales
in 2000. Age standardised mortality for cholelithiasis fell from
about 8.5 to 5.5 per 100 000 population in England from 1979 to
1989, but has not fallen since.271
Case fatality after hospital admission for gallstones fell by
one third in men (from 0.6% to 0.4%) and by 42% in women
(from 0.5% to 0.3%) in England from 1989–90 to 1999–2000.271
Although death rates after admission for gallstones are low,
reported risk factors include acute pancreatitis, liver cirrhosis,
age, acute cholecystitis, and diabetes.421
Mortality from diseases of the pancreas
Acute pancreati t is
Acute pancreatitis was the underlying cause of about 850
deaths in England and Wales in 2000. Population based
mortality for acute pancreatitis in England and Wales increased
slightly from 1.56 per 100 000 population in 1990 to 1.60 in
2000 (table 3.3.2), which had increased from 1.37 per 100 000
in 1980. A slightly lower mortality rate of 1.23 per 100 000
population was reported for Northern Ireland in 1974–83,422
while mortality increased from 2.7 to 4.0 per 100 000 in
Nottingham from 1969 to 1983.423
Table 3.3.4 Case fatality rates (% of cases) after hospital admission for upper gastrointestinal
haemorrhage, as reported from regional studies in the UK
City/region Study period No of cases
Case fatality rate
(%) Authors and reference
NW London 1940–1947 687 9.9 Jones AF, 1947384
Aberdeen 1941–1948 476 13.9 Needham CD and McConachie JA,
1950385
London 1947–1958 325 13.0 Coghill NF and Willcox RG, 1960386
Oxford 1953–1967 2149 8.9 Schiller KF et al, 197084
Birmingham 1963–1974 158 12.0 Hoare AM, 1975387
NE Scotland 1967–1968 817 13.7 Johnston SJ et al, 197386
Birmingham 1971–1973 300 9.7 Allan R and Dykes P, 1976388
Cardiff 1972–1978 583 10.3 Mayberry JF et al, 1981389
Bristol 1974–1976 267 4.4 Brown SG et al, 1981390
West Lothian 1980–1983 326 11.7 Clason AE et al, 1986391
Newport, Gwent 1980–1981 330 15.2 Madden MV and Griffith GH, 198587
Oxford 1981–1982 125 4.8 Berry AR et al, 198485
Bath 1981–1985 NA 10–12 Holman RA et al, 199089
North London 1986 292 4.8 Sanderson JD et al, 1990392
Bath 1986–1988 430 3.7 Holman RA et al, 199089
Nottingham 1986–1989 1147 6.1 Daneshmend TK et al, 1992393
Bridgend 1990 109 4.6 Clements D et al, 1991394
NE Scotland 1991–1993 1098 3.9 Masson J et al, 199690
4 Health Regions in SE
England and Midlands
1991–1993 4185 14 Rockall TA et al, 199591
West of Scotland 1992–1993 1882 8.1 Blatchford O et al, 199792
Newport, Gwent 1993–1995 524 9.4 Kapur KC et al, 1998395
Sheffield 1995–1998 900 8.1 Sanders DS et al, 2004396
Sutton Coldfield 2002–2003 716 14.6 Lim CH et al, 2006397
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Almost all people with acute pancreatitis are admitted to
hospital. Case fatality has fallen over time from about 30% to
roughly 10%, although as there seems to have been little further
improvement in recent years, it remains a lethal disease. Case
fatality at one year after admission for acute pancreatitis fell
only slightly in four counties of southern England from 13.5%
in 1963–74 to 11.8% in 1987–98.303 However, it appears to have
fallen more sharply in Scotland; with reported reductions from
17.6% in 1961–65 to 5.6% in 1981–85,305 and from 9.1% to 6.6%
from 1984 to 1994.306
Other British studies have reported case fatality of 9.1% in
the Wessex region in 1994–95,288 9.0% in the North West
Thames region in 1988–92,424 6.3% in Somerset in 1991–95,290
5.4% in Nottingham in the late 1990s,425 and 17% in
Cottingham in 1998.426 Reported mortality rates for acute
pancreatitis in England have been comparable or slightly
higher than those in Europe. For example, case fatality was
6.1% in Luneberg, Germany from 1980 to 1994,427 5% in an
Italian multicentre study in 1996–2000,428 7.5% in north Jutland
from 1981 to 2000,308 and 10.7% in the Netherlands in 1995.310
Prognosis depends strongly on disease severity, with much
higher case fatality in severe cases; which can be as high as 50%
for surgery or for infected pancreatic necrosis.283 429 For
example, two Scottish studies reported case fatality of 38%
and 43% for pancreatic necrosectomy,430 431 and a study in
London reported mortality of 39% for severe cases.432 The Italian
multicentre study reported case fatality that varied between
1.7% for mild acute pancreatitis and 17% for severe cases,428 a
Swedish study reported mortality of 27% in severe cases,433
while a German study reported mortality of 17% for necrotising
pancreatitis, compared with 5% overall.434
Chronic pancreatit is
Although chronic pancreatitis is rarely recorded as an under-
lying cause of death—in only 77 cases in England and Wales in
2000—it often leads to substantially increased risks of
mortality. For example, an American study identified an SMR
of 3.6 for people who underwent treatment for chronic
pancreatitis, with prognosis influenced strongly by age at
diagnosis, alcohol consumption, and smoking.435 In particular,
chronic pancreatitis often leads to increased risks of pancreatic
cancer,330 436–440 which carries a very poor prognosis.
Mortality from gastrointestinal cancers
Colorectal cancer
Colorectal cancer is the most common cause of death from
gastrointestinal cancer, causing 39% of all gastrointestinal
cancer deaths, and 11% of all cancer deaths, in England and
Wales in 2000. There were over 14 000 deaths from colorectal
cancers in England and Wales in 2000, with a population based
mortality rate of 27 per 100 000, which has fallen in recent
decades.14
Prognosis for colorectal cancer is substantially better than for
most other gastrointestinal cancers. Five year survival rates
after diagnosis with colorectal cancer were 35% for men, and
39% for women in England and Wales between 1996 and
1999.441 These had increased from 31% and 35% respectively, in
1991–95. Over 80% of people with colorectal cancers in Europe
undergo surgical treatment, and five year survival after surgical
resection ranges from 40% to 60% depending on the stage of the
tumour.324
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Table 3.3.5 Percentage five year survival after diagnosis for the main types of gastrointestinal
cancers in various European countries
Country
Gastrointestinal cancer
Oesophageal (%) Gastric (%) Pancreatic (%) Colorectal (%)
Liver (all cases)
(%)
Austria 14 28 9 49 11
Denmark 5 14 2 41 1
Estonia 3 19 1 39 2
Finland 8 21 3 49 4
France 9 25 8 50 8
Germany 8 27 4 48 6
Iceland 25 24 3 52 9
Italy 8 24 4 37 4
Netherlands 12 20 2 55 0
Poland 3 11 4 25 3
Slovakia 8 19 8 39 5
Slovenia 3 16 3 35 0
Spain 9 28 5 48 10
Sweden 14 17 3 51 4
Switzerland 15 24 2 52 3
UK 9 12 3 41 4
Average of the 16
European countries
9.6 20.6 4.0 44.4 4.6
Source: Keighley, 2003.324
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Survival rates for colorectal cancer in the UK have been rising
steadily over the past three decades, but substantial interna-
tional differences suggest that there is considerable scope for
further improvement: five year survival in the UK is lower than
in Europe as a whole (table 3.3.5). The contrast in survival for
the UK and western Europe is particularly marked for colon
cancer, which often presents in an advanced state as an
emergency, with a relatively poor prognosis. This further
indicates that the poor survival in the UK has been mainly
due to late diagnosis. Some studies have linked late diagnoses
in the UK to patients’ GP consultation behaviour: for example,
while rectal bleeding is a common symptom that affects up to
15% of adults,43 and is often an important symptom of colon
cancer,442 443 many patients don’t seek medical advice.444
Survival rates are also lower in Europe than in the USA.445
This has also been attributed to diagnoses at earlier stages in
the USA, as well as a higher proportion of cancers in the USA
that are coded as adenocarcinoma in polyp, and which have a
better prognosis.445
Oesophageal cancer
Cancers of the oesophagus represented over 6000 deaths in
England and Wales in 2000, or 4.5% of all cancer deaths, with a
mortality rate that has increased in recent decades.14
Five year survival after diagnosis with oesophageal cancer in the
UK (9%) is slightly lower than a European average of 9.6%
(table 3.3.5). The poor prognosis is largely due to the spread of
tumours from the wall of the gullet, by the time of diagnosis. In
Europe, only about one quarter of all oesophageal cancers are
operable and, of these, five year survival is only about 20–30%.324
Gastric cancer
Cancers of the stomach are also responsible for 4.5% of all
cancer deaths in the UK. In England and Wales in 2000, there
were a total of 5779 deaths from gastric cancers, with a
corresponding mortality rate of 10.9 per 100 000 population,
which has fallen over time.14
The five year survival of about 12% in the UK is much lower
than a European average of 21% (table 3.3.5). In Europe, only
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Figure 3.3.10 Estimates of age
standardised population based mortality
rates (per 100 000 population) for different
gastrointestinal cancers among men and
women in the UK, eastern Europe, northern
Europe, southern Europe, western Europe,
and in Europe, 1995. (A) For colorectal
cancer; (B) for oesophageal cancer; (C) for
gastric cancer; (D) for pancreatic cancer.
Notes: Western Europe includes Austria,
Belgium, France, Germany, Luxembourg,
Switzerland, and the Netherlands. Eastern
Europe includes Belarus, Bulgaria, Czech
Republic, Hungary, Poland, Republic of
Moldova, Russia, Slovakia, and the Ukraine.
Northern Europe includes Denmark, Estonia,
Finland, Iceland, Ireland, Latvia, Lithuania,
Norway, Sweden, and the UK. Southern
Europe includes Albania, Croatia, Greece,
Italy, Macedonia, Malta, Portugal, and
Spain. Europe refers to all countries listed
above for these four regions. Source: Bray et
al, 1997.328
Gastroenterology services in the UK 27
www.gutjnl.com
group.bmj.com on February 10, 2015 - Published by http://gut.bmj.com/Downloaded from 
about 60% of gastric cancers are resectable when first
diagnosed and surgical resection for cure is only achieved in
about 40% of cases. Five year survival after surgical resection is
closely related to the spread of the tumour, and varies from 95%
for early cancers to only 20% for extensive lesions.324
Pancreatic cancer
Cancer of the pancreas also caused 4.5% of all cancer deaths in
England and Wales in 2000 (6105 deaths), with a population
based mortality rate of 11.5 per 100 000 that has remained
fairly stable since the 1970s.14
Prognosis after diagnosis remains extremely poor. Survival is
about 2% at five years among both men and women in England
and Wales (table 3.3.5).441 A small minority (about 7%) of
pancreatic cancers occur around the distal end of the bile and
pancreatic ducts, present early and have relatively good prognosis.
The rest, however, are located in the main body of the pancreas,
present late and have dismal prognosis. In Europe, only 10% of
pancreatic cancers are resectable, and the overall postoperative
five year survival rate is only 10–15%.324 Prognosis in the UK is
slightly worse than in the rest of Europe (table 3.3.5).
Liver cancer
Liver cancer caused 2091 deaths in England and Wales in 2000
and mortality has been increasing since the 1960s. Age
standardised mortality rates per 100 000 population increased
from 1.29 to 1.93 in women, and from 2.56 to 3.70 in men,
between 1968 and 1996.446
Prognosis for liver cancer is also extremely poor (table 3.3.5).
Five year survival in the UK was recently reported as 4%.324 This
is largely because 95% of liver cancers are secondary deposits
from tumours located elsewhere. Prognosis is slightly worse
than the European average of 4.6% (table 3.3.5).
International comparisons of gastrointestinal cancer
Figure 3.3.10 shows population based mortality rates for each
of the four main types of gastrointestinal cancer in the UK and,
for comparison, with corresponding age standardised rates in
other regions of Europe. Mortality from cancer of the
oesophagus is particularly high in the UK (fig 3.3.10B), among
both men and women, and it is higher than that in all other
European countries presented here, except France (for men)
and Ireland (for women).
Mortality from gastric cancer, which is particularly high in
eastern Europe (fig 3.3.9C), is substantially lower in the UK
than in the rest of Europe. Death rates from colorectal cancer in
the UK are similar to the European average, while mortality
from pancreatic cancers in the UK is about average in women,
but slightly lower in men.
Figure 3.3.11 shows large variation in mortality rates for
colorectal cancer among men across 27 different European
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countries in 2000. Highest colorectal cancer mortality is found
in eastern European countries such as the Czech Republic,
Hungary, and Slovakia, with the UK mortality rate of 18.7 per
100 000 population similar to the European average of 19.1.
Among women, there is much less variation, with the UK again
similar to the European average.
Figure 3.3.12 shows incidence to mortality ratios for color-
ectal cancers in the 27 European countries in 2000. The highest
mortality ratios among men were in Lithuania (0.72), Latvia
(0.70), and Denmark (0.61), and among women in Latvia
(0.70), Iceland, and Lithuania (both 0.63). Mortality ratios in
the UK, 0.55 and 0.53 for men and women, respectively, were
similar to the corresponding European averages.
3.4 Morbidity, quality of life
Although the data for mortality and activity in hospital and
primary care are relatively reliable, they do not describe the
burden of chronic GI diseases on the lives of sufferers. Several
common chronic conditions—gastro-oesophageal reflux disease
(GORD), non-ulcer dyspepsia, irritable bowel syndrome (IBS),
and inflammatory bowel disease (IBD)—have mortality rates
that are similar to those of the general population.447 Consulting
rates vary, with some people more likely to opt for self care or
alternative complementary therapies.53 Activity data reflect the
burden on the health service, therefore, more than on the
population.
Objective evidence or clinical assessment and self reported
symptoms do not match well.20 Because of this there has been
an increasing focus in health care generally, and in gastro-
enterology, in particular, on assessing patients’ health related
quality of life (HRQoL). Measurements of HRQoL can be used
to identify problems of individual patients or populations, to
enhance understanding of diseases, and to assess health
technologies, treatments, and service delivery.448
Using self reported HRQoL, the prevalence of functional GI
disorders in a population in Australia was found to be 34.6%.449
Sufferers were found to be more likely to have impaired mental
health and physical functioning, measured by the SF12, an
effect which was intensified amongst those who sought
treatment. Halder et al emphasised the confounding effect of
the psychological state, and suggested that some of the
association between IBS/dyspepsia and HRQoL can be
explained by psychological factors.450 Gastrointestinal symp-
toms in the elderly were found to be common in a study in
Minnesota, with chronic constipation and chronic diarrhoea
having prevalences of 24% and 14%, respectively. Faecal
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incontinence more than once a week was reported in 3.7%. IBS
was estimated from reported symptoms to be a condition for
10.9%. Only 23% had seen a physician during the previous year,
and attendance did not correlate well with symptom report-
ing.53
Borgaonkar and Irvine’s review of HRQoL measures for GI
diseases summarised research into the impact of chronic GI
disorders on the quality of life of patients.447 HRQoL measures
can be global, generic or disease-specific. Disease-specific tools
have been developed to measure HRQoL for patients in each of
the disease groupings below.
N Symptoms of GORD occur in about 40% of adults each
month, and in 7% daily. Symptoms such as heartburn,
regurgitation, and chest pain substantially impair HRQoL
and over half of patients require treatment. Patients with
GORD were reported to feel as seriously affected as patients
with cardiovascular disease, with SF36 physical functioning
scores worse than for patients with acute myocardial
infarction, and social function scores lower than for patients
with congestive heart failure.
N Dyspepsia occurs in 25% of the general population, with
patients reporting considerable anxiety, abdominal pain,
interruption of daily activities, and decreased sexual drive.
N Irritable bowel syndrome is a commonly experienced
disorder, with a prevalence of up to 22%. Sufferers report
abdominal pain, altered bowel habit, and disturbed sensory
and motor function, as well as symptoms elsewhere in the
body—back pain, headache, dyspareunia, urinary symp-
toms, and sleep disturbances. People with IBS have
significantly poorer SF36 scores than healthy controls, and
patients have difficulty travelling, playing sports, and
attending social events. Sufferers take time off work and
finish their working lives at a young age.
N Patients with IBD have been shown to have impaired HRQoL
compared with healthy controls in physical, emotional, and
social function. Family members and clinicians tend to
underestimate the effects on patients compared with self
reported health status. The most common problems reported
are loose or frequent stools, abdominal pain, worries about
disease flares, cancer or the need for surgery, and social
restrictions. Eighty per cent of sufferers can maintain
employment.
N Anorectal disorders affect 4% of the population. Patients
with anal fissure, constipation, or incontinence have all been
reported to record depressed HRQoL life scores.
N GI cancers account for 20% of all newly diagnosed cancers.
Many do not respond to treatment and require palliative
care. Patients experience side effects of treatment such as
nausea, vomiting, pain, and fatigue, in addition to the
symptoms directly caused by the cancer.
N Patients with hepatitis C were found to record lower SF36
scores than those with hepatitis B across the dimensions of
social functioning, physical role limitation, and energy and
fatigue, although both groups displayed lower scores than
healthy controls.
Overall the burden of GI disease on HRQoL in the general
population is not well described, although there are efforts to
assess impact in some conditions in studies carried out in
various locations. Standardised measures for specific diseases
are being developed and validated, which will help to under-
stand and describe the burden and assess treatments and
models of care.
3.5 Geographical variation
Peptic ulcer
The incidence of peptic ulcer has been higher in Scotland and in
the north of England than further south,66 92 to some extent
because of a higher prevalence of the Helicobacter pylori infection
in the north.451 In primary care, the prevalence of peptic ulcer
has also been reported as two to three times higher in the north
of England than in the south.71
Gastrointestinal haemorrhage
The incidence of upper gastrointestinal haemorrhage is higher
in Scotland and in the north of England than further south.
High incidence rates of upper gastrointestinal haemorrhage
have been reported in the west of Scotland (172 per 100 000 in
1992/93),92 and Aberdeen (117 per 100 000),90 compared with
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A B Figure 3.5.1 Standardised incidence rates
(per 100 000 population) for colorectal,
gastric, oesophageal, and pancreatic
cancers in England, Scotland, Wales, and
Northern Ireland, for the period 1993–
2001. (A) For men; (B) for women. Notes:
Incidence rates are directly standardised to
the standard European population. Sources:
England: National Cancer Intelligence
Centre, Office for National Statistics;
Scotland: Information and Statistics Division,
NHS in Scotland; Wales: Welsh Cancer
Surveillance and Intelligence unit; Northern
Ireland: Northern Ireland Cancer
Registry.215 454–456
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the lower rates of 107 for Trent, 102 for the West Midlands, 99
for South West Thames and 91 for North West Thames.91
Inf lammatory bowel disease
Regional studies of the incidence of Crohn’s disease in the UK
show little systematic geographical variation (table 3.2.2).
However, the highest incidence rates for ulcerative colitis have
been reported in northern regions such as north east
Scotland,134 and north Tees.135 136 The incidence of juvenile
onset Crohn’s disease has been reported as 50% higher
(p,0.001) in northern Scotland than in southern Scotland
during 1981–95, although no significant difference was found
for ulcerative colitis.452
Alcoholic liver disease
There seems to be a substantially higher incidence of alcoholic
liver disease in Scotland than in England. For example, in
1999–2000 the hospital admission rate for alcoholic liver
disease in Scotland, 75.2 per 100 000 population,215 was about
2.5 times higher than the corresponding rate in England during
the four year period, 1999–2000 to 2001–02, 31.4 per 100 000.453
Hepatitis B and C infection
Reported diagnoses of hepatitis B and C infections have been
shown to vary geographically throughout the UK (fig 3.2.4). In
particular, the incidence of both infections since the early 1990s
has been highest in Scotland, with rates about four times
higher than in the rest of the UK. The lowest rates of reported
hepatitis B infections were in Wales, and the lowest rates for
hepatitis C were in Northern Ireland.229
Primary biliary cirrhosis
Some of the highest prevalence rates for primary biliary
cirrhosis in the world have been reported for northern
England: 34.5 per 100 000 population,238 and 24 per 100
000.243 Relatively high rates of 20 and 9 per 100 000 have been
reported for south Wales,244 and the west of Scotland.242
Acute pancreatitis
Reported incidence rates for acute pancreatitis, which is
sometimes associated with heavy alcohol consumption, are
normally substantially higher in Scotland,287 305 306 than in
England.285 288 303 304
Gastrointestinal cancers
Figure 3.5.1 shows incidence rates among men and women,
respectively, for the main types of gastrointestinal cancer in
England, Scotland, Wales, and Northern Ireland during the
period 1991–2002. Among both men and women, the incidence
of colorectal cancer is lowest in England, oesophageal cancer is
most common in Scotland, gastric cancer is most common in
Wales among men, and pancreatic cancer shows little cross-
national variation in incidence among men, but a substantially
reduced incidence rate in Northern Ireland among women.
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For colorectal cancer, there is evidence of a north-south
gradient in incidence among men in Scotland, with the highest
incidence rates in the Shetlands, Highlands, the Grampian region,
and the north of Scotland, but less of a geographical trend for
women (fig 3.5.2). In Wales there is little geographical pattern in
the incidence of colorectal cancer in either men or women
(fig 3.5.3). Importantly, the incidence rates in Scotland and Wales
are standardised using different standard populations, so no direct
comparison of rates can be made across countries.
Figure 3.5.4 shows incidence rates for the main types of
gastrointestinal cancer in different regions of England during
the calendar year 2001. For gastric cancer, there is a clear north-
south gradient, with incidence highest in the north and lowest
in the south. For colorectal cancer, incidence among men is
lowest in London and the south east and highest in the north
and the south west, while for women there appears to be no
clear pattern. Similarly for oesophageal and pancreatic cancers,
no clear pattern is evident. Mortality to incidence ratios for each
of the main types of gastrointestinal cancer also show little
geographical pattern in England (fig 3.5.5).
For each of the main types of gastrointestinal cancer,
table 3.5.1 shows which Welsh unitary authorities have
significantly increased or reduced incidence rates relative to
the rest of Wales. Unlike England, there is no systematic
geographical pattern in the incidence of any of the main
gastrointestinal cancers.
3.6 Socioeconomic factors
Dyspepsia
There is little evidence of an association between dyspepsia and
social class.457 A historical study found a similar incidence of
dyspepsia in private practice and in a dispensary in London
around 1800,458 and a recent study in England and Scotland
reported that symptom prevalence was unrelated to social class,
but that social class affected consultation behaviour, rising
from 17% in social class I to 29% in social class IV.38
Helicobacter pylori infection and peptic ulcer
There is a well recognised association between Helicobacter pylori
infection, socioeconomic group,459 and childhood living condi-
tions,460 which has persisted over time. For example, a recent
study of [13C]urea breath testing for Helicobacter pylori infection
among children in Glasgow, reported a significantly higher
prevalence of 34% among children classified with the least
affluent Carstairs’ deprivation categories, compared with 16%
among the most affluent categories, and 22% among inter-
mediate groups.461
The incidence of peptic ulcer is strongly associated with lower
social class or socioeconomic conditions,147 462 463 largely because
of the higher prevalence of the Helicobacter pylori infection
among people from lower socioeconomic backgrounds.
However, gastric ulcers have been associated with manual
social classes, and duodenal ulcers with non-manual classes.464
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Gastrointestinal haemorrhage
Gastrointestinal haemorrhage is also strongly related to social
class, especially as the most common underlying cause of upper
gastrointestinal haemorrhage is peptic ulcer. A recent study of
the west of Scotland reported that the incidence of upper
gastrointestinal haemorrhage was higher in areas of greater
social deprivation: it was 2.2 times higher in the least affluent
quarter than in the most affluent quarter.92
Inf lammatory bowel disease
Inflammatory bowel disease is not thought to be related to
social class or poverty. Studies of British national birth cohorts
have found no association with social class for either Crohn’s
disease or ulcerative colitis.147 465 In Scotland, though, the
incidence of juvenile onset Crohn’s disease has been reported
as significantly higher in areas of most affluence from 1981 to
1995, although no association was found for ulcerative colitis.452
Irri table bowel syndrome (IBS)
Some studies have reported of an increased prevalence of IBS in
higher social classes, which has been considered as consistent
with an allergic aetiology for IBS. These include studies in
England466 and Australia.467 However, other British studies have
reported of no significant association between IBS and social
class,147 468 and a Danish study also reported no association for
incidence or prevalence of IBS.166 Some studies,166 469 470
although not others,157 471 472 have reported that psychiatric
illness or psychological factors may be of greater importance for
IBS than socioeconomic and lifestyle factors.
Coeliac disease
There is not thought to be a strong association between coeliac
disease and social class or poverty. One British study reported of
a non-significant tendency towards a higher prevalence among
higher socioeconomic groups.186
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Diverticular disease
Socioeconomic factors are thought to influence the incidence of
diverticular disease of the intestine. A Scottish study reported
that diverticular disease was more common in lower than in
higher income groups. It is likely that higher income groups are
more aware of the importance of dietary fibre and more able to
afford protective foods such as fresh fruit and vegetables.473
Liver cirrhosis
A recent study reported that social class is a risk factor for
alcohol related mortality, including liver cirrhosis, with men in
manual occupations significantly more likely than professional
men to die of alcohol related causes. Alcohol seems to be similar
to other psychoactive substances in that problem use is linked
to social structural factors such as poverty, disadvantage, and
social class.474 Another recent study reported that social class
differentials in mortality from liver cirrhosis increased from
1961 to 1981 in England and Wales and in Scotland.475
Hepatitis B and C infections
Both hepatitis B and C are linked to deprivation and poverty.
For example, a study of routine neonatal screening in Scotland
found the highest prevalence of hepatitis C infections in high
deprivation areas, particularly the most deprived areas in
Greater Glasgow476; and a USA study reported of a strong
association between both hepatitis B and C with deprivation,
that was largely related to the impact of poverty on the spread
of the two viruses.477
Acute pancreatitis
The incidence of acute pancreatitis is often much higher in
areas of higher alcohol consumption and lower affluence—for
example, in Scotland compared with the south of England.
However, one prominent British study found no association
between social class and the incidence of acute pancreatitis in
the Nottingham region, but instead found a large excess for
people resident in areas with ‘‘particularly hard drinking
water’’.286
Gastrointestinal cancers
The incidence of gastric cancer, in particular, and cancer of the
oesophagus is highest in deprived or poor areas. In Scotland
from 1991 to 1995, for example, there was a strong social
gradient for gastric and oesophageal cancers, with the highest
Table 3.5.1 Significantly increased and reduced risks of gastrointestinal cancers among men and women resident in Welsh
unitary authorities, 1992–2001
Unitary authority Sex
Gastrointestinal cancer
Colon Rectum Oesophagus Stomach Pancreas
Anglesey Men q
Women q q
Blaenau Gwent Men q Q Q
Women
Bridgend Men Q
Women Q Q Q
Caerphilly Men
Women q
Cardiff Men Q q
Women
Carmarthenshire Men q Q q
Women Q
Ceredigion Men Q Q
Women
Conwy Men
Women
Denbighshire Men
Women Q
Flintshire Men
Women
Gwynedd Men q q q
Women
Merthyr Tydfil Men q Q
Women
Monmouthshire Men Q
Women Q Q
Neath and Port Talbot Men
Women q
Newport Men
Women Q q
Pembrokeshire Men
Women
Powys Men Q Q
Women Q
Rhondda Cynon Taff Men
Women Q Q
Swansea Men q
Women q q
Torfaen Men Q
Women
Vale of Glamorgan Men Q
Women
Wrexham Men Q
Women q
Q denotes significantly (p,0.05) reduced risk, relative to the rest of Wales; q denotes significantly (p,0.05) increased risk, relative to the rest of Wales.
Source: Welsh Cancer Surveillance and Intelligence Unit.455
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incidence in areas having the highest Carstairs’ deprivation scores,
and the lowest incidence found in areas that were the most
affluent (fig 3.6.1). Socioeconomic variation in gastric cancer
incidence occurs to some extent because of the association
between Helicobacter pylori infection and poverty. However, there
were no significant associations between deprivation and
incidence of colorectal and pancreatic cancers; although colorectal
cancer incidence appears to be highest in the most affluent areas.
In England and Wales, use of the ONS longitudinal Study
from 1976 to 1990 showed significantly higher incidence of
gastric cancers among lower social groups, no social inequalities
in incidence of pancreatic cancer, and a significantly higher
incidence of colorectal cancer among women but not among
men in advantaged social groups.478 Colorectal cancer has
similarly been associated with professional or managerial
occupations in another British study,464 and colon cancer with
sedentary occupations in Sweden.479
Population based mortality in Scotland shows similar
patterns to those for incidence, although mortality from
colorectal cancer in the most affluent areas is comparable to
that in the rest of the population (fig 3.6.1). Five year survival
rates in Scotland are positively and significantly correlated with
affluence for colorectal cancer, in particular, and also for gastric
and oesophageal cancer. However, for pancreatic cancers,
which have the poorest prognosis, there is much less scope
for socioeconomic variation in survival.
In England, inequalities in survival for colorectal cancer have
been attributed to earlier surgical resection among people from
more affluent backgrounds, reflecting inequalities in access to
treatment,480 while others have reported lower uptake of
screening among people from more deprived areas.481 482 For
details of the impact of socioeconomic and demographic factors
on consultations in primary care for diseases of the digestive
system, see section 4.3.2.
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Figure 3.5.5 Mortality: Incidence ratios for
colorectal, oesophageal, gastric, and
pancreatic cancers in different regions of
England, 2001. (A) For men; (B) for women.
Source: England: National Cancer
Intelligence Centre, Office for National
Statistics.
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3.7 Costs to society
Costs to the NHS of GI disease are reported in section 4.5 below.
In addition to health services costs, however, GI disease
imposes a considerable burden on the other parts of the UK
economy, as well as to patients and their families.
It was not possible to undertake a study of the full burden of
illness within the time and financial constraints of this review.
However, in 1996 the British Society for Gastroenterology
commissioned the Unit for Policy Research in Science and
Medicine (PRISM) of the Wellcome Trust to undertake a study
to estimate the burden of GI disease in the UK.483 The following
estimates are based on that report.
One major element of burden is the years of working life lost
by those who die of GI diseases before reaching retirement age.
The PRISM study estimated that in 1997 approximately 147 400
person years were lost (from age of death (if 20+) to 65) from
GI diseases in both men and women. They reported that ‘‘… the
burden of gastrointestinal disease in terms of premature death
has been approximately constant in recent years’’. On the
assumption that this burden has remained constant since 1997
and applying their valuation method updated with current
average earnings, the estimated cost of early death by GI
disease in 2004 is £3230m.
A second major element of the burden of GI disease is the
lost productivity due to long term sickness absences from work.
The PRISM study estimated that GI disease causes 46 680
person years of lost productivity or roughly 1.7% of long term
sickness absence in the UK. Applying their valuation method
updated with current average earnings produces an estimated
value of lost productivity in 2004 of £1050m.
With respect to short term sickness absence, the PRISM
study crudely estimated that one fifth of all short term sickness
absences were due to GI diseases. Updating their estimate with
current earnings produces a value of lost productivity estimate
of £2900m.
On this basis, the total estimated cost to the British economy
in 2004 is thus £7180m. Although this figure may be crude, it
identifies an order of magnitude which clearly indicates that GI
morbidity and mortality impose major costs on the British
economy.
In addition to costs for the economy, GI diseases impose
considerable burden on individual patients and their families.
This includes travel and other costs incurred in receiving
treatment and the cost of over the counter drugs, which are not
included in the NHS costs reported in section 4.5.
4 CURRENT SERVICE PROVISION IN THE UK
4.0 Methods and data limitations
The main methods used for the activity analysis in this chapter
involved using routine data sources in the UK to provide
information on hospital activity and costs. The main source
used for hospital inpatient activity was hospital episode
statistics (HES) in England, produced by the Department of
Health. Record linkage allows hospital activity to be determined
for the numbers of people receiving inpatient care, as well as
the numbers of episodes of care. Linked hospital episode data
were provided by the Unit of Health-Care Epidemiology,
University of Oxford.484
Hospital activity for surgical procedures was also obtained
from hospital episode statistics. However, because outpatient
activity data are not yet available for the UK, data were
obtained for outpatients from the USA.
For activity in primary care, the most recent comprehensive
study of consultation patterns in primary care is the fourth
national morbidity study in England and Wales in 1991–92.485
This comprised a representative national sample of 60 general
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Figure 3.6.1 Standardised incidence and mortality rates (per 100 000 population), and five year survival, for colorectal, oesophageal, gastric, and
pancreatic cancer shown for Carstairs deprivation categories in Scotland: cases diagnosed between 1991 and 1995. (A) Incidence; (B) mortality; (C) five
year survival. Notes: Incidence and mortality rates are standardised using the European population. Incidence and mortality rates for oesophageal and
gastric cancers are strongly associated with deprivation (both p,0.001), but those for colorectal or pancreatic cancers are not. Five year survival for
colorectal (p,0.01), oesophageal (p = 0.01), and gastric (p = 0.04) cancers are all associated with deprivation, but that for pancreatic cancers is not.
Carstairs deprivation categories are measured in quintiles. Source: Information and Statistics Division, NHS in Scotland.215
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practices, covering just over half a million registered patients or
1% of the population of England and Wales. This study
followed the third national morbidity survey in 1981–82.486
Some of the main data limitations for investigating activity
include concerns about the accuracy of routine hospital episode
statistics,8–11 as well as increasing doubts that the finished
consultant episode is still a valid measure in a health service
where changing roles and teamwork are increasingly becoming
the norm.11 487 488
A limitation of the investigation of primary care activity is
that the latest comprehensive and freely available study of
consultation patterns in primary care in England and Wales is
the fourth national morbidity study which covers the period
1991–92.
The literature review described in section 5.0.1 has also
contributed to some sections in this chapter. Workforce data
have been collected by an annual census of consultant
gastroenterologists taken on 30 September each year. These
data are cross checked with the Royal College of Physicians
annual census data (coordinated to 30 September each year).
Advertisements in the BMJ and consultant gastroenterology
advisory appointment committees are constantly monitored.
Specialist registrars also complete an annual census, with data
being cross checked against information from the consultant
census, Joint Committee for Higher Medical Training, and by
monitoring movements of the specialist registrar workforce as
they occur. Data on nurses and non-consultant career grade
(NCCG) doctors are collected from the consultant census, from
the RCN directory, and from an unpublished survey of nurses.
4.1 Organisation
The current provision of services for patients with gastrointest-
inal disorders has been summarised in a joint report from the
British Society of Gastroenterology and Royal College of
Table 4.1.1 BSG published guidelines, including work-in-progress
The following guidelines have been published:
Oesophageal manometry and pH monitoring (revised 2006)
Antibiotic prophylaxis in gastrointestinal endoscopy (revised 2001)
Management of patients with short bowel (2006)
Complications of gastrointestinal endoscopy (2006)
Management of inflammatory bowel disease in adults (2004)
Dyspepsia management guidelines (revised 2002). Now NICE
Management of patients with coeliac disease (revised 2002)
Initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease (1997)
A structured approach to colorectal biopsy assessment (1997)
Management of acute pancreatitis (revised 2005)
Informed consent for endoscopic procedures (1999 and 2006)
Use of liver biopsy in clinical practice (2004)
Indications for referral and assessment in adult liver transplantation (2000)
Osteoporosis in coeliac disease and IBD (2000)
Management of iron deficiency anaemia (revised 2005)
UK guidelines on the management of variceal haemorrhage in cirrhotic patients (2000)
Management of irritable bowel syndrome (2000)
Treatment of hepatitis C incorporating the use of PEG interferon (revised 2003)
Management of oesophageal and gastric cancer (2002)
Management of osteoporosis associated with chronic liver disease (2002)
Non-variceal upper gastrointestinal haemorrhage (2002)
Colorectal cancer screening in high risk groups (2002)
Management of patients with coeliac disease (2002)
Diagnosis and treatment of cholangiocarcinoma (Nov 2002)
Diagnosis and treatment of hepatocellular carcinoma (HCC) in adults (2003)
Investigation of chronic diarrhoea (2003)
Resection of colorectal cancer liver metastases (2006)
Enteral feeding in adult hospital patients (Dec 2003)
Pancreatic cancer (2005)
Use of oesophageal dilatation in clinical practice (Feb 2004)
The following guidelines have been published in Gut:
Management of patients with pancreatic, peri-ampullary and ampullary carcinomas (2005)
Management of acute pancreatitis (revised 2005)
Management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (2005)
Management of ascites in cirrhosis (2006)
Diagnosis and management of Barrett’s oesophagus (2006)
http://www.bsg.org.uk/bsgdisp1.php?id = 48c1b0bcae9daa89d36aandh = 1 (accessed 18 December 2006).
Table 4.1.2 NICE guidelines relating to GI disorders
The following guidelines have been published:
Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related
eating disorders (Jan 2004)
Colorectal: service guidance for the NHS in England and Wales improving outcomes for colorectal cancer (Jun 2004)
Dyspepsia: managing dyspepsia in adults in primary care (Aug 2004)
Nutrition support in adults (Feb 2006)
The following guidelines are in development:
Obesity (Dec 2006)
Faecal incontinence (June 2007)
Irritable bowel syndrome (Feb 2008)
http://www.nice.org.uk/page.aspx?o = cg (accessed 18 December 2006).
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Physicians in 2003.489 Common problems include indigestion,
reflux, irritable bowel syndrome, and constipation. Many of
these problems can be diagnosed and treated by the patient’s
family practitioner. Those with worrying or persistent symp-
toms will usually be referred to a consultant gastroenterologist
in outpatients, to identify or exclude organic disease and receive
advice on treatment. Investigations will often include blood
tests, endoscopy, and imaging. If problems arise suddenly or
appear very serious, urgent inpatient assessment and treatment
may be required. Such problems include bleeding from peptic
ulcer, jaundice, acute liver disease, and severe exacerbations of
colitis and Crohn’s disease. In hospitals many GI disorders
require a team approach involving physicians, surgeons,
radiologists, pathologists, specialist and non-specialist nurses,
dieticians, nutritionists, physiotherapists, clinical scientists,
physiologists, speech and language therapists, hypnotherapists,
and psychologists. Some problems will require referral to a
tertiary centre where a specific concentration of expertise is
required to manage serious or rare disorders, both medically
and surgically.
Conventional services for patients with gastrointestinal
disorders reflect the traditional division between the primary
and secondary care sectors. General practitioners usually have
direct access to laboratory, radiological, and endoscopic
investigations, but are required to refer patients to consultant
colleagues in hospitals when a specialist opinion or care is
needed. Not all hospitals provide a full range of diagnostic and
treatment facilities and tertiary referral to a subregional or
regional hospital is often necessary for complex problems.
The management of many gastroenterological conditions has
been reviewed in evidence based guidelines produced by the
British Society of Gastroenterology (table 4.1.1), National
Institute for Health and Clinical Excellence (NICE;
table 4.1.2), and Scottish Intercollegiate Guidelines Network
(SIGN; table 4.1.3). This document will not examine the clinical
management of individual disorders except in the context of
the location and nature of the services required.
4.2 Workforce
Most patients with persistent symptoms suggestive of gastro-
intestinal disease will be managed by a team led by a
gastroenterologist. The Royal College of Physicians has set out
a description of the specialty490 and defined the workload of a
consultant-led gastroenterology team. It is recommended that a
consultant-led team should look after no more than 20–25
inpatients at any one time, the majority being admitted on
emergency take days. In outpatients a consultant physician in
gastroenterology, working alone, in a new patient clinic, should
see 6–8 patients; each allotted 20–30 minutes. When reviewed,
12–15 patients should be seen in a single session.
The Royal College of Physicians recommends that 65–74
consultant programmed activity sessions are required to serve a
population of 250 000, which indicates a need for about six
consultants for such a population. This takes into account the
need to allow for education and training, audit, and service
management. For diagnostic upper gastrointestinal endoscopy
or flexible sigmoidoscopy, a maximum of 10–12 procedures
should be carried out in a single session, allowing 15–
20 minutes for each procedure. Therapeutic procedures will
take at least twice as long, and diagnostic and therapeutic
Table 4.1.3 SIGN guidelines relating to GI disorders
The following guidelines have been published:
Management of colorectal cancer (Mar 2003)
Dyspepsia (Mar 2003)
Management of obesity in children and young people (April 2003)
Management of harmful drinking and alcohol dependence in primary care (Sep 2003, updated Dec 2004)
Management of oesophageal and gastric cancer (June 2006)
The following guidelines are currently in development:
Management of continence within primary care
http://www.sign.ac.uk/guidelines/ (accessed 18 December 2006).
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colonoscopy will usually take 30–40 minutes for each proce-
dure.
The workforce in gastroenterology has expanded substan-
tially over the past few years. The robust data on consultant
gastroenterologist numbers show a rise from 335 to 725 in
England and Wales (fig 4.2.1), with an average expansion of
6.3% a year over the whole of that period (fig 4.2.2). At present
growth rates it will take 13 years to reach the recommended six
consultants per 250 000 population. The total number of
academic gastroenterologists is 118 (England 104, Scotland 10,
Wales 3, and Northern Ireland 1). Currently, in excess of 400
stoma care nurses are listed in the RCN directory and, from a
recent unpublished survey, there are about 100 IBD nurses in
the UK. No data are available on workforce numbers in the
allied professions that support the care of patients with GI
disorders, but there are concerns that expansion has not
matched that in medicine and nursing.
Expansion in consultant numbers has been greater in the
past five years, averaging 7% in England with similar expansion
in Wales and Northern Ireland and slightly less in Scotland
(table 4.2.1). Thus the numbers of gastroenterology consultants
in the UK total 826 (as of 30 September 2004) (table 4.2.2).
This consultant workforce is supported by at least 418
associate specialists (371 England, 18 Wales, 16 Scotland, 13
Northern Ireland) and 312 nurses undertaking duties that a
few years ago would have been deemed the province of
doctors—for example, endoscopy nurses (268 England, 13
Wales, 28 Scotland, 3 Northern Ireland). Neither of the groups
is evenly distributed through regions or principalities, varying
from 3 specialist nurses in Northern Ireland, 6 in Oxford to 32
in Trent and 35 in North Thames (East). For NCCG doctors this
variation ranges from 14 in South Thames (West) to 39 in
South Thames (East). The lack of correlation (direct or inverse)
between consultant numbers, specialist nurse, and NCCG
doctors suggests the distribution has developed in an ad hoc
fashion rather than by formal planning based on population
needs (see table 4.2.3).
In addition the specialist registrar trainees provide substan-
tial service work and any reduction in training numbers (as
seems likely as the number of consultants plateau at a required
level) would need to be replaced by consultants or other
workers of similar skill. Five hundred and fifty specialist
registrars or equivalent currently have posts in the UK (as of 30
September 2004), though 131 are out of programme or
undertaking research so contribute only a proportion of their
time to service delivery (table 4.2.4).
In detailed work reported in Consultant physicians working with
patients490 the need for approximately 1950 consultant gastro-
enterology posts in the UK as a whole (assuming a population
of 59.6 million), providing 1665 whole time equivalent posts,
was demonstrated to deliver acceptable levels of care. This
number allows for a proportion of part time consultants as
estimates suggest such work is increasingly popular. Larger
numbers may be required with the predicted expansion of the
population to 65 million. Typically six to seven will serve a
population of 250 000, with extra needed where other duties
are fulfilled. These will include specialist training (for example,
endoscopy courses), undergraduate teaching, academic and
research roles over and above those expected in a district
hospital. Each team will require additional support staff such as
non-consultant career grade doctors, specialist nurses (with
roles in nutrition, endoscopy, inflammatory bowel disease and
more technical functions—for example, pH and manometry,
videocapsule endoscopy, etc) and the service time provided by
specialist registrars. No clear information exists on likely need
but one could imagine a team consisting of six whole time
equivalent consultants, one to two whole time equivalent non-
consultant career grade doctors, two endoscopy nurses, and two
to three specialist nurses (each providing additional help with
IBD, pH, etc) and one to two specialist registrars being trained
in gastroenterology and general medicine.
The MINuET study491 has concluded that more diagnostic
endoscopies could be undertaken by nurses. The implications of
this are that at least one whole time equivalent specialist nurse,
trained in endoscopy, would be required in each medium sized
district general hospital. In practice, it is unlikely that a nurse
endoscopist would wish only to undertake endoscopies and it is
more probable that other specialist nurse roles would be
included in the job description. On this basis it is predicted that
two whole time equivalent specialist nurses would be required
for each hospital. A survey of 196 endoscopy units, registered
with the Joint Advisory Group for Gastrointestinal Endoscopy
in 2004, identified 149 nurse endoscopists in post in 96 units
(64% of the 150 units that responded).492 On this basis it can be
predicted that approximately 200 nurse endoscopists will need
to be found and trained in the UK, if the majority of diagnostic
procedures are to be undertaken by nurses.
4.3 Activity
4.3.1 Primary care
Routinely collected clinical data are coded and analysed using
the International Classification of Diseases (ICD) for diagnosis
Table 4.2.1 Annual expansion (%) of consultants in different parts of the UK by year
UK regions 30 Sep 2000 30 Sep 2001 30 Sep 2002 30 Sep 2003 30 Sep 2004
England 7.6 5.7 8.0 7.2 6.5
Wales 0 20.0 6.7 6.3 8.1
Scotland 8.8 8.1 3.0 2.9 6.6
Northern Ireland 0 5.3 5.0 9.5 8.0
Table 4.2.2 Numbers of consultants in different parts of the UK by year
UK regions 30 Sep 2000 30 Sep 2001 30 Sep 2002 30 Sep 2003 30 Sep 2004
England 523 552 600 643 688
Wales 25 30 32 34 37
Scotland 62 67 69 71 76
Northern Ireland 19 20 21 23 25
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and Office for Population Censuses and Surveys Classification
(OPCS) for surgical operations and procedures.
During 1991–92, 78% of people consulted a general practice
on at least one occasion. Table 4.3.1 shows the prevalence rate
or percentage of people who consulted for the major disease
groupings (ICD-9 chapters). Of the different gastrointestinal
diseases, 8.7% of people consulted for diseases of the digestive
system, 4.1% consulted for intestinal infectious diseases, 0.1%
consulted for malignant neoplasms of the digestive system, and
0.04% for viral hepatitis (table 4.3.1).
Diseases of the digestive system formed one of the leading
ICD chapters as the cause of people consulting their GP,
following respiratory diseases (30.7% of all people), diseases of
the nervous system (17.3%), musculoskeletal diseases (15.2%),
diseases of the skin and subcutaneous tissue (14.6%),
infectious diseases (14.0%), injury and poisoning (13.9%),
genitourinary diseases (11.3%), and diseases of the circulatory
system (9.3%).
The percentage of patients consulting general practice for
diseases of the digestive system rose by one fifth from 7.2% of
people in 1981–82 to 8.7% in 1991–92 (fig 4.3.1), which was
closer to the 8.2% and 10.0% of people consulting for diseases
for the digestive system in the historical national morbidity
surveys in 1955–56 and 1971–72, respectively.12 The proportion
of people consulting for most other ICD-9 chapters also
increased, although there were reductions for infectious
diseases, mental disorders, and ill-defined diseases.
The total consultation rate for gastrointestinal diseases was
2083 per 10 000 population; or just over one consultation for
every five people in the general population (table 4.3.2). These
comprised 1495 consultations per 10 000 for diseases of the
digestive system, 517 for intestinal infectious diseases, 54
for malignant neoplasms of the digestive system, nine for
benign and other neoplasms of the digestive system, and eight
per 10 000 for viral hepatitis.
Consultation rates per 10 000 population for individual
gastrointestinal diseases are also shown in table 4.3.2. The most
common causes of consultation were ill-defined intestinal
infectious diseases (497 consultations per 10 000 population),
disorders of the function of the stomach (224 per 10 000),
diseases of the oral cavity, salivary glands and jaws (185),
diseases of the oesophagus (169), hernia (104), gastritis and
duodenitis (101), and peptic ulcer (90; table 4.3.2).
For people consulting GPs with gastrointestinal diseases, the
most common causes of consultation were infectious intestinal
diseases (4.0% of people), functional disorders not elsewhere
classified (2.1%), disorders of function of stomach (1.5%),
diseases of the oesophagus (1.0%), and gastritis and duodenitis
(0.7%; fig 4.3.2).
Socioeconomic and demographic influences on
consultations for diseases of the digestive system in primary
care
Consultations for diseases of the digestive system in primary
care in 1991–92 show a strong social class gradient, with
significantly increased rates of consultation for the manual
social classes IV, V, and III manual, and reduced consultation
levels for social classes I, II, and among men in the III non-
manual class (fig 4.3.3A).
Consultation rates for digestive diseases were greatly
increased for Pakistani and Bangladeshi ethnic groups, by
84% among men and 139% among women, but were not
significantly increased or reduced for all other classified ethnic
groups (fig 4.3.3B).
Consulting was reduced among people in full-time employ-
ment, and among women in part-time employment, but was
increased among people who were unemployed or who were
registered long term sick, and for women who were classified as
looking after the home or family (fig 4.3.3C). People living in
council housing and other rented accommodation also had
increased rates of consultation, while people in owner occupied
housing and women in communal accommodation had
reduced consultation rates (fig 4.3.3D).
Increased rates of consultation were also reported for men in
the Midlands and Wales, widowed or divorced people, and
smokers, while people in southern England, people in rural
areas of residence, single women, and non-smokers had
reduced rates of consultation (fig 4.3.4).
4.3.2 Inpatients
Out of 39 million finished consultant episodes (FCEs) in
England during the four year period 1998–99 to 2001–02, 6.5
million (17%) had a gastrointestinal disease as the principal
diagnosis (table 4.3.3); although about 45% of these admissions
were day cases and mainly refer to endoscopic assessments. Of
these, 5.2 million were for diseases of the digestive system, one
million were for malignant neoplasms of the digestive system,
225 820 were for benign and other neoplasms of the digestive
system, 160 160 were for intestinal infectious diseases, and 20
232 were for viral hepatitis.
Diseases of the digestive system was the second ICD chapter
after neoplasms, and excluding ‘‘symptoms, signs, and abnor-
mal findings’’, that was the principal diagnosis for most FCEs
(table 4.3.3). Using record linkage to identify person based
admission rates, as well as episode based rates, diseases of the
Table 4.2.3 Numbers of nurses and associate specialists
contributing to gastroenterology service provision in the UK
UK regions Number of nurses
Non-consultant career
grades
England 268 371
Wales 13 18
Scotland 28 16
Northern Ireland 3 13
Total 312 418
Table 4.2.4 SpR/NTN posts in the UK (as of 30 September 2004)
SpR/NTN posts England Wales Scotland Northern Ireland
Specialist registrar (clinical) 265 10 22 6
Senior registrar 1
Research registrar 99 4 9 3
Out of programme 11 1 1 3
Visiting registrar, inc FTTA 53 10
LAT 28 1 2
Locum/hon consultant 21
Total 478 26 34 12
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digestive system was the ICD chapter that was the principal
cause for most people being admitted to hospital (4.4 million in
England from 1998–99 to 2001–02).484
Figure 4.3.5 shows the percentage of inpatient admissions for
each major body system, after deaths from cancer were
allocated to their respective body systems—for example, when
gastrointestinal cancers were included with diseases of the
digestive system, when respiratory cancers were included with
diseases of the respiratory system, etc. Then, gastrointestinal
diseases were the leading major cause of hospital admission,
either as FCEs (6.55 million; 17% of the total) or as people
admitted (5.00 million; 17% of the total).
In other words, 1 in 39 people were admitted each year with a
principal diagnosis of gastrointestinal disease. This compares with
Table 4.3.1 Rates per 10 000 population for patients consulting general practice, and for the total consultation rate, for the
different ICD-9 chapters, England and Wales, 1991–1992
Diagnosis at consultation
ICD-9
chapter ICD-9 code
Percentage of patients consulting
general practice Consultation rate per 10 000 population
All consultations Serious All consultations Serious
Intestinal infectious diseases: 001–009 4.09 NA 517 NA
Infectious and parasitic diseases I 001–139 13.99 0.09 2 006 12
Viral hepatitis 070 0.04 NA 8 NA
All other infectious diseases 010–069, 071–139 NA NA 1 489 NA
Neoplasms: II 140–239 2.39 0.90 492 287
Malignant, digestive system 150–159 0.13 NA 54 NA
Benign and other neoplasms, digestive 210,211,230,
235.2–235.5
NA NA 9 NA
All other neoplasms 140–149, etc NA NA 436 NA
Endocrine, nutritional, metabolic and
immunity disorders
III 240–279 3.77 1.85 710 419
Diseases of blood and blood-forming organs IV 280–289 0.97 0.08 151 12
Mental disorders V 290–319 7.28 1.13 1 761 350
Diseases of the nervous system and sense
organs
VI 320–389 17.32 1.99 2 848 378
Diseases of the circulatory system VII 390–459 9.31 3.67 2 397 977
Diseases of the respiratory system VIII 460–519 30.70 5.79 6 200 1314
Diseases of the digestive system IX 520–579 8.66 2.29 1 495 414
Diseases of the genitourinary system X 580–629 11.33 0.31 2 050 53
Complications of pregnancy, childbirth
and the puerperium
XI 630–676 1.08 0.19 183 25
Diseases of the skin and subcutaneous system XII 680–709 14.55 0.00 2 289 0
Diseases of the musculoskeletal system and
connective tissue
XIII 710–739 15.21 5.34 3 070 1067
Congenital abnormalities XIV 740–759 0.53 0.29 69 41
Certain conditions originating from the
perinatal period
XV 0.13 0.03 16 4
Symptom, signs and ill-defined conditions XVI 760–779 15.10 0.07 2 340 7
Injury and poisoning XVII 800–999 13.90 0.61 1 946 90
Total gastrointestinal diseases 001–009, 070,
150–159,
210,211, 230,
235.2–235.5,
520–579
NA NA 2 083 NA
All illnesses I–XVII 001–999 78.03 19.84 30 021 5450
Source: McCormick et al, 1995.485
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1 in 60 people admitted each year for genitourinary disease, 1 in 63
for circulatory disease, 1 in 76 for accidents and injury, 1 in 81 for
respiratory disease, and 1 in 90 for musculoskeletal disorders.
Using the criterion of ‘‘any diagnosis’’ rather than ‘‘main
diagnosis’’, a total of 7.5 million people were admitted with
‘‘any diagnosis’’ of gastrointestinal disease during the four year
period (one in 26 people per year), with a corresponding total of
10.0 million FCEs (26% of all FCEs).
Gastrointestinal cancer is the most common cause of hospital
admission of all major cancer groupings. It was the principal
diagnosis of 23% of all cancer FCEs, followed by lymphatic and
haematological cancer (22%) and genitourinary cancer (18%;
fig 4.3.6). FCEs for GI cancers mainly comprised colorectal
cancer (60%), followed by cancers of the oesophagus (12%),
stomach (11%), pancreas (7%), and the liver and intrahepatic
ducts (2%).
The main causes of hospital admission for (non-cancer)
diseases of the digestive system include hernia (12% of all
FCEs), non-infective gastroenteritis and colitis (9%), chole-
lithiasis, cholecystitis and other diseases of the gallbladder, and
gastritis and duodenitis (7%; fig 4.3.7).
Figure 4.3.8 shows hospital admission rates, based on
number of FCEs and on number of people admitted, for some
of the most common diseases and conditions in the general
Table 4.3.2 Consultation rates (per 10 000 population) for patients consulting general
practice for gastrointestinal diseases in England and Wales, 1991–1992
Diagnosis at consultation ICD-9 code
Consultation rate per
10 000 population
Diseases of the digestive system:
Diseases of oral cavity, salivary glands, and jaws 520–529 185
Diseases of oesophagus 530 169
Peptic ulcer 531–534 90
Gastritis and duodenitis 535 101
Disorders of function of stomach 536 224
Other disorders of stomach and duodenum 537 1
Appendicitis 540–543 13
Hernia of abdominal cavity 550–553 104
Crohn’s disease 555 20
Ulcerative colitis 556 26
Vascular insufficiency of intestine 557 0
Other non-infective gastroenteritis and colitis 558 21
Intestinal obstruction without mention of hernia 560 8
Diverticular of intestine 562 40
Peritonitis 567 1
Other diseases of intestines and peritoneum 564–566, 568, 569 413
Chronic liver disease and cirrhosis 571 10
Other disorders of liver 570, 572, 573 1
Cholelithiasis, cholecystitis, and other disorders of gallbladder574–575 36
Other disorders of biliary tract 576 5
Diseases of pancreas 577 6
Gastrointestinal haemorrhage 578 16
Intestinal malabsorption 579 5
Total diseases of the digestive system 520–579 1495
Malignant neoplasms of the digestive system:
Oesophagus 150 10
Stomach 151 10
Small intestine 152 0
Colon 153 18
Rectum, rectosigmoid junction, and anus 154 11
Liver and intrahepatic ducts 155 1
Gallbladder and extrahepatic ducts 156 0
Pancreas 157 4
Retroperitoneum and peritoneum 158 0
Other and ill-defined sites of the digestive system 159 0
Total malignant neoplasms of the digestive system 150–159 54
Benign and other neoplasms of the digestive system 210, 211, 230, 235.2–235.5 9
Infectious intestinal diseases:
Cholera 001 0
Typhoid and paratyphoid fevers 002 0
Other salmonella infections 003 6
Shigellosis 004 2
Other food poisoning (bacterial) 005 2
Amoebiasis 006 0
Other protozoal intestinal diseases 007 1
Intestinal infections due to other organisms 008 9
Ill-defined intestinal infections 009 497
Total infectious intestinal diseases 001–009 517
Viral hepatitis 070 8
Total gastrointestinal diseases 001–009, 070, 150–159,
210 211, 230, 235.2–235.5,
520–579
2083
Source: McCormick et al, 1995.485
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population. The number of people admitted for gastrointestinal
diseases was more than double that for all types of accident,
four times that for ischaemic heart disease, over 10 times that
for stroke and pneumonia, and 20–40 times that for diabetes,
asthma, and all traffic accidents.
4.3.3 Outpatients
Currently HES only includes data on admitted patients. In the
near future, outpatient data will be available on HES online,
but this will not include clinical data.
However, using figures for the USA in 2000, these show that
out of an estimated total of 27.4 million outpatient visits for
gastrointestinal symptoms, the leading gastrointestinal com-
plaint was abdominal pain, cramps and spasms (12.3 million
outpatient visits), followed by diarrhoea (4.06 million), nausea
(3.32), vomiting (2.89), dyspepsia (1.82), constipation (1.33),
anal or rectal bleeding (1.26), and melaena (1.18).493
The leading physician diagnoses for the same 27.4 million
outpatient visits were abdominal pain (5.24 million), gastro-
oesophageal reflux disease (4.62 million), gastroenteritis (3.43),
gastritis (2.4), haemorrhoids (1.57), irritable bowel syndrome
(1.56), non-inguinal hernia (1.54), benign neoplasms of the
colon (1.52), malignant colorectal neoplasm (1.49), inguinal
hernia (1.24), and diverticulosis of the colon (1.00).
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4.3.4 Procedures
Table 4.3.5 shows the total number of surgical procedures
undertaken in England in 2000–01 for the different OPCS-4
chapters, as well as the total numbers of ‘‘main procedures’’
during a given episode, and the numbers of day case
procedures.
Out of a total of 12.7 million procedures, 1.21 million (9.5%)
were performed on the digestive tract and a further 128 886
(1.0%) on other abdominal (principally digestive) organs.
Considering main procedures only, 1.03 million out of a total
of 6.5 million procedures (16%) were performed on the
digestive tract, and a further 97 102 (1.5%) on other abdominal
organs (table 4.3.5).
A total of 5.8 million of the 12.7 million procedures (45%)
were undertaken as day case admissions, including 59% of the
procedures on the digestive tract and 11% of the procedures on
the other abdominal organs (table 4.3.5).
Figure 4.3.9 shows the percentage breakdowns of surgical
procedures on the digestive tract and other abdominal organs in
England in 2000–2001 (A) for all surgical procedures and (B)
for the main surgical procedure during the episode. Most
procedures were performed as day case admissions for
endoscopy examination. The other most common gastrointest-
inal procedures were excisions of gallbladders (42 013, 3% of all
gastrointestinal procedures), emergency excisions of appen-
dices (36 657; 3%), and destruction of haemorrhoids (21 720;
2%; fig 4.3.9).
A total of 17.4 million (17 364 212) bed days were associated
with the total of 6.51 million main procedures. Of these, 2.6
million (2 629 352; 15.1%) were for procedures on the digestive
tract, 1 389 613 on the upper digestive tract, and 1 239 739 on
the lower digestive tract. An additional half a million (519 393)
bed days were for procedures on the other abdominal organs.
Therefore, a total of 3.15 million bed days (18.1% of the total)
were for gastrointestinal procedures, which was second only to
procedures on ‘‘other bones and joints’’ (3.17 million) as the
heaviest burden on hospital beds (fig 4.3.10).
Table 4.3.6 shows surgical procedures on the digestive tract
with mean waiting times to admission in excess of 90 days in
England in 2000–01. Eight of 69 procedures on the upper
digestive tract, 10 of 52 procedures on the lower digestive tract,
and 7 of 61 procedures on other abdominal organs had waiting
times of 90 days or more.
4.4 Voluntary sector patient support groups
Voluntary organisations provide support for patients with
coeliac disease, inflammatory bowel disease, irritable bowel
syndrome, liver disease, and after bowel surgery. These
organisations are listed in Appendix 1. The voluntary sector
plays a major part in the care and support of patients with
chronic gastrointestinal disorders and has conducted many
surveys which document the considerable impact of chronic GI
disorders on the physical, mental, social, and financial health of
those affected.494–497
4.5 Costs to the NHS
As with non-NHS costs reported in section 3.7, a comprehen-
sive costing of all NHS resources devoted to GI disease was not
possible within the time and resource constraints of the present
study. Several key cost areas such as GI cancers (recorded
under cancer rather than GI disease) are not included. For
others, cruder methods were used here than would have been
the case in a more detailed costing exercise. Nevertheless the
costs below give a general picture of costs in the relevant areas.
Hospital costs
Data on the number of FCEs in England for all HRGs for
diseases of the digestive system were obtained from the Royal
College of Physicians iLab using Hospital Episode Statistics.
Activity data for each HRG were multiplied by the relevant NHS
reference cost.498 Table 4.5.1 below shows the total number of
emergency, overnight elective and day cases in 2001–02 and the
associated costs. Total hospital costs (England only) were
£1400m.
Drugs
In 2002, 60 million prescriptions were issued for diseases of the
gastrointestinal system (represented by therapeutic group 1 in
the British National Formulary). The net ingredient cost of these
drugs was £802m, of which £596m was for ulcer healing drugs
and £51m for laxatives, which represents 7.9% of the total
number of prescriptions issued in the UK and 9.5% of the total
UK drug cost.499 These reported costs are solely for the ‘‘net
ingredient cost’’ of the drugs and do not include other cost
items such as containers or dispensing fees.
Primary care
The Office of Health Economics has estimated the cost of
general practitioner consultations in the UK in 2000–01 for
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for diseases of the digestive system in general practice in England and
Wales, 1991–92 according to (A) region of England and Wales; (B) urban
or rural residence; (C) marital status; (D) smoking habit in past week. Note:
Standardised consulting ratio in the general population = 100. Vertical
bars represent 95% confidence intervals. Source: McCormick et al,
1995.485
44 Williams, Roberts, Ali, et al
www.gutjnl.com
group.bmj.com on February 10, 2015 - Published by http://gut.bmj.com/Downloaded from 
diseases of the gastrointestinal system to be £136m. This
represents 7.8% of the cost of all GP visits.
These three elements of NHS costs due to GI diseases give a
total of under £2400m but it must be emphasised that this
understates total NHS costs for the reason given above.
4.6 Problems with existing service provision
4.6.1 Access
Statistical data on actual usage of resources are covered in
section 4.3 and 4.5. Many of the underlying problems
concerned with rising demand and limited access are exam-
ined, providing a more comprehensive reflection than the brief
summary given here. Although many studies give a passing
mention to problems of access, only three studies were found to
cover this topic for GI services in any significant detail. Indeed,
as one would expect, there are clear concerns for a range of
services including endoscopy,500 outpatient management,501 and
open access gastroscopy,502 with specific problems being
excessive workload,502 ways to restrict access as a means to
control costs,500 502 and the inappropriate use of services.501 It
seems that an extensive and systematic study on the problem of
access for the delivery of GI services has yet to be carried out.
4.6.2 Inequalit ies
No significant publications were found on the problems of
inequalities in the delivery of GI services. Only one study—a
brief, opinion based commentary on the topic of the inverse
care law—was found to highlight general issues of inequalities
in the health service.503 One likely reason for the lack of reliable
evidence is that inequality is a much wider ranging concern,
and is generally not confined to specific disciplines of medicine
or health care. Readers concerned with this topic are therefore
advised to consult other sources for an overview of this
problem.
4.6.3 Waiting lists
Five studies were included in this section. Unsurprisingly, a
literature review by Dunnill and Pounder504 found that waiting
times (whether for an appointment or in the outpatient
department) form the bulk of patients’ concerns. Guidelines
set out by the Association of Coloproctology of GB and Ireland
recommend that surgeons should expect to achieve waiting
times of four weeks or less between making a diagnosis of
colorectal cancer and the start of treatment.505 But an audit by
Duff et al506 carried out in the north west of England found that
the median time between referral from the surgeon and the
start of radiotherapy was 40 days, while only four patients (6%
of the sample) received radiotherapy within 28 days of referral.
For bowel cancer, Flashman et al507 showed that most patients
were not referred according to the two week standard set out by
the Department of Health (that is, that all patients suspected by
their GP of having bowel cancer should be seen by a specialist
within two weeks). Clinics did not shorten the overall time to
treatment or improve the stage of disease because the time lags
before referral and after the outpatient appointment caused
major delays. A brief report by Hellier508 outlined the problems
with meeting the two week standard in endoscopy clinics, and
emphasises that in order to make it a realistic possibility and to
avoid distorted referral practices, funding needs to be targeted
at GI outpatient and endoscopy facilities.
4.6.4 Patient safety
Several papers have dealt with patient safety for the treatment
of GI disease. These can be generally divided into the safety of
methods of treatment (such as the use of NSAIDs and
complementary medicine) and procedures (for example, endo-
scopy and surgery). A wide breadth of studies cover various
aspects of treatment,509–518 and are generally beyond the scope of
this report. However, it is worth noting that the main concerns
Table 4.3.3 Annual population based hospital admission rates (per 10 000 population) for ICD-10 chapters, based on numbers of
finished consultant episodes (FCEs) and on numbers of people admitted in England, 1998–99 to 2001–02
ICD chapter ICD-10 code No of FCEs
Admission rate per
10 000 population
No of people
admitted
Admission rate per
10 000 population
Certain infectious diseases: A00-B99 596 468 30.5 511 032 26.1
Intestinal infectious diseases A00-A09 160 160 8.2 143 536 7.3
Viral hepatitis B15-B19 20 232 1.0 15 484 0.8
All other infectious diseases A10-B14,B16-B99 416 476 21.3 352 012 18.0
Neoplasms: C00-D48 5 317 876 271.8 2 367 584 121.0
Malignant neoplasms, digestive C15-C26 987 680 50.5 274 792 14.0
Benign and other neoplasms, digestive D00-01,D12-D13,D37 225 820 11.5 191 480 9.8
All other neoplasms C00-C14, etc 4 104 376 209.8 1 900 792 97.1
Diseases of the blood and blood-forming organs D50-D89 661 852 33.8 341 752 17.5
Endocrine, nutritional and metabolic disorders E00-E90 590 408 30.2 379 100 19.4
Mental and behavioural disorders F00-F99 326 748 16.7 246 500 12.6
Diseases of the nervous system G00-G99 923 780 47.2 677 176 34.6
Diseases of the eye and adnexa H00-H59 1 505 464 76.9 1 342 436 68.6
Diseases of the ear and mastoid process H60-H95 371 340 19.0 351 500 18.0
Diseases of the circulatory system I00-I99 4 273 688 218.4 3 083 240 157.6
Diseases of the respiratory system J00-J99 2 945 864 150.6 2 266 772 115.8
Diseases of the digestive system K00-K93 5 160 944 263.8 4 377 780 223.7
Diseases of the skin and subcutaneous system L00-L99 1 050 452 53.7 905 000 46.3
Diseases of the musculoskeletal system and connective
tissue
M00-M99 2 589 824 132.4 2 168 676 110.8
Diseases of the genitourinary system N00-N99 3 087 232 157.8 2 576 980 131.7
Pregnancy, childbirth and the puerperium O00-O99 908 180 46.4 812 756 41.5
Certain conditions originating in the perinatal period P00-P96 96 748 4.9 82 824 4.2
Congenital malformations Q00-Q99 321 192 16.4 24 9348 12.7
Symptoms, signs and abnormal findings R00-R99 5 317 348 271.7 4 393 120 224.5
External causes of morbidity and mortality V01-Y89 2 966 692 151.6 2 565 944 131.1
Total gastrointestinal diseases A00-A09,B15-B19,
C15-C26,
D00,D01,D12,D13,
D37,K00-K93
6 554 836 335.0 5 003 072 255.7
All diseases and conditions A00-Y89 39 012 100 1993.7 29 699 520 1517.8
Sources: Department of Health, 2004453; Unit of Health-Care Epidemiology, Oxford 2004.484
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in this area are focused on ensuring that sufficient evidence and
research is carried out to assess the safety of new drugs and
treatments for GI disease,509 510 515 which include over-the-
counter drugs,513 unlicensed and off-label drugs,511 prescription
of NSAIDs,512 514 516 complementary medicines used by chil-
dren,518 and endoscopic therapy for acute non-variceal upper GI
haemorrhage.517
As far as the safety of procedures is concerned, most studies
have generally found that upper GI endoscopies are safe
regardless of age and where they are performed.519–522
However, some caveats remain in the area of how the service
is delivered, including a restriction of upper GI endoscopy in
elderly patients (85 years and over) to cases of bleeding (overt
and suspected) and anaemia in order to reduce costs.522 There
are also suggestions that simple diagnostic endoscopies can be
performed safely in the primary care setting, leaving secondary
care units to concentrate on those patients requiring sedation,
who are acutely ill, and who require therapeutic procedures519—
problems on location of care are covered in greater detail in
section 5. Despite these positive findings, endoscopy does carry
some risk. In a study by Quine et al,521 out of 13 036 patients
undergoing endoscopic endoscopy without any therapeutic
intervention, there were seven deaths, and this was expected to
have been an underestimate owing to the reliance on self
reporting by doctors. Another study520 reported significant
complication and death from diagnostic oesophageal gastro-
duodenoscopy as 1 in 1000 and 1 in 10 000 procedures
respectively, but that patients’ sex, age, or preference for
sedation or endoscopist did not affect the morbidity rate.
A report in 2004 from the National Confidential Enquiry into
Patient Outcome and Death523 identified a low mortality from
therapeutic endoscopy, with the exception of percutaneous
endoscopic gastroscopy (PEG), which had a mortality of 6%.
The report made many recommendations to improve the
structure and process of therapeutic endoscopy, including the
importance of careful selection for PEG insertion and ERCP,
and the importance of endoscopy for gastrointestinal haemor-
rhage being undertaken only by experienced endoscopists.
More complications can be found for GI related surgery,
especially for older patients.524 525 For malignant bowel obstruc-
tion, it is suggested that patients should only undergo surgery if
their life expectancy is at least two months,526 but endoscopic
enteral stents for patients with this disease is a safe and cost
effective alternative.527
4.6.5 Information to patients and practit ioners
There seems to be widespread encouragement for initiatives
aimed at improving the information flow between patients and
practitioners.511 513 528–534 Key issues include the need for nurses
and doctors to give relevant and holistic information to patients
undergoing gastroscopy at the right time532; information leaflets
on drugs, illnesses, and diet511 513 529–531; and the need for
practitioners to be more alert and vigilant in identifying the
need to provide information.528 533 534
Studies also highlight specific problems due to poor commu-
nication. Sewitch et al found that a poor or ineffectual
conversation between patients and practitioners increased the
risk of intentional non-adherence to IBD drugs by patients.535 It
is also interesting to note that in a survey of around 800
patients undergoing colorectal cancer screening in the USA by
Greiner et al,536 61% felt they had inadequate or no time to
discuss colorectal cancer with their physician. It was suggested
that new and creative methods are needed to satisfy patients’
information needs and encourage discussion. In the UK, a
study in 1997537 highlighted that the opportunity to educate and
inform patients about IBD in outpatient clinics is often wasted,
as practitioners neglect to mention key information sources
such as the National Association for Colitis and Crohn’s
Disease, especially to patients with long term chronic diseases.
There is evidence that patients are more satisfied with the
information given before and after endoscopy, when it is given
by nurses rather than doctors.523
4.6.6 Speed of diagnosis and complications of care
Not surprisingly, a considerable number of reports have been
published on diagnosis for GI disease. Thirty five studies
examining the topic in great detail were included in this report.
For the most part, these highlight the need for a quick and
accurate diagnosis for a spectrum of GI illnesses, including
IBD,538 539 IBD in children,540 541 IBS,542 543 abdominal pain in the
elderly,544 coeliac disease,174 gastro-oesophageal reflux dis-
ease,545 dyspepsia,546–548 disorders of the large bowel,549 ultra-
short bowel disease,550 functional bowel disorders,551 Crohn’s
disease,552 and acute bowel ischemia.553 Complementing these
are studies which deal specifically with the diagnosis for GI
related cancers.554–561 Some research was also found on the use
of diagnostic procedures (which were largely effective) such as
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colonoscopy and biopsy,562 oesophago-gastroduodenoscopy,563
imaging techniques (for example, computed tomography,
ultrasonography, and MR scan),553 558 push enteroscopy,564 and
molecular-pathological diagnosis.565
However, there is also evidence which points to the possible
complications which may arise during the treatment of patients
or due to the procedures mentioned above, or both. Lang et al
suggest that resources and costs double for patients who
develop complications after undergoing gastroenterological
surgery.566 For upper GI endoscopy, Quine et al warn of the
risk of perforation during diagnostic and therapeutic proce-
dures,521 a problem which seems to be occurring at a significant
rate owing to inexperienced practitioners. A similar concern is
also voiced by a study by Schofield,567 where alleged negligence
comes from the activity of GPs, gynaecologists, and colorectal
surgeons, and patients receive laparoscopic injuries such as
Table 4.3.4 Annual population based hospital admission rates (per 10 000 population) for different gastrointestinal diseases,
based on numbers of finished consultant episodes (FCEs) and on numbers of people admitted in England, 1998–99 to 2001–2002
Diagnosis at admission ICD-10 code No of FCEs
Admission rate per
10 000 population
No of people
admitted
Admission rate per
10 000 population
Diseases of the digestive system:
Diseases of oral cavity, salivary glands, and jaws K00–K14 700 664 35.8 669 884 34.2
Oesophagitis K20 150 944 7.7 135 476 6.9
Gastro-oesophageal reflux disease K21 227 032 11.6 208 516 10.7
Other diseases of oesophagus K22, K23 211 860 10.8 161 348 8.2
Peptic ulcer K25–K28 217 280 11.1 157 828 8.1
Gastritis and duodenitis K29 339 248 17.3 308 424 15.8
Dyspepsia K30 148 200 7.6 144 816 7.4
Other diseases of stomach and duodenum K31 33 848 1.7 28 256 1.4
Appendicitis K35–K37 146 476 7.5 138 136 7.1
Other diseases of appendix K38 5 432 0.3 5 108 0.3
Hernia of abdominal cavity K40–K46 635 620 32.5 596 204 30.5
Crohn’s disease K50 71 632 3.7 44 496 2.3
Ulcerative colitis K51 89 620 4.6 67 140 3.4
Other non-infective gastroenteritis and colitis K52 303 500 15.5 260 488 13.3
Diverticular of intestine K57 211 688 10.8 182 284 9.3
Other diseases of intestines K55,K56,K58–K63 752 812 38.5 632 892 32.3
Diseases of peritoneum K65–K67 31 496 1.6 25 344 1.3
Liver cirrhosis K70, K73, K74 81 080 4.1 46 200 2.4
Other diseases of liver K71,K72,K75–K77 29 072 1.5 22 176 1.1
Cholelithiasis, cholecystitis, and other diseases of the
gallbladder
K80–K82 363 620 18.6 263 420 13.5
Other diseases of biliary tract K83, K87 37 820 1.9 25 800 1.3
Acute pancreatitis K85 64 560 3.3 43 044 2.2
Other diseases of the pancreas K86 33 644 1.7 19 212 1.0
Other diseases of the digestive system K90–K93 273 796 14.0 191 288 9.8
Total gastrointestinal diseases K00–K93 5 160 944 263.8 4 377 780 223.7
Malignant neoplasms of the digestive system:
Oesophagus C15 123 848 6.3 38 240 2.0
Stomach C16 109 532 5.6 37 068 1.9
Small intestine C17 8 612 0.4 3 156 0.2
Colon C18 375 660 19.2 88 924 4.5
Rectosigmoid junction C19 56 328 2.9 13 976 0.7
Rectum C20 199 924 10.2 48 524 2.5
Anus and anal canal C21 10 484 0.5 4 124 0.2
Liver and intrahepatic ducts C22 20 660 1.1 9 200 0.5
Gallbladder C23 3 708 0.2 1 516 0.1
Other and unspecified parts of biliary tract C24 7 432 0.4 3 480 0.2
Pancreas C25 62 064 3.2 22 796 1.2
Other and ill-defined digestive organs C26 9 428 0.5 3 788 0.2
Total malignant neoplasms of the digestive system C15–C26 987 680 50.5 274 792 14.0
Benign and other neoplasms of the digestive system D00–01,D12–13,D37 225 820 11.5 191 480 9.8
Intestinal infectious diseases:
Cholera A00 40 0.0 40 0.0
Typhoid and paratyphoid fevers A01 1 020 0.1 856 0.0
Other salmonella infections A02 5 488 0.3 4 572 0.2
Shigellosis A03 412 0.0 372 0.0
Other bacterial intestinal infections A04 33 656 1.7 28 192 1.4
Other bacterial food borne intoxications A05 632 0.0 536 0.0
Amoebiasis A06 400 0.0 296 0.0
Other protozoal intestinal diseases A07 1 316 0.1 1 160 0.1
Viral and other specified intestinal infections A08 80 064 4.1 74 248 3.8
Diarrhoea and gastroenteritis of presumed infectious origin A09 37 132 1.9 33 264 1.7
Total intestinal infectious diseases A00–A09 160 160 8.2 143 536 7.3
Viral hepatitis B15–B19 20 232 1.0 15 484 0.8
Total gastrointestinal diseases: A00–A09, B15–B19,
C15–C26, D00, D01,
D12, D13, D37, K00–K93
6 554 836 335.0 5 003 072 255.7
Sources: Department of Health, 2004.453 Unit of Health-Care Epidemiology, Oxford, 2004.484
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bowel perforation, bleeding, and major vascular damage. In a
small study of coeliac disease by Hin et al,378 attention has also
been given to problems of underdiagnosis and misdiagnosis.
Clearly, a strong body of evidence exists on providing
adequate diagnostic services, which require appropriate train-
ing and stringent assessment to ensure patient safety. If this is
achieved, the problem that remains is not one of effectiveness,
but of ensuring that a sufficient level of service to support the
inevitable rise in demand is available.
4.7 Drivers for change
4.7.1 New evidence and guidelines about best care
A plethora of literature can be found on a range of topics
concerning guidelines for the care of GI diseases. A total of 45
studies were included for this section of the report, but only a
brief summary will be given here owing to the sheer amount of
information they cover; readers with a special interest in this
area are advised to examine these and other related documents
in greater detail. As with previous sections, evidence here can
be broadly divided into two areas—treatment and procedures.
Some examples include guidelines for the treatment of color-
ectal cancer,505 556 568 569 bowel cancer,507 other GI related
cancers,570–572 Barrett’s oesophagus,573 dyspepsia,546 574–582 IBD,583–
585 H pylori eradication,586–588, and other GI related diseases.589–598
For procedures: colonoscopy,599 600 endoscopy,600–602 and colo-
proctology.603 Despite the quantity of such studies, there
remains a distinct lack of reference to service provision—in
those where such topic was examined, only tentative sugges-
tions are given, or where more substantial studies have been
carried out, conclusions lack an evidence base.574 576 578 598 604–606
In light of these findings, and the general lack of an evidence
based framework for GI service delivery, there is clearly a
pressing need for more research and planning of how services
should be delivered and the resources required to meet the
demand.
4.7.2 Changing incidence of cancer
Colorectal cancer incidence increased by about 20% among men
and by 5% among women from 1971 to 1997. However,
reflecting large improvements in prognosis over time, mortality
rates fell by 20% among men and by 34% among women
(fig 4.7.1A).
For cancers of the oesophagus, incidence and mortality both
increased by about 60% in men 1971 and 1997, illustrating the
poor prognosis associated with oesophageal cancers. Among
women, incidence increased by about 40% and mortality
increased by about a quarter (fig 4.7.1B).
The incidence of gastric cancer fell sharply by 40–50% in both
men and women. Reflecting, improvements in diagnosis and
treatment, mortality fell slightly more sharply than incidence;
by about 60% in both men and women (fig 4.7.1C).
The incidence of pancreatic cancers fell by about one sixth in
men from 1971 to 1997, but remained stable in women. With
extremely poor prognosis for pancreatic cancers, annual
mortality rates closely tracked incidence rates (fig 4.7.1D).
Lip, oral cavity and pharynx
3%
Brain and nervous system
2%
Gastrointestinal
23%
Respiratory, etc
7%
Bone, skin and
breast, etc
7%
Other and
unspecified
18%
Genitourinary
18%
Lymphatic, etc
22%
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Figure 4.3.7 Percentage of hospital admissions, based on number of
FCEs, for diseases of the digestive system in England, 1998–99 to 2001–
02. Sources: Department of Health, 2004.453
Figure 4.3.8 Annual population based hospital admission rates (per 10
000 population) based on numbers of FCEs, and on numbers of people
admitted, for gastrointestinal diseases and for other selected diseases and
conditions in England, 1998–99 to 2001–02.*Gastrointestinal disease
includes diseases of the digestive system, malignant neoplasms of the
digestive system, benign and other neoplasms of the digestive system,
intestinal infectious diseases, and viral hepatitis. Sources: Department of
Health, 2004.453
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Figure 4.7.2 shows slightly updated trends up to 2002 for the
incidence of each of the four main gastrointestinal cancers
separately in England, Wales, Scotland, and Northern Ireland.
They show little further trend for colorectal and pancreatic
cancers, but further increases in the incidence of oesophageal
cancers among men in Scotland and in Wales, and further
reductions in gastric cancer among men and women in all four
countries.
4.7.3 Changing incidence of other gastrointestinal
and liver diseases
For a few gastrointestinal diseases, such as acute appendicitis
and peptic ulcer in most age groups, there has been a fall in
incidence in the UK in recent years. However, for most other
gastrointestinal and liver diseases, there have been increases in
incidence or prevalence over time (see earlier section 3.2).
These include, in particular, liver diseases such as liver
cirrhosis, including alcoholic liver disease, non-alcoholic fatty
liver disease, primary biliary cirrhosis and hepatitis C infection,
which will have a major impact on health care in this area.
There have also been increases in the incidence of acute and
chronic pancreatitis, gallstones disease, upper gastrointestinal
haemorrhage, diverticular disease of the intestine, coeliac
disease, irritable bowel syndrome, and Barrett’s oesophagus.
For some gastrointestinal diseases, such as inflammatory
bowel disease, there is little evidence of a discernible upward or
downward trend in incidence in recent years, even sometimes
after earlier increases during previous decades. However,
because of improvements in treatment, care, and prognosis,
the overall prevalence of these diseases continues to rise.
In summary, the overall burden of gastrointestinal and liver
diseases has increased greatly in the past few decades, and will
continue to rise in the future.
4.7.4 Screening programmes
A significant amount of research has been carried out into
screening and surveillance methods for GI diseases. This is
reflected by a total of 32 studies included in this report. On the
whole, there is strong support for the development and use of
widespread screening programmes for a wide variety of GI
diseases, where the poor prognosis of GI cancers is mainly
attributed to delays in diagnosis.324 Most of the evidence relates
to GI cancers607–611 but also covers diseases such as Barrett’s
oesophagus,573 612 613 Helicobacter pylori,614 GERD,615 and diar-
rhoea.616 The main problems in this area are the economic
costs associated with such programmes–that is, that they need
to be adequately managed and feasible608 610 614 615 617–623; need to
control and ensure high quality screening prac-
tices573 607 612 613 624–628; and need to provide a greater awareness
of the effectiveness of existing and new methods for screen-
ing.611 629–635
Currently the British Society of Gastroenterology recom-
mends colonoscopic surveillance of patients with inflammatory
bowel disease636 and colonic polyps.636
A national screening programme for bowel cancer is to start
in England in 2006.637 This will have significant implications for
endoscopy services.
4.7.5 Genetics
Medical genetics, in the form of Cancer Genetics Services
already impacts on the delivery of GI services, albeit to only a
relatively small extent, for those patients, and their relatives,
who are at increased risk of GI tumours owing to some form of
genetic predisposition and hence require some form of GI
surveillance, usually by colonoscopy.638–640 Cancer genetics is a
rapidly developing field, becoming increasingly sophisticated,
and in the future, clinical genetics input is likely to extend to
other common GI conditions—for example, IBD and coeliac
disease.641 642 Advances in genetics will improve not only the
ability to predict who is, or is not, at risk of certain conditions,
but also improve diagnosis, partly through molecular pathol-
ogy.643 644
Medical genetics will also play a part in other areas of GI
services—for example, predicting a person’s responses to drugs,
Table 4.3.5 Numbers of surgical procedures: all, main, and day case procedures according to OPCS-4 chapter in England 2000–
2001
Surgical procedure OPCS-4 chapter OPCS-4 code
All procedures Main procedures Day case procedures
No (%) No (%) No (%)
Nervous system A A01-A84 238 932 (1.9) 202 455 (3.1) 127 048 (2.2)
Endocrine system and breast B B01-B37 99 845 (0.8) 90 301 (1.4) 25 592 (0.4)
Eye C C01-C86 705 740 (5.6) 410 667 (6.3) 547 550 (9.5)
Ear D D01-D28 125 523 (1.0) 94 788 (1.5) 73 919 (1.3)
Respiratory tract E E01-E63 318 165 (2.5) 205 984 (3.2) 99 373 (1.7)
Mouth F F01-F58 28 0249 (2.2) 235 335 (3.6) 173 268 (3.0)
Upper digestive tract G G01-G82 635 154 (5.0) 561 572 (8.6) 403 190 (7.0)
Lower digestive tract H H01-H62 571 089 (4.5) 474 073 (7.3) 328 653 (5.7)
Other abdominal organs—principally
digestive
J J01–J72 128 886 (1.0) 97 102 (1.5) 13 678 (0.2)
Heart K K01–K71 295 807 (2.3) 195 351 (3.0) 93 205 (1.6)
Arteries and veins L L01–L97 293 139 (2.3) 182 761 (2.8) 86 426 (1.5)
Urinary M M01–M83 672 821 (5.3) 525 198 (8.1) 323 036 (5.6)
Male genital organs N N01–N34 112 939 (0.9) 97 304 (1.5) 74 337 (1.3)
Lower female genital tract P P01–P31 105 450 (0.8) 73 654 (1.1) 56 414 (1.0)
Upper female genital tract Q Q01–Q56 632 020 (5.0) 434 024 (6.7) 364 276 (6.3)
Female genital tract associated with
pregnancy, birth, and puerperium
R R01–R34 947 964 (7.5) 526 861 (8.1) 2 159 (0.0)
Skin S S01–S70 446 162 (3.5) 315 840 (4.9) 246 583 (4.3)
Soft tissue T T01–T96 436 789 (3.4) 306 272 (4.7) 128 271 (2.2)
Bones and joints of skull and spine V V01–V54 91 021 (0.7) 71 820 (1.1) 34 480 (0.6)
Other bones and joints W W01–W92 653 005 (5.1) 536 079 (8.2) 177 102 (3.1)
Miscellaneous and subsidiary
operations
X X01–X59 1 106 086 (8.7) 872 017 (13.4) 544 845 (9.4)
Subsidiary classification of operations Y–Z Y01–Z92 3 806 538 (30.0) 0 (0.0) 1 869 195 (32.3)
All operations A–Z A01–Z92 1 2703 240 (100.0) 6 509 426 (100.0) 5 792 598 (100.0)
Source: Department of Health, 2004.453
Gastroenterology services in the UK 49
www.gutjnl.com
group.bmj.com on February 10, 2015 - Published by http://gut.bmj.com/Downloaded from 
  
Figure 4.3.9 Percentage of different
surgical procedures undertaken on the
digestive tract, and on other abdominal
organs in England, 2000–2001 for (A) all
surgical procedures. Source: Department of
Health, 2004453; (B) main surgical
procedures. Source: Department of Health,
2004.453
Figure 4.3.10 Total number of bed days
for main surgical procedures in England,
2000–2001. Source: Department of Health,
2004.453
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including adverse events (pharmacogenetics), and predicting
response of tumours to treatment (somatic genetics, as opposed
to germline genetics). It is likely that pharmacogenetics will
impact first on avoiding adverse events, with individual
tailoring of prescriptions following later.641 642 645 646 Although
the science of predicting response to treatment from an analysis
of a tumour’s genetics is in its infancy, certainly as far as GI
medicine is concerned, it promises to deliver truly individua-
lised treatment. A considerable amount of work needs to be
done, however, to translate this into practice.644 646–650 More
widespread molecular genetic testing of tumours will also
reveal more people who are genetically predisposed and thus
warrant the attention of cancer genetics services.
4.7.6 Prevention
Studies on the prevention of GI diseases are not as prolific as
might be expected. Only five studies were found to examine the
subject in any significant detail,512 651–654 and even in these
varied in the topics and diseases covered. Among those
included in this review, are the prevention of H pylori,654
traveller’s diarrhoea,653 and NSAID related morbidity and
mortality.512 Muller and Sonnenberg emphasise the beneficial
effects of endoscopy for reducing mortality due to colorectal
cancer and cancers of the large bowel, and outline its crucial
role as a preventative procedure.652 Hulscher et al also discuss
the role of interventions to increase preventative activities in
primary care, and the need for more research to determine their
effectiveness.651
4.7.7 Development of managed clinical networks
The complexity of some disorders has been a driver for the
development of clinical networks that cover many disciplines
across different healthcare organisations. The Calman-Hine
report was the catalyst for clinical networks to support the care
of patients with cancer and it has been proposed that similar
networks be set up for liver disease and hepatopancreatobiliary
surgery.214
4.7.8 Quality assessment of endoscopy
At present, there is no agreed national approach to quality
assessment of endoscopy, but this is now being remedied, after
the appointment of a national clinical lead for endoscopy by the
Department of Health. The following activities are in progress:
N Development of a global rating scale
This is a scale that provides an indication of how a patient will
experience having an endoscopy in an endoscopy unit. There
are 12 items on the scale that reflect two dimensions: quality
and safety of care, and customer care. A recent census in
England using this scale was completed by .90% of endoscopy
units. Further measurements will be done twice yearly. The
scale has been underpinned with objective measures, and a web
reporting system for the scale has been completed
(http:www.grs.nhs.uk, accessed 18 January 2007). The scale
is designed to support quality improvement and help inform
patient choice as well as quality assure endoscopy units.
N Ensuring the appropriateness of endoscopy and referral pathways
This work aims at streamlining the patient pathway. It is likely
that the ‘‘Map of Medicine’’ commissioned by the National
Electronic Library for Health will provide an electronic frame-
work for referral pathways linked to choose and book systems
(http://www.mapofmedicine.com, accessed 21 December 2006).
Table 4.3.6 Surgical procedures of the digestive tract and other abdominal organs with waiting times in excess of 90 days in
England, 2000–01
Surgical procedure
Mean waiting
time (days) No of admissionsSurgical procedure
Mean waiting
time (days) No. of admissions
Plastic operations on stomach 319 214 Other connection of ileum 121 184
Connection of stomach to transposed
jejunum
229 75 Excision of pilonidal sinus 121 5 684
Repair of gall bladder 217 11 Repair of diaphragmatic hernia 118 289
Antireflux operations 213 2 121 Open introduction of prosthesis into bile duct 118 34
Repair of liver 192 96 Revision of antireflux operations 116 107
Fixation of rectum for prolapse 172 357 Other open operations on gall bladder 115 29
Excision of haemorrhoids 167 9 177 Extirpation of lesion of jejunum 114 21
Excision of gall bladder 161 38 373 Excision of lesion of anus 111 7 792
Incision of gall bladder 157 179 Other abdominal operations for prolapse of
rectum
110 660
Repair of anus 151 584 Intra-abdominal manipulation of ileum 107 237
Other open operations on bile duct 133 66 Other operations on pilonidal sinus 98 5 850
Open endoscopic operations on colon 126 50 Other operations on haemorrhoids 93 907
Perineal operations for prolapse of rectum126 1 028
Source: Department of Health, 2004.453
Table 4.5.1 Number of finished consultant episodes and costs (£000) digestive system HRGs:
England 2001–02
Emergency Elective admissions Day cases
Total FCEs 648 000 250 000 839 000
Total costs 762 000 382 000 291 000
Overall total cost 1 435 000
Source: HES activity data from iLab, NHS reference costs.
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N Development of a competency framework
A competency framework for all health professionals working
in endoscopy is currently being prepared. This will form the
basis of certification of trainee endoscopists and endoscopy
assistants.
N Re-validation of established endoscopists
A re-validation methodology for established colonoscopists is
currently being tested. Only those who have successfully
completed this process will be allowed to perform colonoscopy
on patients referred for colonoscopy through the bowel cancer
screening programme which began in 2006.
N Accreditation of endoscopy units
A process for accreditation of endoscopy units is currently being
designed and tested. This peer review type process will replace
the self completed questionnaire accreditation process required
Figure 4.7.1 Trends in standardised
incidence and mortality rates (per 100 000
population) for gastrointestinal cancers,
among men and women in England and
Wales, 1971–97 (A) for colorectal cancer;
(B) for oesophageal cancer; (C) for gastric
cancer; (D) for pancreatic cancer. Source:
Quinn et al, 2001.14
Figure 4.7.2 Trends in standardised
incidence rates (per 100 000 population) for
gastrointestinal cancers, among men and
women in England, Wales, Scotland, and
Northern Ireland, 1991–2002 for (A)
colorectal cancer; (B) oesophageal cancer;
(C) gastric cancer; (D) pancreatic cancer.
Sources: England: National Cancer
Intelligence Centre, Office for National
Statistics; Scotland: Information and Statistics
Division, NHS in Scotland. Wales: Welsh
Cancer Surveillance and Intelligence Unit;
Northern Ireland: Northern Ireland:
Northern Ireland Cancer Registry.215 454–456
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by the JAG (Joint Advisory Committee on Gastrointestinal
Endoscopy). Formal accreditation of units which began in 2006.
N Development of quality and safety markers
The BSG endoscopy committee is currently preparing quality
and safety markers for endoscopy that will underpin the Global
Rating Scale and the accreditation process.
5. MODELS OF SERVICE DELIVERY AND THEIR
EFFECTIVENESS: OVERVIEW OF THE RESEARCH
LITERATURE
5.0 Methods
5.0.1 Systematic review of evidence
To promote a reliable, consistent, and unbiased reflection of
existing research is the principal idea behind the use of
systematic reviews. The establishment of numerous organisa-
tions such as the Cochrane and Campbell Collaborations which
provide up-to-date reviews in the area of health, educational,
and social research, and of course, a proliferation of such
reviews and associated methodology in the traditional aca-
demic arena, underlines the sort of attention directed towards
them over the past decade or so. In comparison with
conventional literature reviews, systematic reviews are
designed to answer a specific question based on research
evidence rather than to provide a general overview of a topic.
Thus, the practical advantages of systematic reviews and the
associated analyses are generally transparent—to deliver a
holistic summary and synthesis of individual pieces of research
evidence which together constitute a stronger body of evidence.
However, the immense resources needed for the retrieval,
appraisal, and synthesis of the relevant literature are a
prominent drawback. Indeed, the inspection of literally
thousands of publications is not uncommon in systematic
reviews, all of which require careful screening for inclusion or
exclusion, from which only a small percentage can be deemed
appropriate for the research question.655–657 Moreover, the
processes undertaken during a review can be contentious,
including claims that the review can be used as a means of
exerting political control over new research; criticisms of the
outcomes derived from it (with respect to relative importance
and methods used); and the way in which users are to be
involved throughout (see, for example, Davies658 and Gough
and Elbourne659 for a more detailed discussion). Although these
concerns are beyond the scope of this report, they represent real
and substantial problems, which should be borne in mind
throughout. What is clear, is that any critical evaluation of
Figure 5.1.1 Conceptual map of the review protocol (adapted from
Horvath and Pewsner661 and Khan et al662).
Table 5.1.1 Keywords
A. Gastroenterology B. Burden C. Services D. Evaluation/study type E. Setting/population
1. Biliary 1. Burden 1. Colonoscopy 1. Appraisal 1. UK
2. Bowel 2. Delay 2. Community care 2. Assessment 2. UK
3. Digestive system 3. Epidemiology 3. Diagnostic 3. Audit 3. Britain
4. Dyspepsia 4. Load 4. Emergency 4. Benefit 4. England
5. Gastroenterology 5. Morbidity 5. Health maintenance organisation 5. Best practice 5. Ireland
6. Gastrointestinal 6. Mortality 6. Management 6. Cohort 6. Scotland
7. Hepatology 7. Need 7. Nurse practitioners 7. Cost 7. Wales
8. Intestine 8. Open access 8. Economic
9. Liver 9. Organisation 9. Effectiveness
10. Pancreatic 10. Pathway 10. Estimate
11. Stomach 11. Planning 11. Evaluation
12. Postoperative 12. Evidence
13. Primary care 13. Experiment
14. Professional roles 14. Health promotion
15. Provision 15. Meta-analysis
16. Rapid access 16. Observation
17. Resources 17. Outcome
18. Role substitution 18. Qualitative
19. Secondary care 19. Review
20. Self care/management 20. Study
21. Self referral 21. Survey
22. Service(s) 22. Trial
23. Surgery 23. Volume
24. Tertiary care 24. Waiting (time, list)
25. Economic evaluation
26. Cost effectiveness analysis
27. Cost utility analysis
28. Cost benefit analysis
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literature should take into account the techniques used in
systematic reviews so as to promote consistency and reliability
and obtain an accurate reflection of the work that is already out
there. For these reasons, particular attention was placed on the
design and development of suitable review methods with which
to conduct a literature review and synthesis for this report.
At the heart of any systematic review is its review protocol.
This consists of explicit criteria for the retrieval of relevant
literature, and includes factors such as keywords, sources of
information (such as databases, periodicals, and reports), and
systematic methods for conducting and managing the search to
enable repeatability—that is, a search that can be performed as
many times as necessary by any researcher using the same
criteria. The final list of factors deemed appropriate for the task
is often referred to as the inclusion and exclusion criteria,
which clearly specify the types of study to be included in the
final analysis, as well as how, where, and with what the search
is to be carried out. These factors ultimately determine the
shape of the literature search, and hence the final outcomes of
the study. The protocol thus represents the methodology which
underpins the research, and forms the basis for the evaluation
of the data obtained. A crucial element in this report was
therefore the design and implementation of a protocol which
adheres closely to the established conventions of systematic
reviews and one which could be applied with a high degree of
repeatability and consistency using the available resources so as
to enhance the quality of information for the final analysis.
Design aspects of review protocols660 were taken into account
to enable a reliable method of literature and data retrieval to be
constructed, particularly for the central aspects of the investi-
gation. It can also be seen later in this section that an extensive
quality appraisal and grading of evidence was carried out to
enhance the interpretation of the findings. The first subject to
be examined was specification of the research question. This
was deemed to be of two parts: (a) the current burden of GI
disease and services (representing the general areas of the
report), and (b) service provision and its effectiveness for GI
disease in the UK (section 5). In order to tackle these areas, two
sets of criteria for the protocol (such as those mentioned above)
needed to be established. The first protocol would be used for
sections dealing with general GI topics (the burden of GI
disease), while the second would be developed to focus on
service provision and its effectiveness for GI treatment.
Figure 5.1.1 provides a map of the various stages of the
protocol to be incorporated.
As can be seen in fig 5.1.1, the report follows the general
structure of a systematic review, with the main difference being
that a broad set search strategy is used for related topics of
interest, while a separate criteria is used for the main area of
study. This approach thus allows key points of interest to be
reviewed systematically, and related areas to be incorporated
into other sections of the review. The remainder of this chapter
outlines the various components of the review protocol used in
this study.
General search strategy
The design of this search is to examine the current burden of GI
disease and services in the UK. It was expected that a wide a
variety of literature would be encountered during the study,
which includes paper based and electronic articles, research
articles, general reports, and systematic reviews. To determine
the basis for inclusion and exclusion, a consideration was made
of the following topics:
N Relevance of content
Searches in electronic databases were carried out using the
keywords shown in table 5.1.1; only those which adhered to the
aims of the report were included. Manifestly, it was not possible
to incorporate every conceivable synonym under each subject
heading as this would not only make the search process
unmanageable but would probably also make the search too
broad for the requirements of this report. Nevertheless, the
words shown in table 5.1.1 were defined after thorough
consultation with subject experts and librarians, and can be
considered accurate for the purpose. Furthermore, terms used
as part of medical subject headings (MeSH) produced by the
National Library of Medicine were used where permissible
(such as Cochrane) as a thesaurus to cover a broad range of
keywords and synonyms. Although keywords, synonyms, and
MeSH terms allow a considerable amount of literature to be
retrieved, the specificity and appropriateness of content might
require a more detailed examination because publications may
or may not be relevant even with the presence of certain
keywords. Consequently, an in-depth assessment of abstracts
and, where required, the entire article or report, was carried out
by researchers and subject experts where the appropriateness of
content was uncertain. A more detailed description of this and
actual search techniques can be found below.
N Setting and population
Although a comparison of results from other countries would
have been useful, this was outside what could be realistically
achieved in the given time frame. Publications were thus
restricted primarily to those relevant to the UK, but no
stipulations were made about the population studied (such as
men and women).
N Date of research
Despite the emphasis on current issues pertaining to the burden
of GI disease, older articles and reports are also of interest
because they allow for interesting comparisons, particularly for
the rate of development. As a consequence, no restrictions were
placed on date (in the majority of databases used in this study,
this would include studies published between 1966 to present),
but primary focus was placed on more up-to-date literature.
N Research methods
No specific requirements were made of certain study types or
experimental designs. The expectation was that a wide variety
of publications would be obtained for general concerns of GI
disease (owing to the breadth of the subject), including survey,
evaluative, and experimental studies. All types of study design
were thus included in the search criteria, and included those
published in peer reviewed academic journals, relevant reports,
and systematic reviews. Owing to the wide range of sources, an
important concern was that of literature assessment with
respect to the overall quality of the articles used (that is, the
reliability of the results) and the grading of evidence (see
below).
 
Figure 5.1.2 Search strategy.
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N Language
An inherent problem for any extensive literature review is that
highly relevant articles and reports may be written in a
language other than English. Given the report’s primary focus
on GI disease in the UK, this particular problem was not
expected to be too important. Nevertheless, to guard against
possible exceptions, and in particular, the obvious pitfall of
excluding potentially relevant studies, the decision was made
not to exclude on the basis of language. As far as resources
permitted, the aim was to obtain and translate relevant foreign
publications for the report where English titles and abstracts
indicated potential relevance.
N Inclusion and exclusion procedure
After a systematic search of the relevant sources (a discussion
of the criteria is given below), a detailed screening of the
articles retrieved was required to determine final inclusion or
exclusion. To maximise the consistency and accuracy of this
process, a pilot test was undertaken in which two researchers
(one of whom is a gastroenterologist) carried out inclusion and
exclusion on the same set of articles. Although perfect
agreement is difficult to achieve, discrepancies were examined,
from which a standard protocol was developed. The final set of
articles were then individually screened and categorised into
one of two groups—include (including borderline cases with
some degree of relevance) and exclude.
The next stage was thus the development of the actual search
strategy to incorporate these various requirements. The crux of
this process is defined by the terms set out in table 5.1.1.
Although these help to increase the accuracy and specificity of
the search, there are literally tens of thousands of combinations
(that is, searches) possible by using a word from each of the
five columns, making the workload virtually unmanageable.
Despite this apparently colossal task, the use of Boolean
operators (AND, OR, NOT) allowed the search to be conducted
with greater efficiency. The fields in which individual terms
were searched are article/report keywords, abstracts, title, and
where possible, MeSH categories.
The configuration of Boolean operators and keywords is
shown in fig 5.1.2. This procedure sets the specificity of the
search, and can easily be broadened or narrowed, if necessary,
depending on the quantity of articles retrieved. Should it be
found, for instance, that a search combining all five columns in
table 5.1.1 yields results which are too specific (exemplified by a
low number of studies retrieved), the search can be broadened
by combining terms from only four columns, and so on.
Although great care must be exercised throughout (it might be
the case that the paucity of studies is due to the fact that very
little has been written about the subject in question, rather
than an inherent problem with the search strategy), this
iteration was employed during the search process until the
team was satisfied that coverage and specificity were adequate.
The primary sources of literature are shown in table 5.1.2.
Most of these are electronic databases available via the internet
where the search strategy described above is implemented.
Although these provide comprehensive coverage of relevant
sources of information, further searches were carried out of
other sources (such as general internet searching, citations
from relevant articles, and articles identified by existing GI
projects within the department) using the same stipulations on
content as described above.
Search cri teria for service provision
After the general search, a separate search strategy was
developed for the key area of the report: the provision of
services and their effectiveness for GI treatment. Among the
criteria, attention was placed on specifying the literature with a
more appropriate set of search terms. Inevitably, there would be
a degree of overlap between this and the general search
described in the previous section owing to certain similarities in
the nature of content. But because search strategies are rarely
foolproof and do not find all the desired material, this search
helped to identify a greater number of relevant articles.
The definition of new keywords for the key area was
established by using those shown in table 5.1.1 and after a
further consultation with subject experts. The revised search
terms shown in table 5.1.3 are similar to those for the general
search, with the differences being four columns as opposed to
five (the burden of disease is excluded, thus making this search
broader than the previous one), and four additional keywords
relating to the subject of effectiveness. This aside, all other
stipulations are the same as those described in the previous
section: characteristics of literature; use of keywords from each
of the four columns with Boolean operators (as before, the
number of columns can be reduced to allow coverage to be
broadened as necessary); literature sources; and the process of
inclusion and exclusion. The new search strategy was brought
together using the technique shown in fig 5.1.2.
Quality assessment and grading of evidence
Techniques of quality assessment are commonly applied to gain
insight into the credibility and reliability of studies being
examined. Although the measurement of quality (in this case,
the likelihood of the methods generating unbiased results) is
inherently difficult,657 numerous techniques have been devel-
oped to enable the quality of research methodology to be
gauged with better clarity (see Verhagen et al663 for discussion).
Given the time frame and resources permitted for this study, it
was decided that an extensive examination of quality would
not be feasible. Nevertheless, it was deemed necessary that a
tool be adopted to analyse and ensure that the literature used is
of an acceptable level of quality during the synthesis of
evidence. In addition to quality, there was also a need to
establish a means of grading the evidence (for example,
systematic reviews, cohort studies, and expert opinion) in
order to measure the overall strength of recommendations.
Used together, the two techniques allowed studies to be
assessed independently irrespective of study design, and graded
collectively for the purpose of formulating clear and evidence
based recommendations for GI service delivery. The following
two subsections outline the methods used in this study.
Quality assessment
The purpose of this exercise is to provide a quantitative
assessment of the quality of studies irrespective of their study
design. Given that some study types are generally considered to
be more reliable than others (for instance, systematic reviews
are generally regarded as more reliable evidence than, say,
Table 5.1.2 Primary literature sources
Academic journals: hand searching; journal databases; reference lists;
existing projects
Centre for Reviews and Dissemination (CRD—includes DARE database)
Cochrane Collaboration
Embase
Health management and policy database (HMIC)
Medline
National Institute for Health and Clinical Excellence (NICE)
NHS Service Delivery and Organisation (SDO); Department of Health
Other internet based sources—for example, Institute for Food Research; Gut
Week
SIGLE (grey literature)
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consensus opinion—see next section), it was important that
each study included in this report be assessed for its individual
quality, rather than its design. The benefit of this approach is
that extra weighting (if indeed justified) can be assigned to
studies which are regarded as of a lower level of evidence, but
which are nevertheless carried out with sufficient rigour to
justify the findings carrying greater significance. The result is
that the true quality of the evidence can be captured with
greater clarity and the interpretation of recommendations can
be enhanced.
Possible instruments available for this purpose include the
Maastricht, Delphi, and Jadad lists (designed predominantly
for randomised controlled trials (RCTs) and experiments), and
the AGREE tool (for the assessment of clinical practice
guidelines developed by the Appraisal of Guidelines Research
and Evaluation Collaboration664). These are typically measure-
ment/rating scales which share broad themes in an examina-
tion of the appropriateness, transparency, relevance, and hence
quality, of the chosen methodology for the research question.
Of those instruments suitable for this report, the AGREE tool
seemed to be the most appropriate. Designed as a generic and
relatively compact scale, it measures the quality of reporting
and recommendations of clinical guidelines, and has been used
by a wide range of medical institutions for evaluative purposes.
Similar to tools such as the Delphi and Jadad lists, it covers
various aspects of quality concerning clinical research. Some of
the advantages of this tool include a concise 23 question/item
scale as compared with the 40-plus items in the Delphi list665
and the comparatively simplistic three item Jadad list666, a wide
range of general components (as opposed to strict requirements
on specific study designs such as RCTs), and its easy
modification to suit the requirements of this study. Statistical
tests conducted by Cluzeau et al667 also found a good level of
reliability for individual sections and of the scale as a whole
(Cronbach’s a between 0.64 and 0.88, which exceeds or is close
to the recommended value of 0.7668).
Table 5.1.3 Keywords for key areas of report
A. Gastroenterology B. Services C. Effectiveness/study type D. Setting/population
1. Biliary 1. Colonoscopy 1. Appraisal 1. UK
2. Bowel 2. Community care 2. Assessment 2. UK
3. Digestive system 3. Diagnostic 3. Audit 3. Britain
4. Dyspepsia 4. Emergency 4. Benefit 4. England
5. Gastroenterology 5. Health maintenance
organisation
5. Best practice 5. Ireland
6. Gastrointestinal 6. Management 6. Cohort 6. Scotland
7. Hepatology 7. Nurse practitioners 7. Change 7. Wales
8. Intestine 8. Open access 8. Conventional
9. Liver 9. Organisation 9. Cost
10. Pancreatic 10. Pathway 10. Economic
11. Stomach 11. Planning 11. Effectiveness
12. Postoperative 12. Estimate
13. Primary care 13. Evaluation
14. Professional roles 14. Evidence
15. Provision 15. Experiment
16. Rapid access 16. Future
17. Resources 17. Innovation
18. Role substitution 18. Health promotion
19. Secondary care 19. Meta analysis
20. Self care/management 20. Observation
21. Self referral 21. Outcome
22. Service(s) 22. Qualitative
23. Surgery 23. Review
24. Tertiary care 24. Study
25. Survey
26. Trial
27. Volume
28. Waiting (time, list)
29.Economic evaluation
30. Cost effectiveness analysis
31. Cost utility analysis
32. Cost benefit analysis
Table 5.1.4 Hierarchy of evidence
Level of evidence Type of evidence
1 High quality or well conducted meta-analyses, systematic reviews of randomised control
trials (RCTs), or RCTs with a low risk of bias and direct topic relevance
2+ High quality or well conducted case-control or cohort studies with a low risk of confounding,
bias or chance and a good probability that the relationship is causal; RCTs without direct
topic relevance
22 RCTs, case-control, cohort studies, or surveys with a risk of confounding bias, or chance that
the relationship is not causal
3 Non-analytic studies (for example, case reports, case series)
4 Expert opinion, formal consensus, and policy documents
Guidelines Guidelines set by clinical groups (for example, NICE, BSG, AUGIS)—see quality assessment
for an appraisal of these
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The AGREE tool evaluates quality via questions within each
the following sections:
(a) Scope and purpose
(b) Stakeholder/participant involvement
(c) Rigour of methodological development
(d) Clarity and presentation
(e) Applicability and relevance
(f) Editorial independence.
As can be elicited from the above, all parts of the tool can be
made directly applicable through minor adjustments of
terminology for a quality appraisal of the literature used in
this report. Through a consultation with subject experts and
those with relevant expertise, such as statisticians and
questionnaire designers involved with the project, appropriate
modifications, mostly involving minor changes to words and
phrases to make them relevant to literature, were made: the
final instrument consists of 22 questions/items, and can be
found in Appendix 2. The decision was made to use a three
point Likert scale to measure the agreement, disagreement, or
undisclosed information (such as methodology) for each item:
0 = not specified (little or no evidence); 1 = disagree (some
evidence); 2 = agree (good or strong evidence). A total score
for each article was then calculated to obtain an indication of
overall quality.
As a means of piloting the tool for validity and consistency,
20 articles were chosen at random and appraised by two project
researchers. Scores for each item were assigned after reading
the articles in detail and further discussion, and then total
scores were calculated for each article included in the report;
this score was simply a percentage calculated as the sum of
scores for each of the 22 items divided by the maximum
possible score, 44—thus, a paper with a total score of 22
obtained 50%. The next step was to determine how these scores
could be usefully interpreted as an indication of quality.
Although there are no clear guidelines for this, the general
observation was that the higher the score, the greater the rigour
and quality of the article, and hence the following intervals
were used as a general indicator of quality (S = score):
N S(45%—generally poor quality of evidence; falls short in a
few key areas of quality (see (a) to (f) above)
N 45%,S,65%—generally reliable quality of evidence; falls
short in one or more key areas of quality
N S>65%—good quality of evidence; falls short only in a few
items of quality.
Next, Cohen’s k669 was calculated in SPSS (Statistical Package
for the Social Sciences) to determine the degree of agreement
between the two assessors. Interrater reliability between two
assessors was 0.894 for the 20 articles, indicating a strong
degree of consistency. Because of resource limitations, the
decision was then made for one assessor to appraise all the
remaining articles in the study.
Grading of evidence
In addition to quality assessment, a means of classifying the
evidence needed to be established in order to reflect the
strength and type of evidence that has been used to formulate
recommendations. The appropriateness of this approach,
however, depends on the study question. Evidence hierarchies
typically used for this purpose, being focused on effectiveness,
may not fully acknowledge the validity of other studies which,
despite taking into account a much wider range of issues, may
be considered to be of a lower level.670 As this study focuses on
service delivery, which encompasses a broad range of subject
matter, which cannot always be measured or assessed easily by
intervention studies of effectiveness, it would not be a complete
surprise to find that the evidence collected for it reflects those
studies which are placed lower down in the hierarchy, hence
reducing the overall grades of recommendation. Nevertheless, it
was thought that used in conjunction with quality appraisal,
the grading of evidence would help to provide a wholesome
reflection of existing research, and would provide a conven-
tional framework within which to proceed.
The hierarchy used in this study is based on that documented
in the Centre for Reviews and Dissemination (CRD)660 and
NICE.671 But in light of the issues raised above, some minor
modification (mainly to reduce the number of groups in the
hierarchy) was made to allow for a wider range of studies to be
graded with greater ease (table 5.1.4).
Using this hierarchy, recommendations can be classified by
the strength of evidence on which they were based (see
table 5.1.5—adapted from CRD660; NICE671). However, in this
document conclusions have been drawn, but recommendations
have not specifically been made.
5.0.2 Focus group with patient and carer
representatives
A discussion session with the Patient and Carer Network was
held at the Royal College of Physicians, London, on 8 December
2004. Its aim was to highlight some of the key problems
associated with the delivery of services in gastroenterology
based on the review of evidence described above, and to get
views on these from patients and carers which could be
reflected in this report. Three researchers from the project team
Table 5.1.5 Classification of recommendations
Class Evidence
A N At least one meta-analysis, systematic review, or RCT rated as 1, and directly applicable to the target
population, or
N A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1, directly
applicable to the target population and demonstrating overall consistency of results
N Evidence drawn from a NICE technology appraisal.
B N A body of evidence including studies rated as 2+, directly applicable to the target population and
demonstrating overall consistency of results, or
N Extrapolated evidence from studies rated as 1
C N A body of evidence including studies rated as 22, directly applicable to the target population and
demonstrating overall consistency of results, or
N Extrapolated evidence from studies rated as 2+
D N Evidence level 3 or 4, or
N Extrapolated evidence from studies rated as 22, or
N Formal consensus
D (G) N A body of evidence from guidelines published by clinical groups (for example, NICE, BSG, AUGIS).
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attended and designed the objectives for the session—JGW
(observer/GI expert), HS (facilitator), and BI (scriber). After the
review of evidence described above, four main topics for
discussion were identified and presented by the facilitator for
discussion. These were:
1. Greater self management by patients
2. Endoscopy outside hospitals
3. Should endoscopy be carried out by nurses or doctors?
4. Where should services be located—for example, primary,
secondary, tertiary, specialist care?
A total of 11 patient and carer representatives were present
on the day, and gave permission for the discussion to be
recorded electronically for transcription. Two independent
observers were also present, but did not partake in the debate.
Discussions on each topic lasted for around 20 minutes, and
participants were encouraged to raise their views. It was felt by
the research team that a number of important concerns were
raised in this session, and these have been incorporated into the
results sections of this report.
5.1 Results
5.1.1 Literature search and synthesis
Using the methods described in section 5.0.1, a total of 5039
articles (1830 for search 1 and 3209 for search 2) were identified
by the literature search for potential inclusion in the report.
Further screening by two project researchers for inclusion and
exclusion (see section 5.0.1) reduced the final number of articles
included to 394. A further 38 articles and reports were identified
through hand searching of related sources (such as reports, the
internet, and periodicals), which gave a final total of 432 for the
main sections of the document. Articles obtained but not used are
given in table A.14 in Appendix 4.
Given the broad nature of topics covered in the report, and
that some articles cover many subjects, the next stage was to
categorise each article into its main areas of relevance. This was
performed by one researcher who, for each included article,
skim-read and recorded the topics covered (for example,
incidence, mortality, quality of life). From here, the recording
of evidence was compiled by assigning each of the articles to an
appropriate section of the report, and then into summary
tables. Details of each article (such as topics covered, quality
score, grade of evidence, and key findings) were recorded so
that an overall synopsis (or where appropriate, a recommenda-
tion) of the main topics could be derived.
5.1.2 Economics of GI services
A total of 153 articles were identified which dealt with some
aspect of the economics of GI disease. The review was limited to
studies undertaken in the UK, partly to keep the number of
studies manageable but also because of recognised problems in
transferring cost and cost effectiveness results between
countries.672
The main overall message from the review is that there is a
paucity of high quality economic studies in this area. The
evidence for the economic burden of gastrointestinal disorders,
and the cost effectiveness of treatment is summarised in section
5.5. Articles obtained but not used are given in table A.15 in
Appendix 4.
5.2 Developments in service delivery
Shared care
Both the Department of Health673 674 and the British Society of
Gastroenterology jointly with the Royal College of Physicians489
recommend that high quality services should be delivered
locally whenever possible, with blurring of the traditional
primary/secondary care divide, and should aim at promoting
independence and self management when appropriate. An
analysis of routine data suggests that more efficient use of
services would result from greater integration between primary
and secondary care,675 676 and this is recommended by the Royal
College of Physicians of London, Royal College of General
Practitioners, and the NHS Alliance for the improved manage-
ment of chronic disease.677 The evidence for this, however, is
from a study which examined the 11 leading causes of bed
use—that is, it did not focus on GI disease. Two studies
included an economic component for palliative care schemes
for patients with cancer. Neither showed a difference between
control and intervention groups.517 621
A rapid review of strategies to facilitate transferring
specialised care into the community found some evidence to
support moving diagnostic testing and outpatient follow-up to
primary care, but the studies did not deal with GI disorders.678
For inflammatory bowel disease, there is a strong evidence that
patients benefit, and there is less demand on conventional services
when comprehensive patient education is combined with easy
and rapid access to specialist care when needed,679–683 although
overall costs are broadly unaffected.679 682 Possibly, these findings
could be extrapolated to other chronic gastrointestinal disorders,
particularly irritable bowel syndrome.684 The particular problems
faced by adolescent people with inflammatory bowel disease and
the need for support in the transition from paediatric to adult care
has been emphasised by the National Association for Colitis and
Crohn’s Disease (NACC).685
Total parenteral nutrition can be delivered at home686 and is a
safe alternative to early surgery in complicated Crohn’s disease.
It can also be cheaper,687 but increased resources will be needed
if it is to be implemented for inoperable cancer.688 There are no
economic evaluations of home parenteral nutrition for malig-
nant disease and AIDS.687
Treating patients at home is not a cheaper alternative to
inpatient care. The evidence for this, however, is from studies
that did not focus on GI disease. Further research is needed,
and treatment at home as an alternative to inpatient care
cannot, at the present time, be recommended.689
The Royal College of Pathologists set recommendations on
specimens of limited or no clinical value, which might lead to a
reduction of pathology workload,603 but the cost effectiveness of
this remains to be assessed.
Table A.1 summarises the articles examined for shared care.
Primary care
NHS policy supports the development of the concept of general
practitioners with special interest,690 though endoscopy is the
only facet of gastroenterology that is covered in the recom-
mendations.691 However, although 16% of GPs were already
providing specialist interest services in 1998,692 693 there is
currently no evidence to support the cost effectiveness of these
changes.693 694
Few studies have examined the economic implications for
primary care of H pylori testing and eradication.695 It is unclear
whether such a strategy would be cost effective as an initial
management strategy in primary care.696
Outreach educational interventions have been shown to
improve appropriateness of referral to secondary care of
patients with dyspepsia.580 However, before it is more widely
used, further investigation is required to assess the overall cost
effectiveness of this expensive intervention.697 A self help
guidebook has been shown to reduce the number of primary
care consultations for IBS, with cost savings.681
There is a high level of patient satisfaction with those units
that currently offer endoscopy in primary care.698 Currently, no
evidence exists to support the clinical and cost effectiveness of
such roles,693 699 and the professional view is that they should be
additional to, rather than a substitute for, secondary care.699
58 Williams, Roberts, Ali, et al
www.gutjnl.com
group.bmj.com on February 10, 2015 - Published by http://gut.bmj.com/Downloaded from 
More research is needed. The problem of training136 700 701 and
governance702 703 will need to be examined carefully.
There is, as yet, no published evidence for the safety, clinical
or cost effectiveness of undertaking endoscopy or minor
gastrointestinal surgery in diagnosis and treatment centres.
Research is needed.
Table A.2 summarises the articles examined for primary care.
Secondary services
A review of the literature published between 1980 and 1998
found a paucity of high quality studies that dealt with the
effectiveness of specialised care in general hospitals.704
However, there is some evidence that patients admitted with
gastrointestinal bleeding, acute pancreatitis, and acute liver
disorders fare better when looked after by appropriate
specialists.704–707
article, do not drop –>
Six studies looked at access to specialist care; there is a
serious underprovision of a colonoscopy service in most NHS
hospitals. Training in colonoscopy is often inadequate and
improved practice should result from better training. Unless
there is a dramatic increase in manpower and resources
available for lower GI investigations, the introduction of a
national screening programme would rapidly overburden
already inadequate facilities.556 A shortage of resources for
coloproctology also exists708; some assessments of resource
needs have been performed in cancer services.709 Although there
is very little evidence on the cost effectiveness of CT
colonography, this technique is widely available in the UK,
although experience and throughput vary considerably. Limited
CT scanner facility is the major barrier to further dissemina-
tion.710 There is also some evidence that greater access to
specialist paediatric gastroenterology services for children with
a suspicion of IBD should be sought.576 None of the above
literature included proper economic evaluation, apart from the
MINuET study of nurse endoscopy, which concluded that there
would be no cost benefit, when compared with doctors.491
Notwithstanding the absence of cost benefit, there is now
strong evidence that there should be a shift from doctors to
nurses for diagnostic upper and lower GI endoscopy in
hospitals.491 560 711–715 Other studies with an economic component
which have examined the role of the nurse in undertaking tasks
traditionally performed by doctors include upper GI endo-
scopy,174 529 managing children with GI disease,103 screening for
colorectal cancer,716 running dyspepsia clinics,542 and adminis-
tering propofol during endoscopy.717 Again, none included a
proper economic evaluation. Research to evaluate the clinical
effectiveness of other professionals in roles traditionally filled
by doctors, such as dietician-led coeliac clinics, is needed. The
need for governance and accountability issues to be examined
as roles change has been emphasised by the BSG.718
Long term follow-up of patients with extensive ulcerative
colitis, or patients receiving immunomodulators, or patients
with Crohn’s disease is appropriate.584 Colorectal cancer
complicating ulcerative colitis is most commonly identified in
patients who have been lost to hospital follow-up.719 720
Table A.3 summarises articles examined for secondary
services.
Tertiary services
The Senate of Surgery of Great Britain and Ireland recommends
that surgical care should be provided locally, but that patients
should be moved to a centre of excellence for further specialist
care when appropriate.721 It is the view of professional societies
that complex hepatology, hepatobiliary surgery, and liver
transplantation should also be delivered in specialist, tertiary
centres.214 722 For complex hepatology the expert opinion is that
this should be supplemented by clinical networks of specialists
in secondary care.214
Many individual studies suggest that complex surgery for
cancer, including upper723 724 and lower gastrointestinal,559 560 725
hepatobiliary,373 726–728 and pancreatic malignancy,716 729–732
should be performed at specialist centres which look after
larger numbers of patients with these diseases. A systematic
review by the NHS Centre for Reviews and Dissemination
confirms this view.557 However, an analysis, also from the NHS
Centre for Reviews and Dissemination, points out that the
evidence comes from methodologically weak studies which do
not sufficiently take account of differences in case mix, and
thus probably overestimate the impact of volume of activity on
the quality of care. It also highlights the fact that there is very
little research (and none in the UK) that directly evaluates the
effects of mergers on costs.733 An international literature review
suggests that it is not possible, on present evidence, to define
the optimal configuration of services for oncology.734 A retro-
spective analysis of routinely collected data by surgeons in a
district general hospital concluded that pancreatic surgery
could be performed safely in such locations with good short and
long term outcomes.735 Conversely, there is no clear evidence
that distance from specialist services is associated with poorer
outcomes.733
The implications for district hospitals of increasing concen-
tration of specialist services in tertiary centres have not been
formally modelled and a detailed review of concentration and
choice warns of increasing costs without proven improvements
in quality for all patients.733 Other evidence shows that after
adjusting for prognosis and treatments, cost-volume relation-
ships become U-shaped, reflecting more active intervention by
higher volume doctors along with little activity and long stays
for low volume doctors. This non-linear relationship between
cost and volume suggest that highly concentrated cancer care
might lead to inefficient resource allocation.716 Furthermore, it
may denude secondary care of the expertise needed to manage
less serious gastrointestinal and hepatic disorders.733 A sys-
tematic review of more than 100 studies in the international
literature found little evidence to suggest that merging
hospitals will result in better patient outcomes.736
Thus the optimum configuration of secondary and tertiary
services remains uncertain on present evidence, and it cannot
be assumed that improvements in outcome or efficiency will be
achieved by increasing the number of patients seen by a unit or
individual practitioner through concentration of specialised
skills on a single site. An equally valid conclusion is that
improvements are derived from better training and experience
of practitioners, with access to well trained colleagues in other
disciplines, and supported by adequate facilities. An over-
whelming conclusion is that high quality research is needed,
and that either radical change should await the findings, or be
rigorously evaluated as it is implemented.
Table A.4 summarises articles examined for tertiary services.
5.3 Patient perspectives on service delivery
Topics discussed at the patients’ workshop centred on four
subjects identified from the review of policy and research
evidence as of current concern (the brief sent to the participants
is attached in Appendix 3):
N Greater self management by patients
N Provision of endoscopy services outside hospitals
N Changing roles: should nurses or doctors carry out endos-
copies and care of patients with chronic conditions?
N Location of services: specialisation versus local care.
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Greater self management by patients
Workshop participants were generally positive about the idea of
greater self management, which would bring the benefits of a
greater sense of control, and reduce anxiety about wasting the
time of health professionals. Information and access to services
when needed were felt to be key.
‘‘As long as people are informed…[they] are very happy to
self manage their conditions; they don’t want to keep going
off to hospitals, GPs etc, which are all getting more difficult to
see these days anyway (participant 14).
For the access to services, it’s all very well saying ‘‘if you’re
unwell, give us a call and arrange an appointment’’, but if
you do that you may not be able to get in through the door.’’
(participant 21)
Ability to self care was seen as more than simply being
informed, however, and concern was expressed about those
people who may agree to look after themselves but may not
actually be able to achieve this without some support.
‘‘The consultation is 10 or 20 minutes in hospital, how are
you able to assess if the person is suitable for self
management?’’ (participant 21)
Flexibility and continuity of care were considered important,
with different patients having varying levels of need for
support, and a perception that in a self management model,
patients may be more likely to be treated by new professionals
when they seek care than in a traditional model.
‘‘Continued care is totally lost and frustration comes in for
the patient, especially endoscopies. You know, different
people doing endoscopies at different visit and giving
different information to the patients’’ (participant 27)
Further to this, concern was expressed that GPs or others
coming into contact with a patient attempting to achieve a
greater level of self management may not understand the
patient’s level of control and may undermine the model.
‘‘I find that difficult because when you go into the hospital
you have your plan of treatment and what your input is, and
you go to your GP and you don’t get the same level of
interaction.’’ (participant 21)
Provision of endoscopy services outside hospitals
Primary concerns expressed by participants in the workshop
centred around risk and safety.
‘‘There’s obviously a risk factor. The one concern is there’s
got to be the backup to deal with that and the safety issues
that come with it.’’ (participant 12)
‘‘I have great concerns about this. There are GPs with special
interests operating and carrying out endoscopy in smaller
hospitals and patients are not offered sedation because,
leaving out whether it is safe or not, they don’t have
resuscitation facilities.’’ (participant 14)
Participants were quite cautious about this model, and
questioned whether, again, continuity of care would be
adversely affected. There was a feeling that it might take time
for patients to develop confidence in a system outside hospital.
‘‘just because when you go into an endoscopy unit… it gives
you that little bit of reassurance. I suppose it’s just that you’re
not used to going down to the GP to have that done, but
maybe over time people will get more used to it. There’s
bound to be lots of hesitation.’’ (participant 21)
Some benefits were mentioned, related to local access and
quality of facilities:
‘‘I think location has quite a bit to do with it because there
are some parts of the country where hospitals are a long way
away, whereas the local centre may be down the road. That
would affect you and your ability to get to hospital when
there’s no public transport and you don’t have a car.’’
(participant 11)
‘‘Most people that I talk to really accept the diagnostic
centres and …think they are excellent because most people
do not want to go into hospital and don’t like the atmosphere
of hospitals. They find the centres to be more accessible,
attractive, comfortable to be in…’’ (participant 23)
A distinction was made between minor, routine procedures
that could be done locally and more complex investigations that
needed to be carried out by specialist staff. There was concern
that the most important thing was that the operator had the
appropriate training and expertise.
‘‘Is there not a difference between what are fairly minor
things and very major things where I think most people will
travel to a centre of excellence but for a slightly lower level of
access? If I had cancer I would want to go to a centre of
excellence.’’ (participant 23)
‘‘Things like screening could be done at GPs for conve-
nience, but anything more than that… needs expertise…in
an ideal situation, then yes, I would like the endoscopy done
near my home…but under the prevailing conditions, I think it
would be dangerous to have a blanket statement saying that
it’s safe to do endoscopies in GPs surgeries.’’ (participant
27)
Changing roles: should nurses or doctors carry out
endoscopies and care of patients with chronic
conditions?
There was cautious support for changing roles in relation to
endoscopies and aftercare, with an emphasis again on training,
safety, and continuity of care. The importance of management
of the ‘‘whole’’ patient was emphasised, whether this be done
by a nurse or doctor.
Although some participants were positive:
‘‘I want to support the role of nurses because they have a
good track record in specialist roles in diabetes, cancer.’’
(participant 25)
there was still some anxiety about the safety of care by
nurses:
‘‘Presumably the nurses would have a backup of a doctor
within the vicinity while this was taking place should
something go wrong? That would be my worry.’’ (participant
19)
One participant seemed to sum up the feelings of the group:
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‘‘At the end of the day the label’s pretty irrelevant in some
ways. I could go to a doctor and get really good care and
say doctors are brilliant, but you go to the doctor and not be
happy. Or you could go to a nurse and it’s brilliant. The label
is irrelevant so long as the standard of training is equal to
what they are doing.’’ (participant 21)
Location of services: specialisation versus local care
Views on this topic were mixed, and participants referred to
their own experiences of specialist or local care to illustrate
associated problems. This was clearly a complex topic, with
many considerations and varied personal preferences.
‘‘I think local expertise is important to me… the family has to
be involved, it should be easier for them to visit, and should
be nearby. For those reasons I am prepared to put up with
slightly less expertise, but adequate and safe enough.’’
(participant 27)
‘‘I’ve had a complicated gastric operation that had to be in
[remote specialist centre]. That causes me a lot of problems
because I’m isolated from my family and friends and that
worries me.’’ (participant 24)
On the other hand, specialist care was valued by others, even
at a distance:
‘‘On a personal level, I’d be happy to go to the specialist
centre because I have a specialised condition and I have
confidence in the unit that I go to. So I’m prepared to travel
rather than go local.’’ (participant 19)
It was seen as an important subject that may be eventually
decided through local and national policy rather than on the
basis of research evidence.
‘‘It’s such a major debate, not just for GI… on the whole
because the people for local hospitals are so vocal in their
campaign, that I think it is going to happen. And that may
mean that there won’t be those centres of excellence that
there should be. It’s a huge issue which, at the end of the
day, will be decided politically.’’ (participant 23)
Participants understood the complexity of the debate:
‘‘I don’t think taking expertise away from hospitals is a good
thing because you are narrowing down the number of
people who can get access. Locality is important.’’
‘‘I think I’d support that view in terms of access, because if
you have to have emergency access and go by ambulance,
you may not be able to go to the specialist centre… [but] to
the [local] hospital. So if they didn’t have that expertise, it
would be a disadvantage, but I agree that complex surgery
needs to be done at specialist centres.’’ (participants 21, 25)
There was concern that some may benefit at the expense of
others, with increased specialisation of services.
‘‘I think it’s got the potential of affecting people differently.
You take somebody who’s got a diagnosis of mental health,
learning, old age, whatever—there’s less likelihood of early
diagnosis. The issue of having somebody to support them in
hospital may be more of an issue. My concern is that
…selection out of particular groups because you have a
highly specialised service which doesn’t actually want
them…is a price paid by the minority of the population for
having a better service for other people.’’
Summary of key findings from the patient workshop
Greater self management by patients
N Cautious support was expressed for greater self manage-
ment—as long as care was taken to assess the ability of
patients to self manage, continuity of care could be
maintained, and services could be accessed when required.
Provision of endoscopy services outside hospitals
N Views were mixed, with benefits of local access being
recognised but concerns expressed about safety and con-
tinuity of care.
Changing roles: should nurses or doctors carry out endosco-
pies and care of patients with chronic conditions?
N Participants agreed that appropriate training and skill level
were more important than who delivers care, and the policy
was supported if nurses were able to manage the ‘‘whole’’
patient safely.
Location of services: specialisation versus local care
N Little consensus was reached across the group, with some
participants expressing a preference for local care and others
valuing specialist care, even at a distance. The needs of
minority groups were emphasised.
5.4 Economic burden of GI disease
Studies which attempted to estimate the burden of GI disease
tended to focus on individual conditions or on specific elements
of the total burden. Only one study483 attempted a comprehen-
sive costing of GI disease. It estimated the total burden in 1997
to be roughly £8000m, which included £3000m to the NHS and
personal social services.
A further 20 studies attempted specifically to cost GI
conditions: IBD,737 738 IBS,739–741 GI cancer,324 upper gastrointest-
inal disease (UGI),697 742–744 traveller’s diarrhoea,653 non-specific
abdominal pain,745 colic,746 GERD,16 and dyspepsia.747 748 A
further paper examined the economic consequences of waiting
time for gallbladder surgery.749 Estimated costs are not
presented here because of wide variations in the methods used
and in the quality of the studies. Even the better studies, such
as that on dyspepsia,747 pointed out the limitations of the
study’s external validity.
Modelling exercises dominated. Studies which extrapolated
local results to the UK as a whole failed to deal with the
geographical differentiation across the country. Most used a
prevalence based approach, whereas an incidence based
approach would have sought to estimate the lifetime costs of
managing a cohort of patients first diagnosed in a given year.
Most studies were merely ‘‘snapshots’’ based on national
statistics and aimed only at indicating the possible scale of
the problem without claiming precision. Suggestions for future
research focused on ways to improve the quality/accuracy of
routinely collected data, and on the need for prospective cohort
multicentre studies to confirm results from modelling exercises.
Table A.5 summarises the articles examined for economic
burden of GI disease.
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5.5 Cost effectiveness of GI services
One hundred and twenty seven articles examined the cost
effectiveness of alternative forms of service delivery. As with
the burden of illness studies, these were also of varying quality.
Primary care
Fifteen studies looked at management of GI disease in primary
care.
Few studies have examined cost effectiveness and no studies
of sufficient power have yet been performed in general practice
populations to investigate the role of H pylori and the
implication for primary care.582 No attempt has been made to
measure quality of life after eradication therapy in patients with
peptic ulceration. Further research is needed to quantify the
risks and to test the value of screening elderly patients for H
pylori before using NSAIDs. To determine whether or not a
subgroup of patients with H pylori related chronic gastritis and
non-ulcer dyspepsia would benefit from eradication therapy a
longer follow-up period is needed. Until this is determined, the
treatment of non-ulcer dyspepsia with eradication therapy
should remain a research activity.582
The available clinical and economic information about
NSAIDs is limited, and the publication of numerous poor
quality studies has corrupted the knowledge base. However,
there does seem to be enough evidence to indicate that
expenditure on NSAIDs could be considerably reduced and
adverse effects avoided if practitioners were persuaded to
change their behaviour.514 A growing body of evidence suggests
that information provision on its own does not lead to
substantial changes in practice. More active strategies, such
as ‘‘academic detailing’’ using evidence based educational
outreach, show promise, but their cost effectiveness has not
yet been evaluated rigorously.514
Educational intervention concerning GPs’ management of
patients with dyspepsia, to control dyspepsia costs without
increasing demand for endoscopy, could lead to a £25m saving
each year.750 However, proper multicentre RCTs are needed to
support the cost effectiveness of this approach.
It is unclear whether a strategy to test for H pylori and then
eradicate it is as cost effective as initial management strategy in
primary care. Future trials should evaluate the cost effective-
ness of this strategy compared with empirical prescribing.751
The remainder of the studies, although they investigated the
management of GI patients in primary care, were mainly based
on either qualitative or review work exploring the safety of
endoscopy performed in primary care, the effect of guidelines
for the management of IBD, the development of GPwSI (GPs
with special interests in gastroenterology); a survey of GPs
requirements for support from secondary care; the effect of
bulletin findings on patient’s management; and the effect of H
pylori testing results on referral rate. None of the studies
included an economic measurement.
Table A.6 summarises the articles examined for primary care.
Specialist care
Nine studies looked at access to specialist care; there is a serious
underprovision of colonoscopy service in most NHS hospitals.
Training in colonoscopy is often inadequate and improved
practice should result from better training. Unless there is a
dramatic increase in manpower and resources available for
lower GI investigations, the introduction of a national screen-
ing programme will rapidly overburden already inadequate
facilities.752 There is a shortage of resources for coloproctol-
ogy753; some assessment of resource needs has been performed
in cancer services.754 Although there is very little evidence on
the cost effectiveness CT colonography, this techniques is
widely available in the UK; however, experience and through-
put varies considerably. Limited CT scanner facility is the major
barrier to further dissemination.755 There is also some evidence
that greater access to specialist paediatric gastroenterology
services for children with suspected IBD should be sought.756
None of the above publications included a proper economic
evaluation.
Table A.7 summarises the articles examined for access to
specialist care.
Role of nurses
Four studies with an economic component examined the role of
nurses in performing a variety of GI services, including upper
GI endoscopy,712 managing children with GI disease,757 screen-
ing for colorectal cancer,758 running dyspepsia clinics,759 admin-
istering propofol during endoscopy.717 Again, none included a
proper economic evaluation. A multicentre RCT comparing
nurses and doctors undertaking diagnostic upper and lower GI
endoscopy has shown that doctors are more cost effective than
nurses in carrying out these procedures.491
Table A.8 summarises the articles examined for the role of
nurses in GI services.
Home parenteral nutrit ion
Two studies760 761 looked at the cost effectiveness of home
parenteral nutrition (HPN). There is some evidence that home
parenteral nutrition (HPN) is a cheaper alternative than
hospital care. No economic evaluations of HPN for malignant
disease and AIDS have been made.760
Table A.9 summarises the articles examined for HPN.
Surveil lance programmes
Nine articles with an economic component were identified.
Intensive follow-up after resection for colorectal cancer was
shown to be more effective and more cost effective than
conventional follow-up,601 producing an incremental cost for
each life year saved of £3402 over conventional follow-up. This
is very low compared with other life extending interventions,
indicating that on economic grounds, intensive follow-up after
curative resection for colorectal cancer should become normal
practice. Large RCTs are needed to evaluate the cost effective-
ness of specific surveillance tools.
A number of economic modelling exercises have examined
population screening/eradication programmes for H pylori. One
modelling exercise estimated that a programme to screen for
and eradicate H pylori in a population of one million 45 year
olds would produce an incremental cost for each life year saved
of £14 200,614 which again is low compared with other life
extending programmes. Another619 showed that population
screening for H pylori was a cost effective way of preventing
gastric cancer and peptic ulcer disease, producing an incre-
mental cost for each life year saved at age of 40 of £5860, but
this result was sensitive to H pylori prevalence, the degree of
opportunistic eradication, the discount rate, the efficacy of
eradication on gastric cancer risk, the risk of complicated peptic
ulcer disease and gastric cancer associated with H pylori
infection, and the duration of follow-up. Many assumptions
are required in modelling exercises of this type. However, when
these assumptions were varied in sensitivity analyses, the
incremental cost for each life year saved rarely exceeded £20
000 over an 80 year follow-up, although it did for shorter
periods. Population H pylori screening may be cost effective in
the long term (over 25 years). However, before it can be
recommended further evidence is needed to resolve some of the
uncertainties, particularly about the efficacy of eradication on
risk of gastric cancer, the risk associated with complicated
peptic ulcers, and the effect of more widespread opportunistic
testing of patients with dyspepsia. The long duration between
the age of screening and the incidence of gastric cancer means
that screening does not become cost effective for several
62 Williams, Roberts, Ali, et al
www.gutjnl.com
group.bmj.com on February 10, 2015 - Published by http://gut.bmj.com/Downloaded from 
decades. Before screening can be recommended on economic
grounds further evidence is needed to resolve some of the
uncertainties, particularly with regard to the time horizon and
the discount rate.
Table A.10 summarises the articles examined for surveillance
programmes.
Dyspepsia and endoscopy
Quite a few studies examined endoscopy. One used modelling
to examine a wide range of different situations in which
endoscopy is given for patients with dyspepsia.34 Results
showed that endoscopy is not cost effective in patients with
low risk of malignancy, but targeting had major impacts on cost
effectiveness ratios. Restricting endoscopy to those with
continuous epigastric pain or symptoms of less than one year’s
duration, or both, improved the incremental cost for each life
year saved from £50 000 to £8400. Estimates of incremental
cost per life year saved for men of various ages ranged from
£454 000 at age 40 to £15 779 at age 70. Results for women
showed similar reductions at older ages, which provides good
evidence of the need to restrict endoscopy in younger age
groups.34 When the initial strategies for managing dyspepsia
were examined, a comparison of early endoscopic investigation
with acid suppression showed that the cost of additional
endoscopies was offset by a significant reduction in the number
of PPIs prescribed and outpatient attendance. The overall
management cost of prompt endoscopy was £420 compared
with £340 for empirical management.697
Table A.11 summarises the articles examined for dyspepsia
and endoscopy.
This review shows that economic evidence on the delivery of
GI services is patchy and of variable quality. Very few studies
were full economic evaluations and the limited economic
evidence they produced—for example, of potentially large cost
savings to be gained by changing from one model of service
delivery to another—emphasises the need for comprehensive
economic evaluations in this area.
Summary points
N Multicentre studies are needed
N Studies should take the societal perspective
N Methodological problems/challenges of economic evalua-
tions of primary/secondary care interphases have been
highlighted
N Insufficient evidence is available to support a positive
correlation between volume and patients outcomes. This
relationship needs further assessment.
Table A.15, Appendix 4, lists the references not used for the
economic review and the reason why.
5.6 Information infrastructure
The requirements for information and IT support for gastro-
enterology have been published by the British Society of
Gastroenterology.762 This describes the need for patient focused
records that will provide access to appropriate information in
the increasingly wide variety of contexts in which patients will
receive health care, including self management. The most
pressing immediate need is for universal support for the
widespread introduction of systems to support gastrointestinal
endoscopy. The requirements include booking, patient informa-
tion, consent, results, reporting, and quality assurance. A
survey of gastrointestinal units in 2001 found that one third
of respondents from the UK were still using paper reporting
systems.763 Many other aspects of gastroenterology need better
information support, including all contacts with professionals
and specific clinics, where acquisition of data should be used to
monitor quality of care. It is hoped that patient focused systems
will be developed in the future, which will enable support for
patient care through a wide variety of situations in which the
patient receives care.
There is presently no national dataset to enable comparative
monitoring of activity and performance in gastroenterology.
There are concerns about the quality of routinely captured
data.11 Common standards for records and for data collection
are needed to improve this,764 and to enable performance
monitoring, monitor quality and training, inform service
developments, and enable high quality clinical and health
services research.765 There is evidence that routinely captured
clinical data would enable health technology assessment by
RCT if the data were more widely available and of improved
validity.766 767 The data required to support gastrointestinal
endoscopy are available on the British Society of
Gastroenterology website (http://www.bsg.org.uk, accessed 26
December 2006), and requirements are being developed for
other areas of the specialty.
6. DISCUSSION
6.1 Strengths and weakness of methods used
As detailed in the methods chapter and at the start of each
chapter, four main methods of data collection were used to
gather evidence for this review: review of published evidence;
use of routinely available data; patient workshop; and
consultation with professionals in gastroenterology. The
strengths and weaknesses of each of these methods are
considered below, with implications for strength of recommen-
dations made in this report assessed in section 6.2.
Review of published evidence
As we applied currently defined and accepted standards to the
review of effectiveness of service delivery, this section of the
report is comprehensive and systematic. Validated tools were
used to assess the quality of papers and level of evidence
provided, with more than one reviewer independently grading
papers. Full details of the search and of papers retrieved are
presented through search results and tables. Other sections of
the report are comprehensive and have retrieved key data and
publications, although the methods used to identify sources
have relied to some extent on existing knowledge and
collections of materials. With extensive feedback sought from
a variety of specialist professional and patient groups it is
unlikely that key sources have been either overemphasised or
overlooked.
Routine data
Several main sources of routine data were used in compiling
this report: cancer surveillance and registry units across the UK;
the Office of National Statistics (ONS) and its predecessor, the
Office of Population Censuses and Surveys (OPCS); the
Department of Health; and communicable disease surveillance
units across the UK. In addition to well described generic
limitations of routine data, the different data sources have their
own particular strengths and weaknesses.
Limitations of cancer surveillance and registry data include
concerns about variability in case ascertainment and complete-
ness of registrations over time and between different registry
regions. The major limitation of mortality data from the ONS
and the OPCS is that it is based on underlying cause of death
alone, and therefore underreports true mortality for many
gastrointestinal diseases; major concerns have also been raised
about the accuracy and completeness of hospital episode
statistics from the Department of Health. The main limitation
of data on hepatitis B and C infections from communicable
disease surveillance units is that they are based on reported
laboratory diagnoses only. As most people who are infected
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with these viruses are undiagnosed, the reported laboratory
data are thought to account for only about one quarter of all
cases.
Despite these limitations, these are the best data that are
available for portraying the burden of gastrointestinal disease
in the UK. Coverage is national, with standardised definitions
and inclusion criteria agreed. They have provided the empirical
basis for many publications in scientifically acclaimed interna-
tional clinical journals, as well as National Service Frameworks
and other policy documents.
Patient workshop
The limitations of the focus group carried out with patient
representatives recruited from the RCP volunteers are acknowl-
edged. The views reported in this document can only be taken
to represent a flavour of the views of patients. Participants
included patients and patient representatives, who were
perhaps unusually articulate and able to interact as members
of a group. Nevertheless, the findings complement the review
findings, presenting a different side of the picture on the
problems of service delivery arrangements that are currently
undergoing change, which were discussed at the workshop.
Consultation with professionals from within the
specialism of gastroenterology
Feedback has been sought through the BSG membership, and
other societies, and has been collated from individual responses
as well as from a wide range of specialty and patient groups
that support the care of patients with GI disorders. Only that
feedback which was supported by further evidence has been
incorporated.
6.2 Strengths and weaknesses of evidence presented in
report
Using a mixed methods approach in this review has allowed
any weaknesses inherent in one method to be complemented
by the strengths of another approach.
The systematic review of effectiveness of models of service
delivery has been enriched through contextualisation, with the
national policy agenda described; presentation of data describ-
ing burden of disease, current activity, economic costs, and
workforce implications; and the views of patients and profes-
sionals represented. This has allowed a comprehensive docu-
ment to be developed. Some aspects of the review—such as the
perspective of patients to current developments in service
delivery—would be more comprehensively and rigorously
pursued through primary research, and the data presented in
this report can only be taken as a taster of views. This has
resulted in recommendations for further research, as existing
evidence is thin. Indeed, an overwhelming conclusion of the
report is that the evidence base for the development of services
needs to be strengthened before further investments are made
in shaping the delivery of services.
6.3 Research in gastroenterology
Although over 900 references have been used to inform this
review, the evidence identified has often been weak and there
are many gaps in areas where evidence is needed. The annual
reports of the Health Technology Assessment and NHS Service
Delivery and Organisation Research Programmes document
relatively few studies in gastroenterology.
A coordinated approach to clinical and health services
research in gastroenterology, such as the one being introduced
for cancer, in gastroenterology would improve the identification
of research questions and priorities, funding strategies, patient
and carer involvement, and the research infrastructure. It is
hoped that the UK Clinical Research Collaboration will promote
and enable more research into the diagnosis, treatment, and
care of patients with GI and hepatic disorders.
7. CONCLUSIONS
7.1 Burden of disease
N The burden of gastrointestinal and liver disease is heavy for
patients, the NHS, and the economy (sections 3.2–3.4, 3.7,
4.3–4.5, 4.7.2, 4.7.3, 5.5).
N Gastrointestinal disease is the third most common cause of
death, after circulatory and respiratory disease (section 3.3).
N Gastrointestinal cancer is the leading cause of death from
cancer (section 3.3).
N Gastrointestinal disease is the most common cause of
admission to hospital for both the total number of people
admitted and the total number of episodes of care (section
4.3).
N There have been large increases in the incidence of liver
diseases, such as alcoholic liver disease, non-alcoholic fatty
liver disease, biliary cirrhosis, and hepatitis C infection,
which have major implications for future healthcare needs
(section 3.2).
N There have also been increases for most other gastrointest-
inal diseases—in particular, for oesophageal and colorectal
cancers, acute and chronic pancreatitis, gallstone disease,
upper gastrointestinal haemorrhage, diverticular disease,
and Barrett’s oesophagus (section 3.2).
N Chronic gastrointestinal disorders such as dyspepsia, gastro-
oesophageal reflux disease, and irritable bowel syndrome are
highly prevalent; and coeliac disease is far more common
than previously considered (section 3.2).
N Socioeconomic deprivation is linked to a number of
gastrointestinal diseases, including increased risks of gastric
and oesophageal cancers, hepatitis B and C infections, liver
cirrhosis, peptic ulcer, upper gastrointestinal haemorrhage,
and poorer prognosis for colorectal, gastric, and oesophageal
cancers (section 3.6).
N There is substantial variation in the incidence and prevalence
of many gastrointestinal disorders in the UK. For example,
peptic ulcer, Helicobacter pylori infection, upper gastrointest-
inal haemorrhage, alcoholic liver disease, acute pancreatitis,
and oesophageal cancers are all more common in Scotland
and northern England than in southern regions (section
3.5).
N Impact on patients is neither fully nor accurately reflected in
statistics describing mortality and activity (sections 3.3, 4.3).
N The burden on patients health related quality of life has been
found to be substantial for their symptoms, activities of daily
living, and employment (section 3.4).
N Conditions with a high level of disruption to patients’ lives
include: gastro-oesophageal reflux disease (GORD), dyspep-
sia, irritable bowel syndrome, anorectal disorders, GI
cancers, and chronic liver disease (section 3.4).
N Overall, the burden of GI disease on health related quality of
life (HRQoL) in the general population seems to be high,
although the burden is not systematically nor comprehen-
sively described (section 3.4).
7.2 Service delivery
N An extensive and systematic study of the problem of access
for the delivery of GI services has yet to be carried out
(section 4.6.1; level of evidence: 22 at best).
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N There is a lack of significant literature relating to inequalities
in the delivery of GI services (section 4.6.2; level of evidence:
4).
N Waiting times form the bulk of patients’ concerns. There
seems to be great difficulty in meeting government
standards for referral and treatment (section 4.6.3; level of
evidence: 22 at best, and guidelines by the Association of
Coloproctology of GB and Ireland).
N Most studies show that GI related drugs and procedures are
safe. There is a need for more research on the safety of
patient initiated drugs and procedures for the treatment of
GI disease (section 4.6.4; level of evidence: 1).
N There is a need to increase awareness and the implementa-
tion of initiatives aimed at improving the information flow
between patients and practitioners (section 4.6.5; level of
evidence: 22 at best).
N There is a strong body of evidence on diagnostic services, and
the need to develop and implement appropriate training and
stringent assessment to ensure patient safety (section 4.6.6;
level of evidence: 2+).
N There is a substantial amount of work detailing guidelines
for care, but there is a distinct paucity of rigorous, evidence
based studies dealing with service provision (section 4.7.1;
level of evidence: 1).
N There is strong support for the development and use of
widespread screening programmes for a wide variety of GI
diseases. These need to be properly researched to determine
how they are managed, their effectiveness, and their cost
effectiveness (section 4.7.4; level of evidence: 1, section 5.5).
N Emphasis should be given to developing interventions to
increase preventative activities in primary care, and more
research to determine their effectiveness and cost effective-
ness (section 4.7.6; level of evidence: 1).
N More research is needed to establish a robust evidence base
for models of service delivery (section 5.2).
N Overall there remains a paucity of cost effectiveness evidence
particularly from multicentre studies in GI service delivery
(section 5.5).
N There is strong evidence for a shift in care towards greater
patient self management for chronic disease in appropriate
circumstances, and supported by adequate circumstances
and access to services (section 5.2; level of evidence: 1).
N The development of GPs with a special interest in gastro-
enterology is supported in primary care but the clinical and
cost effectiveness needs to be researched (section 5.2).
N In hospital, patients with gastrointestinal disorders should
be looked after by specialists (section 5.2; level of evidence:
2+).
N More diagnostic endoscopy should be undertaken by trained
nurses, although such procedures are not more cost effective
than when carried out by doctors (section 5.2; level of
evidence: 1).
N Complex surgery for gastrointestinal and hepatobiliary
cancer should be performed by specialists who operate on
large numbers of patients (section 5.2; level of evidence: 2+).
N There is insufficient evidence to support a greater concen-
tration of specialists in tertiary centres. More research is
needed, especially on the impact on secondary services,
before further changes are implemented (section 5.2; level of
evidence: 2+).
N The solution proposed for hepatology is to combine tertiary
specialist centres for complex liver disease and transplanta-
tion with a network of specialists in secondary care, but we
found no evidence for the clinical or cost effectiveness of this
approach (section 5.2; level of evidence: 4).
N There is an urgent need for better IT and information
support for clinical care in gastroenterology (section 5.6;
level of evidence: 22).
7.3 Workforce
N Consultant gastroenterologist numbers need to increase to
about 1900 posts (1625 WTE). Six consultants are required
to provide full services and emergency cover for a typical
district general hospital population of 250 000 (section 4.2;
level of evidence: 22).
N Gastroenterology teams led by consultants, but including
appropriate non-consultant career grade staff, dieticians,
and specialist nurses, need to be developed in all hospitals,
with integrated specialist training where appropriate (sec-
tion 4.2; level of evidence: 4).
N More nurses should be trained to undertake upper and lower
diagnostic endoscopy (section 5.2; level of evidence: 1).
7.4 Future research
More research is needed into delivery and organisation of
services for patients with gastrointestinal and liver disorders, in
particular:
N The clinical and cost effectiveness of GPs with a special
interest in gastroenterology and endoscopy (section 5.2).
N The clinical and cost effectiveness of undertaking endoscopy
or minor gastrointestinal surgery in diagnostic and treat-
ment centres (section 5.2)
N The reconfiguration of specialist services and the potential
impact on secondary and primary care and on patients
(section 5.2)
N The clinical and cost effectiveness of clinical networks
(section 5.2).
N The relationship between volume and patient outcome needs
further assessment (section 5.2).
N To account for geographical differences, future research
should be based mainly on multicentre studies.
The establishment of the UK Clinical Research Collaboration
will provide an opportunity to increase clinical and health
services research in gastroenterology. It is important that the
investment that is being made supports the growth of research
into the care of diseases which are responsible for high
morbidity and mortality, and are a significant burden on the
patient, the NHS, and the economy (section 6.3).
8. ANNEX: SUMMARY OF ARTICLES USED
Note on methodology – rationale for presentation of
results in tables
The review of evidence of effectiveness of service delivery
arrangements followed the CRD methods for systematic
reviewing, with the primary literature search designed to
identify papers concerned with service delivery. Results of the
search are presented in section 5.2. All papers identified
through this search were screened, and those that were
relevant to any section of the report were summarised and
graded. Papers cited in section 5.3, concerned with effectiveness
of models of service delivery, are matched with tables (A.1–
A.11) which provide further details of the research setting,
study design, and key results, as well as their AGREE score and
grading for level of evidence where relevant.
Additional papers for other sections of the report were
identified through topic-specific searches (burden of disease;
quality of life; health economics of GI) and through existing
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Table A.12 Summary of articles identified through systematic search by section
ID and authors Research setting and year of study Study design Sample size Topic of document
Level of
evidence
Quality score
(AGREE) (%)
Section 3.1 Spectrum of disease
Jenkins
541 UK (2001) Commentary, review of
evidence
NA Paediatric IBD 3 52
Cumberland et al
358 UK (not specified—circa 2003) Survey and follow-up 85 Practices; over
1000 cases
Infectious intestinal disease in
England
22 73
Dominitz et al
783 USA (not specified—circa 2002;
data between 1987 and 1996)
Analysis of routine data Sample taken from
746 130 births
Infants born to mothers with IBD 2+ 66
Sheridan et al
745 UK (1990) Analysis of routine data;
survey
100 Patients; 52
clinicians
Abdominal pain and resource
implications
22 73
De Lillo and Rose
784 International (2000) Commentary; appraisal of
evidence
Around 50 articles Bowel disorders in geriatric patients 3 57
Hislop and Heading
785 UK (2000–01) Survey and analysis of
routine data
53 clinicians Impact of alcohol related disease 22 61
Lunniss et al
359 UK (data taken between 1995
and 2002)
Analysis of patient data 629 Patients Faecal incontinence 22 66
McKiernan et al
373 UK (1993–95) Analysis of patient data;
survey
93 Cases Biliary atresia 22 64
Plevris et al
786 International, with emphasis on
UK (1998)
Commentary; review of
evidence
Around 120 articles Management of acute liver failure 3 61
Morris
787 International (1991) Commentary; review of
research
Around 80 articles Non-ulcer dyspepsia 3 59
AGA
788 USA (2001) Review of evidence; expert
commentary
Over 125 articles Prevalence and costs of GI diseases 2+ 68
De Dombal
544 International; emphasis on UK
(1994)
Commentary; review of
evidence
Around 7 articles Acute abdominal pain 3 57
Section 3.2 Incidence (includes prevalence)
Jenkins
541 UK (2001) Commentary; review of
evidence
NA Paediatric IBD 3 52
Cumberland et al
358 UK (Not specified—circa 2003) Survey and follow-up 85 Practices; over
1000 cases
Infectious intestinal disease (IID) in
England
2+ 73
Bodger
737 International, with emphasis on
UK (2002)
Commentary; appraisal of
evidence
Around 60 articles Cost of illness of Crohn’s disease 3 66
Hislop and Heading
785 UK (2000–01) Survey and analysis of
routine data
53 Clinicians Impact of alcohol related disease 22 61
Gut Week
103 UK (2004) Public information leaflets;
commentary
NA Digestive health in the UK 3 36
Lunniss et al
359 UK (data between 1995 and
2002 taken)
Analysis of patient data 629 Patients Faecal incontinence 22 66
Ghanchi and Rembacken
789 UK (2003) Review of evidence;
commentary
Around 130 articles IBD 3 70
Morris
787 International (1991) Commentary; review of
research
Around 80 articles Non-ulcer dyspepsia 3 59
Mamula et al
790 International; emphasis on USA
(data between 1977 and 2000
taken)
Analysis of routine data 82 Patients IBD in children under 5 years of age 22 70
AGA
788 USA (2001) Review of evidence; expert
commentary
Over 125 articles Prevalence and costs of GI diseases 2+ 68
McNamara et al
581 International; emphasis on USA
(2000)
Review of evidence; expert
commentary
Around 70 articles Non-ulcer dyspepsia (NUD) 22 64
Wong et al
791 China and Hong Kong (2002) Survey of Chinese population 2209 Survey
responses
Gastro-oesophageal reflux disease
(GERD)
22 80
Pimentel et al
792 USA (not specified—circa 2000) Survey; analysis of patient
data
448 Patients Small intestinal bacterial
overgrowth (SIBO) and IBS
2+ 66
De Dombal
544 International; emphasis on UK
(1994)
Commentary; review of
evidence
Around 7 articles Acute abdominal pain 3 57
Loftus
102 International (2004) Review of evidence Around 170 articles IBD 22 59
Russel
793 International (2000) Review of evidence;
commentary
Around 50 articles Incidence of IBD 3 55
Moum and Ekbom
794 International (2002) Review of evidence Around 90 articles Incidence of IBD 3 55
Wilson et al
153 International (2003) Systematic review 15 Articles Prevalence of IBD 1 66
Farrokhyar et al
795 International (literature between
1950 and 1999 taken)
Review of evidence Around 200 articles Epidemiology of IBD 1 66
Lapane et al
796 USA (data between 1992 and
1996 taken)
Analysis of patient data 133 839 Patient
records
Effect of NSAID use 2+ 68
Chiang et al
797 Australia (2001) Analysis of patient data 167 Patients Acute pancreatitis management 2+ 68
Fass et al
798 USA (1992–95) Analysis of patient data;
survey
505 Patients Functional bowel disorders (FBD)
and sleep disorders
22 73
Parry et al
799 UK (2000–01) Case-control study 482 Patients IBS and bacterial gastroenteritis 2+ 75
Bernstein et al
800 Canada and USA (data between
1984 and 1996 taken)
Analysis of data Not specified, but a
large number
Extra-intestinal diseases in IBD 22 59
Payne and Saul
801 UK (data between 1994 and
1998 taken)
Survey and analysis of data 12 239 Responses Common disorders in long term
illnesses
22 61
Ruigomez et al
802 UK (1994) Analysis of data 2956 Patients Follow-up of patients with IBS 22 50
Sanders et al
174 UK (1999–2001) Cross sectional intervention 1200 Participants Diagnosis of coeliac disease 2+ 70
Waddell and Hislop
357 UK (not specified—circa 1999
onwards)
Analysis of patient data 390 Patients Impact of alcohol related disease 22 59
BSG
574 UK (2002) Guidelines NA Guidelines for dyspepsia
management
22 45
ONS
803 UK (2001) National data Cancer trends between
1950 and 1999
Cancer trends in England and
Wales
2+ 66
Kennedy and Jones
22 UK (Not specified—circa
1997–2000)
Cross sectional survey 3179 Survey responses Prevalence of gastro-oesophageal
reflux symptoms
22 64
Watson et al
144 UK (data between 1980 and
1999 taken)
Retrospective study of patient
data
107 Patients IBD in children 22 57
Rockall et al
91 UK (1993) Analysis of patient data 4185 Cases Incidence and mortality from
GI haemorrhage
22 57
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ID and authors Research setting and year of study Study design Sample size Topic of document
Level of
evidence
Quality score
(AGREE) (%)
Metcalf et al
243 UK (data between 1987 and
1994 taken)
Analysis of patient data 160 Cases Incidence and prevalence of
primary biliary cirrhosis in
Newcastle Upon Tyne
22 61
Blower et al
804 UK (1990–91) Analysis of routine data 620 Cases Upper GI disease and NSAID use 2+ 57
Sawczenko et al
805 UK (1999) Survey 739 Responses Childhood IBD 22 50
James et al
238 UK (data between 1987 and
1994 taken)
Collection and analysis of
patient data
770 Cases Primary biliary cirrhosis 22 52
McKay et al
306 UK (data between 1984 and
1995 taken)
Analysis of patient data Over 10 000 cases Acute pancreatitis 22 57
Griffin et al
806 UK (2002) Analysis and summary of
patient data
3361 Cases Summary of incidence and
mortality rates for upper GI cancers
3 43
Cooper et al
807 UK (2001) Analysis of NHS Direct data Over 150 000 calls Calls to NHS Direct and GI
diseases
22 55
CSCG
808 UK (2003) Commentary NA Response to NICE service
guidance on upper GI cancers
Guideline 41
Jones
809 International (1999) Review of evidence Around 20 articles Methodological considerations 3 68
Feuer
595 International (1999) Commentary; review of
evidence
Around 20 articles Management of intestinal
obstruction
3 50
NHS, NICE
810 UK (2004) National commentary;
guidelines; recommendations
NA Improving the outcomes in
colorectal cancer
Guideline 70
South Wales Cancer
Network
754
UK (2003) Service guidelines;
recommendations
NA Configuration of services 3 45
Aerts and Penninckx
266 Europe (2003) Review of evidence;
commentary
Around 30 articles Burden of gallstone disease 22 52
Ashorn
811 Europe (2003) Review of evidence;
commentary
Around 20 articles Paediatric GI disease 3 43
Delvaux
210 Europe (2003) Review of evidence;
commentary
Around 30 articles Diverticular disease of the colon 3 48
Delvaux
812 Europe (2003) Review of evidence;
commentary
Around 40 articles Faecal incontinence 3 55
Delvaux
813 Europe (2003) Review of evidence;
commentary
Around 30 articles Functional bowel disorders and IBS 3 50
McNamara
319 Europe (2003) Review of evidence;
commentary
Around 40 articles Pancreatic disease 3 50
Burroughs and
McNamara
227
Europe (2003) Review of evidence;
commentary;
Around 30 articles Liver disease 3 50
Talley et al
53 USA (1987–90) Survey of random sample of
population
328 Survey responses Prevalence of gastrointestinal
symptoms in the elderly
22 70
Section 3.3 Mortality
Gut Week
103 UK (2004) Public information leaflets;
commentary
NA Digestive health in the UK 3 36
Munkholm
814 International (2003) Review of evidence; commentaryAround 25 articles Incidence and prevalence of
colorectal cancer
3 57
AGA
788 USA (2001) Review of evidence; expert
commentary
Over 125 articles Prevalence and costs of GI diseases 2+ 68
de Dombal
544 International; emphasis on UK
(1994)
Commentary; review of
evidence
Around 7 articles Acute abdominal pain 3 57
Davis et al
815 International (1990) Analysis of data Data from 1968 to
1987
International cancer mortality
trends
22 64
Stanley et al
816 International (1988) Review of trends Around 20 articles Mortality trends 22 59
Khan et al
817 International (data between
1979 and 1998 taken)
Analysis of mortality data Not specified, but a
large amount of data
Mortality trends 22 57
Cucino and Sonnenberg
818 USA (data between 1991 and
1996 taken)
Analysis of mortality data Data of around 5000
patient deaths
Occupational mortality 22 57
Farrokhyar et al
795 International (literature between
1950 and 1999 taken)
Review of evidence Around 200 articles Epidemiology of IBD 1 66
Maroun et al
819 Canada (not clear—circa late
1990s)
Analysis of data; review of
evidence
NA; cases taken from
databases
Costs of cancer management 22 73
Fernandez et al
820 Europe (data between 1955and
1989 taken)
Analysis of data Not specified (but a
large amount)
Trends in pancreatic cancer
mortality
2+ 61
La Vecchia et al
821 Europe (data between 1970 and
1996 taken)
Analysis of data Not specified (but a
large amount)
Trends in primary liver cancer
mortality
2+ 55
Maheswaran et al
822 UK (1993–95) Analysis of mortality data Over 10 000 cases Trends in stomach cancer 2+ 61
Taylor-Robinson et al
446 UK (data between 1968 and
1996 taken)
Analysis of mortality data A large amount Mortality rates from intrahepatic
cholangiocarcinoma
22 57
ONS
803 UK (2001) National data Cancer trends between
1950 and 1999
Cancer trends in England and
Wales
2+ 66
Payne et al
823 UK (1991) Cross sectional survey 3877 Survey responses Comparison of prevalence rates 22 73
Rockall et al
91 UK (1993) Analysis of patient data 4185 Cases Incidence and mortality from GI
haemorrhage
22 57
Sharp et al
824 UK (data between 1968 and
1992)
Analysis of cancer data Not specified, but a
large amount
Cancer incidence and mortality 22 50
Blower et al
804 UK (1990–1991) Analysis of routine data 620 Cases Upper GI disease and NSAID use 2+ 57
Pye et al
825 UK (1995–1996) Analysis of patient data 910 Patients Carcinoma of the oesophagus and
stomach
22 57
James et al
238 UK (data between 1987 and
1994 taken)
Collection and analysis of
patient data
770 Cases Primary biliary cirrhosis 22 52
McKay et al
306 UK (data between 1984 and
1995 taken)
Analysis of patient data Over 10 000 cases Acute pancreatitis 22 57
Bray et al
328 Europe (1995) Analysis of mortality data Not specified, but a
large amount
Cancer incidence and mortality 2+ 66
AUGIS
826 UK (2002) Analysis and summary of
patient data
3361 Cases Summary of incidence and mortality
rates for upper GI cancers
3 43
Rockall et al
398 UK (1993–94) Collection and analysis of
patient data
Over 5000 cases Outcomes after acute upper GI
haemorrhage
22 57
Tekkis et al
827 UK (1999–2001) Analysis of patient data 8077 Patients Operative mortality in colorectal
cancer
22 70
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NHS, NICE
671 UK (2004) National commentary;
guidelines; recommendations
NA Improving the outcomes in
colorectal cancer
Guideline 70
South Wales Cancer
Network
754
UK (2003) Service guidelines;
recommendations
NA Configuration of services 3 45
Burroughs and
McNamara
227
Europe (2003) Review of evidence;
commentary
Around 30 articles Liver disease 3 50
Section 3.4 Morbidity
Morris
787 International (1991) Commentary; review of
research
Around 80 articles Non-ulcer dyspepsia 3 59
Waddell and Hislop
357 UK (not specified—circa 1999
onwards)
Analysis of patient data 390 Patients Impact of alcohol related disease 22 59
Payne et al
828 UK (1991) Cross sectional survey 3877 Survey responses Comparison of prevalence rates 22 73
McCulloch et al
829 UK (1999–2002) Cohort study; analysis of
patient data
955 Patients Mortality and morbidity in gastro-
oesophageal cancer surgery
22 64
Smith et al
775 UK (not specified—circa 2003) Survey of people with IBS
symptoms
486 Cases Management of IBS in primary
and secondary care
22 66
Spechler
20 International (1992) Review of research Around 30 articles Epidemiology of GERD 3 66
Section 3.5 Geographical variation
Talley et al
830 International (not specified—circa
1995 to 2000)
Survey of communities Over 5000 survey
responses
Classification of GI symptoms 22 70
Wong et al
791 China and Hong Kong (2002) Survey of Chinese population 2209 Survey
responses
Gastro-oesophageal reflux disease
(GERD)
22 80
Loftus
102 International (2004) Review of evidence Around 170 articles IBD 22 59
Russel
793 International (2000) Review of evidence;
commentary
Around 50 articles Incidence of IBD 3 55
Moum and Ekbom
794 International (2002) Review of evidence Around 90 articles Incidence of IBD 3 55
Farrokhyar et al
795 International (literature between
1950 and 1999 taken)
Review of evidence Around 200 articles Epidemiology of IBD 1 66
Maheswaran et al
822 UK (1993–95) Analysis of mortality data Over 10 000 cases Trends in stomach cancer 2+ 61
Bray et al
328 Europe (1995) Analysis of mortality data Not specified, but a
large amount
Cancer incidence and mortality 2+ 66
Levenstein et al
831 International (data between 1991
and 1996 taken)
Survey of patients 2002 Patients Cross-cultural variation in patients
with IBD
22 75
Section 3.6 Socioeconomic factors
Dominitz et al
783 USA (not specified—circa 2002;
data between 1987 and 1996)
Analysis of routine data Sample taken from
746 130 births
Infants born to mothers with IBD 22 66
Hislop and Heading
785 UK (2000–01) Survey and analysis of
routine data
53 Clinicians Impact of alcohol related disease 22 61
Neumann and Cooper
32 UK (data between 1989 and
1996 taken)
Analysis of patient data 1101 Patients Ethnic differences in gastro-
oesophageal disease
22 68
Wong et al
791 China and Hong Kong (2002) Survey of Chinese population 2209 Survey
responses
Gastro-oesophageal reflux disease
(GERD)
22 80
Loftus
102 International (2004) Review of evidence Around 170 articles IBD 22 59
Longobardi et al
832 USA (1999) Analysis of data 23 649 Records Work losses due to IBD 22 66
Longobardi et al
833 Canada (1999) Analysis of data 23,649 Records Work losses due to IBD 22 66
Fass et al
798 USA (1992–95) Analysis of patient data;
survey
505 Patients Functional bowel disorders (FBD)
and sleep disorders
22 73
Danese et al
834 International (2004) Expert commentary;
summary of evidence
Around 40 articles IBD and environmental factors 3 48
Payne and Saul
801 UK (data between 1994 and
1998 taken)
Survey and analysis of data 12 239 Responses Common disorders in long term
illnesses
22 61
Kennedy and Jones
22 UK (not specified—circa
1997–2000)
Cross sectional survey 3179 Survey
responses
Prevalence of gastro-oesophageal
reflux symptoms
22 64
McKinney et al
835 UK (data between 1960 and
1990)
Analysis of cancer data Not specified, but a
large number
Oesophageal and gastric cancer
incidence
22 52
Bray et al
328 Europe (1995) Analysis of mortality data Not specified, but a
large number
Cancer incidence and mortality 2+ 66
Dean et al
836 USA (1999) Survey of patients 11 604 Responses Work productivity and gastro-
oesophageal reflux disease (GERD)
22 75
Bernstein et al
837 Canada (1995–96) Survey and analysis of
patient data
Not clear, but a large
number
Socioeconomic factors associated
with IBD
22 55
Sands et al
552 USA (patients between 1991
and 1997)
Analysis of patient data 345 Patients Risk of early surgery for Crohn’s
disease
2+ 64
Vaughn et al
838 UK (not specified—circa 1998) Survey of patients and their
relatives
Not clear—around 29
patients
Expressed emotion during the
course of IBD
22 59
Crane and Martin
839 UK (not specified—circa 2002) Survey of patients 58 Patients Social learning, affective state, and
passive coping in IBD and IBS
22 68
Sewitch et al
534 Canada (Not specified—circa
2001)
Survey of patients and
physicians
10 Gastroenterologists
and 200 patients
Patient-physician correlates in IBD 22 75
Casati and Toner
840 International (2000) Review of evidence;
commentary
Around 70 articles Psychosocial aspects of IBD 3 55
Sewitch et al
841 Canada (1999) survey of patients 200 Patients Psychosocial aspects in IBD 3 70
Soo et al
842 International (studies from 1966
to present)
Systematic review 4 Studies Psychological interventions for
non-ulcer dyspepsia
22 80
Guthrie
843 International (2002) Review of evidence 3 Studies Psychodynamic-interpersonal
therapy for functional bowel
disorders
3 52
Kisely
844 UK (1996–97) Analysis of patient data 65 204 Patient records Multiple readmissions 22 59
Moum
585 International (2000) Review of evidence Around 80 articles Medical treatment for IBD 3 64
Tojek et al
845 USA (not specified—circa 2000) Survey of patients 62 Patients Health status in IBD 22 75
Jahnsen et al
846 Norway (not specified—circa
2003)
Population based study 60 Patients Body composition in patients with
IBD
2+ 66
de Rooy et al
687 Canada (not specified—circa
2001)
Survey of patients 259 Patients Concerns of patients with IBD 22 68
Ward et al
738 International (circa 1998) Review of evidence Around 40 articles Management of IBD 22 70
Hatch
847 Not specified—appears to be
USA (circa 1996)
Case study 2 Patients Treatment of bowel obsessions 3 70
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Guthrie et al
848 UK (not specified—circa 2003) Survey of patients; analysis
of patient data
107 Patients Cluster analysis to define patient
subgroups for IBS
22 75
Drossman
849 International (1999) Review of evidence Around 40 articles Psychosocial factors in IBS 3 66
Payne et al
823 UK (1991) Survey of population in
Rotherham
3877 Survey responses Deprivation and morbidity 22 70
Section 3.7 Quality of life
Pachler and Wille-
Jorgensen
850
International (2002–03 (no
restriction on date of studies)
Systematic review 8 Studies Quality of life (QoL) after rectal
resection for cancer
1 75
Yacavone et al
851 International (review of evidence:
1966 to 1999)
Review of evidence Around 80 articles QoL in gastroenterology 2+ 68
Simren et al
852 Sweden (not specified—circa
2002)
Survey of patients 83 Patients QoL in IBD 22 66
Rubin et al
676 UK (not specified—circa 2003) Survey of patients 409 Responses QoL in IBD 22 68
Halder et al
450 USA (not specified—circa 2003) Case-control study 112 Patients; 110
controls
GI disorders and QoL 2+ 66
Hahn et al
853 UK and USA (not specified—circa
1999)
Survey of patients Around 600 patients Impact of IBS on QoL 22 66
Blondel-Kucharski et al
854 France (not specified—circa 2001) Survey of patients 231 Patients QoL in Crohn’s disease 22 66
Akehurst et al
740 UK (1998) Survey of patients 161 Patients QoL and cost impact of IBS 2+ 77
Gonsalkorale et al
855 UK (not specified—circa 2002) Survey of patients 78 Patients Cognitive change in patients during
IBS
22 70
Moayyedi and Mason
747 UK (1992–94) Analysis of patient data;
survey of patients
Not clear; over 8000
patients
Economic consequences of
dyspepsia
3 82
Borgaonkar and Irvine
447 International (2000) Review of evidence between
1966 and 1999
Around 140 articles QoL measurement in gastrointestinal
and liver disorders
2+ 80
El-Serag et al
856 International (2001) Systematic review of evidence
between 1980 and 2001
17 articlesArticles QoL of people with IBS 1+ 77
Koloski et al
449 Australia (not clear—circa
1996–2000)
Survey of random sample of
population
2910 Survey
respondents
Impact of functional GI disorders on
QoL
22 70
O’Keefe et al
857 USA (1987–90) Survey of random sample of
population
530 Survey responses Bowel disorders and its impact on
QoL in the elderly
22 75
Gralnek et al
858 USA (1994–1998) Survey of patients 877 Patients Impact of IBS on health related QoL 22 73
Section 4.1 Care pathways
McNamara et al
581 International; emphasis on USA
(2000)
Review of evidence; expert
commentary
Around 70 articles Non-ulcer dyspepsia (NUD) 22 64
Association of
Coloproctology of GB
and Ireland
505
UK (2001) Specification of guidelines NA Guidelines for the management of
colorectal cancer
Guideline 61
CSCG
808 UK (2003) Commentary NA Response to NICE service guidance
on upper GI cancers
Guideline 41
Pfau et al
859 USA (1997–1999) Implementation of care
pathway
421 patients Clinical care pathway for the
management of acute nonvariceal
upper GI bleeding
22 77
Kisely
844 UK (1996–1997) Analysis of patient data 65204 patient records Multiple readmissions 22 59
Feuer
595 International (1999) Commentary; review of
evidence
Around 20 articles Management of intestinal obstruction 3 50
Section 4.2 Workforce
Garvican
607 UK (1998) Commentary; cost analysis NA Colorectal cancer screening 3 70
Duff et al
506 UK (2002) Audit 65 Patients Waiting times for treatment of rectal
cancer in northwest England
3 52
Slade et al
860 UK (not specified—circa 1998) Survey of patients; treatment
intervention
232 Patients Serological testing for H pylori to
reduce workload
22 61
Lamy and McNamara
861 Europe (data between 1996 and
2001)
Survey of experts Not clear—around 25
European countries
Gastroenterology and hepatology
services in Europe
3 59
Association of
Coloproctology of GB
and Ireland
753
UK (2001) Analysis of audit data; expert
commentary and
recommendations
8 Main sources of
audit data
Resources for coloproctology 3 52
Section 4.3.1 Primary care
Cumberland et al
358 UK (not specified—circa 2003) Survey and follow-up 85 Practices; over
1000 cases
Infectious intestinal disease (IID) in
England
2+ 73
Section 4.3.2 Inpatients
Hislop and Heading
785 UK (2000–01) Survey and analysis of
routine data
53 Clinicians Impact of alcohol related disease 22
Waddell and Hislop
357 UK (Not specified—circa 1999
onwards)
Analysis of patient data 390 patients Impact of alcohol related disease 22
Section 4.3.3 Outpatients
Rayner et al
862 UK (1997–98) Analysis of patient data 1203 Patients Outpatient review practices 22 57
Section 4.3.4 Procedures
Westbrook et al
863 Australia (data between 1986
and 1990 taken)
Analysis of patient data Unclear—over 17 000
cases
Upper GI tract investigations in the
elderly
22 61
Grassi
864 Italy (data between 1991 and
1999)
Commentary on data Not clear, but a large
number
Endoscopy activity 4 36
BSG
865 UK (1987) Commentary; review of
evidence
Around 20 articles Requirements for colonoscopy 3 57
Section 4.6.1 Access
Froehlich et al
500 Switzerland; comparisons with
UK (1994–95)
Review of evidence;
analysis of patient data
8135 Patients Overuse of upper GI endoscopy in
primary care
22 61
Gralnek
501 International (2002) Commentary NA Outpatient management of low risk
non-variceal upper GI haemorrhage
4 50
Silcock and Bramble
502 UK (1994) Survey 333 Responses Survey of current practice in open
access gastroscopy (OAG)
22 68
Section 4.6.2 Inequalities
Watt
503 UK (2002) Commentary NA The inverse care law 4 39
Section 4.6.3 Waiting lists
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Association of
Coloproctology of GB
and Ireland
505
UK (2001) Specification of guidelines NA Guidelines for the management of
colorectal cancer
Guideline 61
Flashman et al
507 UK (2000–01) Audit 249 Patients Two week standard for bowel
cancer
22 61
Duff et al
506 UK (2002) Audit 65 Patients Waiting times for treatment of
rectal cancer in northwest England
3 52
Parente et al
866 Italy (1999–2000) Audit 142 Patients Audit of gastroscopy 22 61
Dunnill and Pounder
504 UK (articles between 1966 and
2002)
Literature review Around 40 articles Outpatient services 22 70
Hellier
508 UK (1999–2001) Survey of GI units 210 GI units Two week target for investigation
cancer patients
3 55
Section 4.6.4 Patient safety
Van Kouwen et al
522 Netherlands (1994–98) Analysis of endoscopy
services and patient data
218 Patients Upper GI endoscopy for older
patients
22 57
Navarro and Hanauer
509 International (2003) Review of evidence;
commentary
Around 70 articles Safe treatment for IBD 3 59
Akehurst and Kaltenthaler
510 International (trials between 1987
and 1998)
Review of RCTs 45 RCTs Treatment of IBS 1 66
Dick et al
511 UK (2002) Analysis of prescriptions 308 Patientsand 777
prescriptions
Use of unlicensed and off-label
drugs in paediatric GI diseases
22 61
Chan and Graham
512 International (2004) Review of evidence Around 60 articles Prevention of NSAID GI
complications
3 73
Sheen and Colin-Jones
513 International; emphasis on UK
(2001)
Review of evidence Around 100 articles Over-the-counter drugs for GI
diseases
3 68
Abbas et al
520 Not specified—circa 2003) Survey of patients; analysis
of patient data
1287 Patients Outpatient upper GI endoscopy 22 64
Bloor and Maynard
514 UK (1996) Review of evidence Around 40 articles Prescription of NSAIDs 3 73
Feagan
515 International (2003) Review of evidence Around 90 articles Maintenance treatment for IBD 2+ 61
Ripamonti et al
526 International (1993) Literature review Around 40 articles Management of bowel obstruction
in patients with cancer
22 75
Cook et al
517 International (articles from 1966
onwards)
Meta-analysis 30 RCTs Endoscopic therapy for acute non-
variceal upper GI haemorrhage
1 73
Page et al
524 USA (Patientsbetween 1989 and
1999)
Analysis of patient data Over 100 patients Surgical risk in elderly patients with
IBD
22 59
Moorthy et al
525 UK (data between 1991 and
2001)
Analysis of patient data 48 Patients Patients undergoing laparoscopic
surgery for Crohn’s disease
22 64
Yim et al
527 Not specified—probably USA
(1996–99)
Analysis of patient data 29 Patients Enteral stents for patients with upper
GI obstruction
2+ 64
Heuschkel et al
518 USA and UK (2000) Survey of patients 208 Survey responses Complementary medicine used by
children for IBD
22 80
Quine et al
521 UK (1991) Survey of clinicians 39 Hospitals; 383
clinicians
Audit of upper GI endoscopy 22 64
Section 4.6.5 Information to patients and practitioners
Dick et al
511 UK (2002) Analysis of prescriptions 308 Patients and 777
prescrip-tions
Use of unlicensed and off-label
drugs in paediatric GI diseases
22 61
Sheen and Colin-Jones
513 International; emphasis on UK
(2001)
Review of evidence Around 100 articles Over-the-counter drugs for GI
diseases
3 68
Sewitch et al
534 Canada (not specified—circa
2001)
Survey of patients and
physicians
10 Gastroenterologists
and 200 patients
Patient-physician correlates in IBD 22 75
Stone et al
141 UK (2002) Analysis of patient data Over 86 000 patients Management of IBD 22 73
Sewitch et al
535 Canada (1999) Survey of patients and
clinicians
10 Clinicians; 153
patients
Patient non-adherence to
medication in IBD
22 75
Mansfield et al
537 UK (not specified—circa 1997) Survey of clinicians and
patients
732 Patients; 6
gastroenterology clinics
Information for patients about IBD 22 64
Thompson et al
532 UK (not specified—circa 2003) Survey of patients and nurses 402 Patients; 62 nurses Information for patients undergoing
gastroscopy
22 73
Hawkey and Hawkey
530 UK (not specified—circa 1989) Survey of patients 751 Survey responses Information for patients with GI
diseases
22 70
NICE
671 UK (2004) Summary of guidelines NA Information leaflet for patients 3 30
Greiner et al
536 USA (2002) Survey of patients Not clear—around
800 patients
Barriers to colorectal cancer
screening
22 70
Institute of Food Research
529 UK (2004) Information and advice to
the public
NA Diet and health 3 41
Mukherjee et al
528 UK (not specified—circa 2001) Qualitative study 24 Patients Parents’ experiences of IBD 22 75
Section 4.6.6 Diagnosis
and complications in care
Jenkins
541 UK (2001) Commentary, review of
evidence
NA Paediatric IBD 3 52
Mamula et al
790 International; emphasis on USA
(data between 1977 and 2000
taken)
Analysis of routine data 82 Patients IBD in children under 5 years of age 22 70
de Dombal
544 International; emphasis on UK
(1994)
Commentary; review of
evidence
Around 7 articles Acute abdominal pain 3 57
Gatta et al
561 Europe (not specified—data
collected between 1988 and
1999)
Analysis of cancer data 2720 Patients Colorectal cancer in Europe 22 59
Camilleri
543 USA (2001) Review of evidence;
commentary
Around 170 articles Management of IBS 3 64
Limpert et al
554 USA (patients between 1992 and
2002 were used
Analysis of patient data 181 Patients Colon and rectal cancer in the
elderly
22 61
Sanders et al
174 UK (1999–2001) Cross sectional intervention 1200 Participants Diagnosis of coeliac disease 2+ 70
Spray et al
540 UK (patients between 1994 and
1998 were used)
Analysis of medical records Around 100 patients IBD in children 2+ 52
Hamilton and Sharp
556 UK (evidence between 1966 and
2002 taken)
Assessment of clinical
guidelines
Around 100 articles Guidelines for the diagnosis of
colorectal cancer
2+ 66
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Ofman et al
545 USA (not specified—circa 2002) Application of decision
analysis
NA Management strategies for gastro-
oesophageal reflux disease
22 75
Brignoli et al
548 Switzerland (not specified—circa
1997)
Case-control study 1078 Patients Diagnostic strategies for dyspepsia 2+ 70
Summerton and Paes
549 UK (1997–98) Survey; audit 275 Responses Clinical assessment of patients with
large bowel symptoms
22 70
Farmer et al
539 USA (not specified—circa 2000) Evaluation of practice;
analysis of patient data
119 Patients Diagnostic accuracy for IBD 22 61
Shah et al
562 USA (1995–98) Review of patient data 168 Patients Use of colonoscopy and biopsy 22 61
Erickson and Glick
563 International (studies between
1974 and 1982 taken)
Review of evidence Around 80 articles Benefits of
oesophagogastroduodenoscopy
22 61
Drossman et al
551 USA (1996–98) Survey of patients 211 Patients Factors pointing to the severity of
functional bowel disorders
22 70
Sands et al
552 USA (patients between 1991 and
1997)
Analysis of patient data 345 Patients Risk of early surgery for Crohn’s
disease
2+ 64
Lang et al
566 Finland (1996–97) Observational study 503 Patients Resource use in gastroenterological
surgery
22 70
Tunaci
558 International (2002) Commentary NA Imaging of GI cancers 3 52
Quine et al
867 UK (1991) Audit 15 Hospitals in East
Anglia and northwest
England
Audit of upper GI endoscopy 22 59
Parry et al
564 UK (not specified—circa 2001) Retrospective study of
patient data
52 Patients Push enteroscopy 22 61
Diamanti et al
550 Italy (not specified—circa 2002) Analysis of patient data 6 Patients Patients with ultra-short bowel
disease
22 52
Yasui et al
565 International (cancer cases
between 1993 and 1998)
Analysis of cancer cases 9241 Cases Molecular-pathological diagnosis
of GI tissues for cancer
histopathology
22 68
Schofield
567 UK (data between 1994 and
1998 taken)
Review of medical cases 245 Cases Medical negligence in
coloproctology
3 57
Hansen et al
547 Denmark (1991–92) Interview of patients 612 Patients Management of dyspeptic patients
in primary care
22 70
Talley et al
546 International (1991) Review of evidence Around 180 articles Classification and guidelines for the
diagnosis and management of
functional dyspepsia
3 80
Mulcahy et al
868 UK (data between 1989 and
1998 taken)
Retrospective review of
patients data
9795 Patients Patterns of sedation use for
diagnostic gastroscopy
22 55
Hin et al
378 UK (1996–97) Case finding study 30 Patients Coeliac disease in primary care 22 66
Schmulson and Chang
542 International (1999) Review of evidence Around 50 articles Diagnostic approach to IBS 3 70
Martin et al
555 UK (1994) Analysis of patient data;
survey
115 Patients Delays in the diagnosis of
oesophagogastric cancer
22 61
Angelelli et al
553 International (2003) Review of evidence;
commentary
Around 40 articles Computed tomography and acute
bowel ischaemia
3 66
Berg et al
538 International (2001) Review of evidence;
commentary
Around 40 articles Acute surgical emergencies in IBD 3 64
Rockey et al
869 USA (2000–04) Comparison of imaging tests 614 Patients Comparison of colon imaging tests 2+ 82
Halligan and Atkin
870 UK (2005) Commentary NA Virtual colonoscopy 4 55
Section 4.7.1 Guidelines for care
Chiang et al
797 Australia (2001) Analysis of patient data 167 Patients Acute pancreatitis management 2+ 68
BSG
574 UK (2002) Guidelines NA Guidelines for dyspepsia
management
Guideline 45
Hamilton and Sharp
556 UK (evidence between 1966 and
2002 taken)
Assessment of clinical
guidelines
Around 100 articles Guidelines for the diagnosis of
colorectal cancer
2+ 66
Association of
Coloproctology of GB and
Ireland
505
UK (2001) Specification of guidelines NA Guidelines for the management of
colorectal cancer
Guideline 61
Flashman et al
507 UK (2000–01) Audit 249 Patients Two week standard for bowel
cancer
22 61
Kubba and Whyman
606 UK (1994) Survey of clinicians 81 Responses Survey of practice amongst Scottish
gastroenterologists
22 59
DoH
605 UK (2004) Guidelines NA Renal services implementation
strategy
Guideline 45
Rockall et al
398 UK (1993) Analysis of patient data 2531 Patients Management of upper GI
haemorrhage
22 57
Limburg and Ahlquist
569 International; emphasis on USA
(2002)
Commentary NA Management of colorectal cancer 4 45
Ahmed et al
571 International (studies from 1996
onwards)
Systematic review Four RCTs Supportive care for patients with GI
cancer
1 75
McNamara et al
581 International; emphasis on USA
(2000)
Review of evidence; expert
commentary
Around 70 articles Non-ulcer dyspepsia (NUD) 22 64
Meineche-Schmidt
871 Denmark (1999–2000) RCT and follow-up 829 Patients Healthcare consumption 2+ 57
Wexner et al
600 USA (2001) Commentary; consensus NA Principles for privileging and
credentialing for endoscopy and
colonoscopy
4 52
Bardou et al
572 USA (1999–2002) Case-control study Over 80 000 patients Treatment of oesophageal cancer 2+ 70
Bodger et al
596 UK (not specified—circa 1996) Analysis of physicians’
practice data
9 GPs Prescriptions in primary care 22 66
Delaney et al
579 International (2003) Systematic review 20 RCTs Management strategies for
dyspepsia
1 82
Fisher et al
599 USA (1995–1996) Analysis of patient data 3546 Patients Mortality and follow-up
colonoscopy after colorectal cancer
2+ 61
Moum
585 International (2000) Review of evidence Around 80 articles Medical treatment for IBD 3 64
Feuer
595 International (1999) Commentary; review of
evidence
Around 20 articles Management of intestinal obstruction 3 50
Conio et al
591 International (2001) Commentary; review of
evidence
Around 80 articles Endoscopic treatment of
pancreatico-biliary malignancies
3 57
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Talley et al
546 International (1991) Review of evidence Around 180 articles Classification and guidelines for
the diagnosis and management
of functional dyspepsia
3 80
Drossman et al
551 International (not specified—circa
1994)
Survey of patients 270 Patients Measuring health status and
severity of illness for functional
bowel disorders
22 77
Jeffery et al
568 International (studies from 1966
onwards)
Systematic review 5 RCTs Follow-up strategies for colorectal
cancer
1 75
Axon et al
602 UK (not specified—circa 1995) Audit; survey of clinicians 350 General
physicians, 400
surgeons, 477
gastroenterologists,
70 GPs
Guidelines on appropriate
indications for upper GI endoscopy
2+ 77
Allum et al
570 UK (2002) Review of evidence;
recommendations
Around 340 articles Guidelines for the management of
oesophageal and gastric cancer
Guideline 75
Raine et al
593 UK (2002) Qualitative research into GPs’
beliefs
46 GPs GPs’ perceptions of chronic disease
syndrome and IBS
22 73
Carter et al
584 UK (2004) Review of evidence;
recommendations
Around 150 articles Guidelines for the management of
IBD
Guideline 75
Ryder
594 UK (2003) Review of evidence;
recommendations
Around 150 articles Guidelines for the diagnosis and
treatment of hepatocellular
carcinoma
Guideline 75
Verma and Giaffer
588 UK (not specified—circa 2001) Survey of patients; analysis of
patient data
Around 1000 patients H pylori eradication 22 77
Milne et al
872 UK (1993) Survey of gastroenterologists 670 Survey responses H pylori and upper GI disease 22 64
Parry et al
578 UK (1995) Survey of GPs 140 GPs GPs’ management of dyspepsia in
primary care
22 73
Probert et al
604 UK (not specified—circa 1993) Survey of gastroenterologists 236 Survey responses Gastroenterologists’ care profile for
patients with IBD
22 61
Whitaker et al
589 UK (1997) Commentary; review of
guidelines for care
Around 50 articles Management of GI disease in
primary care
3 59
Paton
590 UK (1992–93) Economic analysis; RCT 255 Patients Comparison of two treatments for
gastro-oesophageal reflux disease
2+ 64
Wright et al
586 UK (not specified—circa 2001) Analysis of patient data 6037 Patients Implementation of H pylori
eradication therapy
22 61
NICE
577 UK (2003) Guidelines NA Managing adult patients with
dyspepsia
Guideline 57
Spiegel et al
575 International; emphasis on USA
(2002)
Review of guidelines; economic
modelling
Around 120 articles Competing strategies for dyspepsia
management
22 75
Bodger et al
576 UK (1995–1996) Observational study 340 Patients Implications of BSG dyspepsia
guidelines
22 68
Association of
coloproctology of GB
and Ireland
505
UK (1999) Guidelines for coloproctology NA Guidelines for coloproctology Guideline 45
Manes et al
601 Italy (1998) Analysis of patient data 706 Patients Appropriateness and diagnostic
yield of upper GI endoscopy in
an open access system
22 64
Tremaine et al
583 USA (1997) Survey and analysis of
patient data
Not clear—around
100 patients
Practice guidelines in IBD 2+ 61
Section 4.7.2 Incidence of cancer
Forman et al
873 UK (data up to 1992; published
2003)
Analysis of data Over 1.5 million cases Cancer prevalence in the UK 22 66
Munkholm
814 International (2003) Review of evidence;
commentary
Around 25 articles Incidence and prevalence of
colorectal cancer
3 57
AGA
788 USA (2001) Review of evidence; expert
commentary
Over 125 articles Prevalence and costs of GI diseases 2+ 68
Sant et al
874 Europe (2001) Analysis of routine data 1 836 287 Patient
records
Cancer survival rates 22 57
Stanley et al
816 International (1988) Review of trends Around 20 articles Mortality trends 22 59
Askling et al
875 Sweden (data between 1952 and
1995 taken)
Analysis of patient data 114 102 Records Colorectal cancer rates 2+ 52
Lynch and de la Chapelle
876 International; emphasis on USA
(2003)
Commentary; review of
evidence
Around 100 articles Hereditary colorectal cancer 3 52
ONS
441 UK (data between 1991 and
2001)
Update on cancer survival
rates
NA Cancer survival rates NA NA
Sharp et al
824 UK (data between 1968 and
1992)
Analysis of cancer data Not specified, but a
large amount
Cancer incidence and mortality 22 50
McKinney et al
835 UK (data between 1960 and
1990)
Analysis of cancer data Not specified, but a
large amount
Oesophageal and gastric cancer
incidence
22 52
Pye et al
825 UK (1995–96) Analysis of patient data 910 Patients Carcinoma of the oesophagus and
stomach
22 57
Bray et al
328 Europe (1995) Analysis of mortality data Not specified, but a
large amount
Cancer incidence and mortality 2+ 66
Bardou et al
572 USA (1999–2002) Case-control study Over 80 000 patients Treatment of oesophageal cancer 2+ 70
Rhodes and Campbell
877 International (2002) Review of evidence Around 70 articles Inflammation and colorectal cancer 3 61
AUGIS
826 UK (1999) Commentary and
recommendations
NA Service provision 4 35
Section 4.7.4 Screening
(includes surveillance)
Mpofu et al
611 International; emphasis on UK
(2004)
Systematic review 9 Key reports Strategies for detecting colon
cancer
1 84
Rozen et al
608 International (2002) Expert commentary;
recommendations
NA Worldwide cancer screening 3 73
Mandel et al
609 USA (longitudinal study—results
from 70s, 80s, and 90s)
Analysis of patient data 46 551 Participants Screening for colorectal cancer 2+ 64
Garvican
607 UK (1998) Commentary; cost analysis NA Colorectal cancer screening 3 70
Doria-Rose et al
633 USA (data between 1994 and
2000 taken)
Analysis of patient data Over 70 000
participants
Screening intervals 22 70
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Lin et al
613 USA (1999) Survey of clinical practice 103 Responses Current practices in Barrett’s
oesophagus
22 73
UK Colorectal Cancer
Screening Pilot Group
610
UK (2000–03) Pilot/audit 271 646 Participants Screening for colorectal cancer 22 64
Hill et al
628 UK (not specified—circa 2000) Assessment of practice 109 Families Screening for colorectal cancer 22 57
Kronborg
627 Europe (1992) Assessment of guidelines Around 50 articles Screening guidelines for colorectal
cancer
22 68
Dubinsky et al
623 USA (2000) Economic and statistical
analyses
Not specified Economic issues for competing
diagnostic strategies
22 75
Gerson et al
615 USA (2003) Economic modelling Not specified, but a
large amount
Cost effectiveness of endoscopic
screening and surveillance for GERD
22 73
Lewis
878 USA (2000) Commentary NA Screening of colorectal cancer 4 43
Macafee and Scholefield
632 UK (2002) Commentary; review of
evidence
Around 40 articles Screening of colorectal cancer 3 57
Ganz et al
626 USA (1999) Survey; RCT 36 Provider
organisations
Screening of colorectal cancer 2+ 68
Gross et al
612 USA (1998) Survey of gastroenterologists 279 Survey responses Management of Barrett’s oesophagus 22 80
Loeve et al
621 USA (circa 2000—projected data
between 1993 and 2023)
Data simulation Baseline data from
routine sources and
expert opinion
Colorectal cancer screening 22 77
Rae
630 Australia (data between 1987
and 1996 taken)
Analysis of patient data 3845 Patients Community screening for colorectal
cancer
22 61
Nietert et al
620 USA (circa 2002) Economic modelling NA Cost effectiveness of screening for
chronic gastroesophageal refulx
disease
22 75
Ramsey et al
617 USA (data between 1993 and
1999 taken)
Analysis of patient data 206 Patients Costs of screening for colorectal
cancer
22 70
Sonnenberg et al
879 USA (1998) Economic modelling NA Costs of screening for colorectal
cancer
22 70
Renehan et al
618 UK (2002) Review of evidence 5 RCTs Cost effectiveness of surveillance
for colorectal cancer
2+ 80
Helm et al
625 International; emphasis on USA
(not specified—circa 2003)
Review of evidence;
commentary
Around 60 articles Strategies for colorectal cancer
screening
3 80
Taylor et al
629 UK (not specified—circa 2000) Survey of patients 4153 Survey
responses
Acceptability of flexible
sigmoidoscopy screening
22 64
Bejes and Marvel
624 USA (not specified—circa 1992) Case-control study 546 Patients Offering colorectal cancer
screening to patients
22 61
Cotton et al
635 USA (2000–01) Non-randomised trial 615 Patients Virtual colonoscopy 22 64
Hur et al
634 USA (2004) Mathematical modelling Data from 1998 to
2002
Computed tomographic
colonography
22 70
Section 4.7.5 Genetics
Lynch and de la
Chapelle
876
International; emphasis on USA
(2003)
Commentary; review of
evidence
Around 100 articles Hereditary colorectal cancer 3 52
Polito II et al
880 USA (data between 1985 and
1991)
Analysis of patient data 552 Patients Genetic anticipation in Crohn’s
disease
22 55
Yasui et al
565 International (cancer cases
between 1993 and 1998)
Analysis of cancer cases 9241 Cases Molecular-pathological diagnosis of
GI tissues for cancer histopathology
22 68
Morris-Yates et al
881 Australia (participants between
1984 and 1986)
Structured interviews of
patients; genetic modelling
686 Individual twins Genetic contribution to functional
bowel disorders
22 70
Faybush et al
882 Canada (patient data between
1984 and 1995)
Analysis of patient data 315 Patients Generational differences in IBD:
genetic, bias, and temporal effects
issues
22 59
Section 4.7.6 Prevention
Chan and Graham
512 International (2004) Review of evidence Around 60 articles Prevention of NSAID GI
complications
3 73
Muller and Sonnenberg
652 USA (1988–93) Analysis of patient data Over 16 000 patients Prevention of colorectal cancer 2+ 55
Hulscher et al
651 International (review of studies
from 1966 onwards)
Systematic review 55 Studies Prevention in primary care 1 77
O’Connor and Sebastian
654 Europe (2003) Review of evidence;
commentary
Around 60 articles Burden of H pylori in Europe 3 50
Section 4.7.6 Devolution
Greer
883 UK (2004) Commentary; review of
evidence
Around 30 articles Devolution and the NHS 3 52
Section 4.7.7 Managed cancer networks
CSCG
808 UK (2003) Commentary NA Response to NICE service guidance
on upper GI cancers
Guideline 41
South Wales Cancer
Network
754
UK (2003) Service guidelines;
recommendations
NA Configuration of services 3 45
Section 4.7.8 Quality assessment
Garvican
607 UK (1998) Commentary; cost analysis NA Colorectal cancer screening 3 70
Association of
Coloproctology of GB
and Ireland
505
UK (2001) Specification of guidelines NA Guidelines for the management of
colorectal cancer
Guideline 61
Lilford et al
884 UK (not specified—circa 2004) Review of evidence Around 90 articles Managing performance in acute
medical care
3 73
Rockall et al
885 UK (1993–94) Collection and analysis of
patient data
Over 5000 cases Outcomes after acute upper GI
haemorrhage
22 57
Johansen et al
886 USA (applicable internationally)
(2000)
Commentary NA Quality and outcomes assessment
in GI endoscopy
3 45
Dougall et al
887 UK (1997) Survey of patients 84 Patients Patient experiences of an open
access flexible sigmoidoscopy service
22 77
Feuer and Broadley
888 International (studies from 1966
onwards)
Systematic review 25 Articles Surgery for malignant bowel
obstruction in GI cancers
2+ 73
Fletcher
889 Australia (1997) Review of evidence Around 40 articles Management of peptic disease 3 64
Bodenheimer et al
890 USA (2002) Case study Four healthcare
organisations
Improving primary care for chronic
illness
3 61
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van der Eijk et al
891 International (2000) Literature review Around 80 articles Quality of care in IBD 3 68
Gilmore et al
892 UK (1991) Audit 1500 Completed
audit forms
Audit of liver biopsy 22 61
Jones
809 International (1999) Review of evidence Around 20 articles Methodological considerations 3 68
McCulloch et al
829 UK (1999–2002) Cohort study; analysis of
patient data
955 Patients Mortality and morbidity in gastro-
oesophageal cancer surgery
22 64
Kurlberg et al
893 Sweden (2004) Commentary NA Access to patient information 3 43
Bass et al
695 UK (1994) Analysis of patient data 762 Patients Frequent attendants at a
gastroenterology clinic
22 61
Palmer and Morris
894 UK (2004) Commentary NA Colonoscopy practice in England 4 41
Bowles et al
752 UK (not specified—circa 2003) Survey of clinicians and
patients
9223 Cases Colonoscopy practice in the UK 22 66
Macarthur et al
895 UK (1993) Audit of deaths from large
bowel surgery
187 Cases Deaths from large bowel surgery 22 61
van der Eijk et al
896 International (1998) Observational study/survey Physicians and health
workers from 8
countries
Best practice in IBD 22 73
Eaden et al
897 UK (not specified—circa 1998) Survey of clinicians 341 Responses Screening for colonic cancer by
gastroenterologists
22 64
Section 5.1 Where should services be provided (primary, secondary, tertiary—includes patient roles)?
Scott et al
898 Canada (not specified—circa
2003)
Survey of patients 14 Patients Use of complementary therapies for
IBD
22 55
Hinton
899 UK (not specified—circa 1994) Survey 415 Patients; focus on
77 of these
Transfer of care from home to
hospital
22 45
Shepperd and Iliffe
689 International (1996–2001) Systematic review 16 Trials Hospital versus home care 1 66
Barrett et al
900 UK (1998–99) Retrospective study; analysis
of routine data
903 Patients Description of intermediate care
service
22 57
Gill and Martin
901 New Zealand (1995–97) Analysis of patient data 3351 Patients Distance from hospital 22 59
South Wales Cancer
Network
754
UK (2003) Service guidelines;
recommendations
NA Configuration of services 3 45
Whynes and Thornton
902 UK (not specified—circa 1998) Economic/statistical analysis Not clear—data for
around 18 wards
Concentration in primary care 22 61
Section 5.2 What types of services should be provided (includes current provision)?
Gonsalkorale et al
903 UK (not specified—circa 2002) Survey of patients 232 Patients Hypnotherapy in IBS 22 75
van Dam et al
904 Not specified—probably
international (not specified—circa
2004)
Review of clinical trials Review of around 10
papers
Review of computerised
tomographic colonography (CTC)
2+ 70
Podolsky
905 Not specified—probably
international (2004)
Expert commentary NA CTC 4 41
Silcock and Bramble
502 UK (1994) Survey 333 Responses Survey of current practice in open
access gastroscopy (OAG)
22 68
Baron et al
906 USA (2002–03) Cohort study 498 Patients Demand for colonoscopy 2+ 66
Cheung et al
907 UK (1999) Survey and structured
interviews
160 GPs Shared care in gastroenterology 22 61
Moody et al
772 UK (not specified—circa 1993) Survey of GPs 259 Responses GPs views on requirements for
gastroenterology services
22 70
Smith et al
908 UK (not specified—circa 2000) Survey of patients 100 Responses Impact of a nurse-led counselling
service
22 68
Ilnyckyj et al
909 Canada (1996–1997) Observational study 70 Patients Gastroenterology consultation 22 64
Pasricha
910 Not specified—probably
international (2004)
Expert commentary NA Future of therapeutic endoscopy 3 52
Axon
911 UK (1998) Expert commentary NA Open access endoscopy in Britain 4 50
DoH
912 UK (2001) National commentary;
recommendations
NA Upper GI cancers Guideline 48
Richards et al
760 International (1997) Systematic review 256 Studies Home parenteral nutrition (HPN) 1 77
Talley and Spiller
913 International (not specified—circa
2002)
Review of evidence Around 140 studies IBS 3 70
Nord
914 USA (1999) Expert commentary NA Developments in Endoscopy 4 57
Jones
770 UK (1996) Expert commentary NA GI disease in primary care 3 59
van der Eijk et al
896 International (1998) Observational study/survey Physicians and health
workers from
8 countries
Best practice in IBD 22 73
Abuksis et al
915 Israel (1998) RCT 142 Patients A patient education programme 2+ 68
Lewin van den Broek et al
916 Netherlands (1995–97) RCT 349 Patients Management strategies for
dyspepsia
2+ 66
Delaney and Moayyedi
917 Predominantly UK (not
specified—circa 2003)
Evidence-based assessment Around 160 articles Dyspepsia management 22 57
Heaney et al
918 UK (1993–96) Analysis of patient and GP
data
1872 Cases Open access gastroscopy in Royal
Victoria Hospital, Belfast
22 55
Pye et al
825 UK (1995–96) Analysis of patient data 910 Patients Carcinoma of the oesophagus and
stomach
22 57
Association of
Coloproctology of GB
and Ireland
505
UK (2001) Specification of guidelines NA Guidelines for the management of
colorectal cancer
Guideline 61
Hansen et al
919 Denmark (1987–88) Survey of patients and GPs 436 Patients Efficacy of open access endoscopy 22 68
Section 5.3 Who should deliver/perform services and/or procedures (for example, endoscopies)?
Eaden et al
897 UK (not specified—circa 1998) Survey of clinicians 341 Responses Screening for colonic cancer by
gastroenterologists
22 64
Paisley et al
920 UK (1994–96) Analysis of patient data 222 Patients Role of the surgical trainee 22 59
Chin and Newton
921 UK (not specified—circa 1996) Survey 167 Surgical trainees Training in minimal access surgery 22 66
Pardo et al
922 Spain (1998–99) Retrospective study; analysis
of patient data
620 Patients Impact of physician speciality 22 61
Waye et al
923 International (2001) Expert commentary NA Who is permitted to do endoscopy? 4 36
Bini et al
924 USA (1998–99) Analysis of routine data 197 Patients Impact of specialists 22 68
Table A.12 Continued
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ID and authors Research setting and year of study Study design Sample size Topic of document
Level of
evidence
Quality score
(AGREE) (%)
Eaden et al
925 UK (data between 1985 and
1999 taken)
Survey of clinicians 13 Clinicians Variation between generals and
specialists
22 68
Barrison et al
926 UK (2001) Expert commentary and
recommendations
NA Provision of endoscopy services in
general hospitals
4 45
Quine et al
521 UK (1991) Survey of clinicians 39 Hospitals; 383
clinicians
Audit of upper GI endoscopy 22 64
NHS CRD
560 UK (2004) National commentary;
guidelines; recommendations
NA Improving the outcomes in
colorectal cancer
Guideline 70
Lim et al
927 UK (1995) Survey of clinicians 453 Responses H pylori serology and management 22 68
Cockel et al
928 UK (1976–79) Survey 173 Responses GI endoscopy services 22 66
Meyer et al
710 USA (1993) Analysis of patient data Over 1.3 million cases Differences between generalists and
specialists
22 68
Knight-Davis et al
929 UK (1996) Survey of clinicians 350 Responses Cross-cover for physicians 22 59
Association of
Coloproctology of GB
and Ireland
753
UK (2001) Analysis of audit data; expert
commentary;
recommendations
8 Main sources of
audit data
Resources for coloproctology 3 52
Chen and Rex
717 International (2004) Commentary;
recommendations
NA Nurse administered sedation for
endoscopy
3 59
Nightingale and Hogg
930 UK (2003) Review of evidence;
commentary
Around 40 articles GI advanced practitioners 3 64
Section 5.4 What are the key issues concerning changing roles and general practitioners with a special interest (GPwSI)?
Farthing et al
931 UK (1993) Peer reviewed expert
commentary and
recommendations
NA Service provision 3 59
Colin-Thome
932 UK, NHS (2002) Commentary NA GPwSI 4 43
Birch
933 UK, NHS (2004) Commentary; guidelines NA GPwSI 3 52
AUGIS
826 UK (1999) Commentary;
recommendations
NA Service provision 4 35
Pearson et al
934 Boston, USA (1996) Survey of general internists
and gastroenterologists
91 Survey responses Study of consultations provided to
general internists by
gastroenterologists.
22 75
Williams et al
935 UK (2002) Commentary;
recommendations
NA The role of GPwSI 3 66
DoH and RCGP
691 UK (2003) Commentary;
recommendations
NA Implementing GPwSI Guideline 45
DoH and RCGP
936 UK (2002) National guidelines NA GPwSI roles Guideline 25
Ryan
937 UK (2002) Commentary NA Role of GPwSI in respiratory disease 4 30
Gruffydd-Jones
938 UK (2003) Brief commentary NA Framework for GPwSI 3 55
Kernick
939 UK (2003) Commentary NA Economic perspectives on GPwSI 4 52
Richardson
940 UK (2002) Commentary; interviews NA Rise of GPwSI 4 50
Table A.12 Continued
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Table A.13 Summary of articles examined after consultation feedback
ID and
authors
Research
setting and
year of study Study design Sample size Topic of document Key results and conclusions
Level of
evidence
Quality score
(AGREE)
Barry et al941 UK (data
between 1995
and 2000)
Comparative
study
110 Patients Cancer staging Special interest radiology improves the
perceived preoperative stage of gastric cancer
2+ 57%
Bassi et al708 UK (2000) Single centre
retrospective study
479 Patients Cost of IBD treatment The study represents the first detailed
characterisation of the scale and determinants
of costs of illness for IBD. Hospitalisation
affected a minority of patients but accounted
for half the total direct costs
2+ 66%
Carter et al584 International
(2004)
Guidelines NA Management of IBD Guidelines commissioned by BSG for the
management of IBD in adults
Guidelines 55%
Rubin et al*136 UK (NA) Retrospective
case reviews
568 Patients Epidemiology and
management of IBD
Prevalence rates, but not incidence rates, for IBD
are substantially higher than described in UK
populations. GPs make a significant contribution
to meeting the healthcare needs of these patients
3 66%
Axon*719 International
(NA)
Review of
evidence
NA Cancer surveillance
in ulcerative colitis
Regular clinical follow-up is important. At 8–10
years after their first attack, total colonoscopy
should be performed with multiple biopsy
specimens to check for colitis
4 41%
Lim et al*720 UK (data
between
1978–1990)
Retrospective
cohort study
128 Patients Follow up of patients
with ulcerative colitis
Low grade dysplasia diagnosis is not sufficiently
reliable to justify prophylactic colectomy.
Conservative management of established low
grade dysplasia cases should not be rules out
2+ 61%
Fullerton942 International
(projections for
2000)
Economic
evaluation
NA Economic impact of
functional digestive
disorders
The economic impact of functional GI disease is
large. Economic estimates are useful in policy
decision making for the allocation of healthcare
resources
3 50%
Robinson
et al943
UK (NA) RCT 458 Patients Self help
interventions for IBS
Introducing a self help guidebook results in a
reduction in primary care consultations, a
perceived reduction in symptoms, and
significant health service savings
2+ 68%
Provenzale
et al704
International
(1980–1998)
Literature
review
2157 Articles; 10
included
Specialised and
general GI care
Gastroenterologists may provide better care
than other provider types for certain disorders.
1 80%
Norton and
Kamm944
UK 2002 Discussion N/A Specialist nurses in
gastroenterology
Specialist nurses can take on some tasks
traditionally carried out by doctors, although
evidence concerning safety and effectiveness is
lacking. It is not necessarily cheaper to substitute
nurses for doctors. A multidisciplinary approach
is advocated, in which the skills of one
professional group are complemented by the
skills of the other
5 N/A
Robinson
et al*681
UK (NA) RCT 203 Patients Ulcerative colitis
care
Self management of ulcerative colitis accelerates
treatment provision and reduces doctor visits,
and does not increase morbidity. This approach
could be used in long term management of many
other chronic diseases to improve health service
provision and use, and to reduce costs
2+ 68%
Wade945 UK 1983 Observational
comparative
interview
follow-up study
215 Patients, 142
in district health
authorities with
stoma care nurses,
73 in districts
without stoma
care nurses
Psychological
symptoms in
colostomy patients
after surgery and
the benefits of
stoma care nurses
Short term outcomes were improved in the stoma
care district patients, although there were no
differences at one year. 10% of patients who
reported that they were well were anxious or
depressed. Physical symptoms were associated
with psychiatric morbidity. Psychiatric referral
was suggested to be inappropriate, as medical
referral may be more helpful in resolving
problems
22 45%
Erwin-Toth and
Spencer946
USA, not given,
published 1991
Questionnaire
follow-up of
patients after
ostomy surgery,
convenience
sample
52 Volunteers
were recruited, 39
completed forms
were received
Patient assessed
quality of care
High satisfaction but results limited by
methodological weaknesses, acknowledged
by authors
22 29%
Maule758 USA 1994
published
Prospective
non-randomised
controlled study
1881 Intervention
patients; 730
control patients
Effectiveness of
screening for
colorectal cancer
by nurses compared
with doctors
Depth of insertion of sigmoidoscope was greater
in those examined by doctors. There was no
difference in the proportion of examinations that
were positive for adenomas or cancer. A higher
proportion of patients whose examination was
normal and were examined by nurses returned
for follow-up
2+ 57%
Moshakis
et al*714
UK Published
1996
Comparative
study
50 Trainer and
50 pupil cases
Competence of
nurses with training
to undertake
endoscopies
Quality and accuracy were assessed as equal
between groups, with 60 cm insertion achieved
in a similar number of cases. Nurses can be
taught to practise flexible sigmoidoscopy
efficiently and safely.
22 23%
Schoenfeld
et al*715
USA Published
1999
Randomised
controlled trial
162 Patients
intervention group;
166 patients
control group
Accuracy of polyp
detection, depth of
insertion and
complication rate for
flexible
sigmoidoscopy:
comparison of
nurses and doctors
No differences in detection of polyps or
frequency of complications were found,
suggesting nurse endoscopists may perform
screening flexible sigmoidoscopy as safely
and as effectively as gastroenterologists
1 59%
*These articles were cited in the text.
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9. APPENDICES
Appendix 1: Charities with an interest in the care of
patients with gastroenterological and liver disorders
(through patient support or research or both)
Appendix 2 AGREE tool for quality assessment
Score each of the following questions using a three-point Likert
scale:
N 0—Not specified (little or no evidence)
N 1—Disagree (some evidence)
N 2—Agree (good or strong evidence)
Scope and purpose:
1. The overall objective(s) of the research is (are) clearly
described.
2. The research question(s) covered by the methodology is
(are) clearly described.
3. The recipients to whom the research is meant to apply are
clearly described.
Stakeholder/participant involvement:
1. The research is carried out by relevant professional groups.
2. The participants’ views and preferences have been sought.
3. The target users of the research are clearly defined.
4. The research has been piloted among participants.
Rigour of development:
1. Methods to search for evidence have been specified (for
example, systematic review, unbiased screening, search
strategy).
2. The techniques for formulating the results have been
specified.
3. The advantages, disadvantages, and risks are considered in
the results.
4. There is an explicit link between the results and the
supporting evidence (sufficient relevant references).
5. The research has been externally reviewed before its
publication, or published in peerb reviewed sources.
6. A procedure for updating the research is provided, or for
primary studies, a clear indication of what further research
is needed.
Clarity and presentation:
1. The results are clear and unambiguous.
2. The different options for conducting the research are
clearly presented, or for primary studies, a description of
the pros and cons of each method.
3. Key points in the results are easily identifiable.
4. The research is supported with tools for application (for
example, computer support, documentation, reference
guide for reviews/guidelines), or for primary studies, a
clear path for dissemination and potential implementa-
tion.
Applicability:
1. The potential barriers in applying the results have been
discussed.
2. The potential cost implications of applying the results have
been considered.
3. The research presents key (review) criteria for monitoring
and/or audit purposes (for example, cost should be ,£100;
time ,7 days).
Editorial independence:
1. The research is editorially independent from the funding
body.
2. Conflicts of interest among research members have been
recorded.
Appendix 3: Brief sent to participants for the patient
workshop
Specific questions to be answered
(a) Greater self management by patients
There is good evidence to show that if patients with chronic
illnesses such as inflammatory bowel disease or irritable bowel
syndrome are given enough information and are supported by
expert services that are easy to reach, they can manage with
fewer hospital and GP appointments. This could be used for a
wide variety of chronic illnesses, which would reduce demand
on NHS services.
What is your view on such an approach?
(b) Endoscopy outside hospitals
It has been suggested that more endoscopies (internal
examination of the gut through a tube) should be carried out
in special centres or in local GP surgeries instead of hospital,
which may be easier for patients but may mean that these tests
would be less available in hospital. Research is needed to find
out whether these tests would be safe and effective, if
undertaken outside hospitals.
What is your view on such tests being carried out in
places other than hospitals?
(c) Nurses or doctors?
There is good evidence that nurses do a good job when
undertaking endoscopy to help make a diagnosis. Also, patients
prefer nurses doing the test to doctors. This suggests that
nurses should take over routine diagnostic endoscopy from
doctors. There is some evidence (that is less strong) that nurses
should also take over the continuing care of certain patients
with chronic gastrointestinal problems.
What would you feel about seeing a nurse rather than
a doctor for these tests and appointments?
(d) Where should services be located?
There is some evidence that major operations for gastrointest-
inal problems should be performed at specialist centres that
serve large populations because the results may be better.
However, this would take away expertise from local hospitals,
1 Bardhan Research and Education Trust of Rotherham (BRET)
2 Barrett’s Oesophagus Foundation
3 British Association for the Study of the Liver (BASL)
4 British Liver Trust (BLT)
5 Children’s Liver Disease Foundation
6 Coeliac UK
7 Colon and Rectal Disease Research Foundation of GB and Ireland
8 Colon Cancer Concern
9 CORE (new name for the Digestive Disorders Foundation)
10 Crohn’s in Childhood Research Association (CICRA)
11 Foundation for Liver Research
12 Guildford Undetected Tumour Screening (GUTS)
13 The Ileostomy and Internal Pouch Support Group (IA)
14 IBS Network
15 National Association for Colitis and Crohn’s Disease (NACC)
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where specialist care will still be needed, particularly for
emergency problems.
What is more important to you—having services
available locally or being treated by specialists, even
if i t is further away?
Open discussion
What else would be important to you about the way services for
gastrointestinal problems are provided?
Appendix 4: Articles not used in this report
Table A.14 lists the articles not used in this report, and table
A.15 the articles not used for economic analysis.
Table A.14 Articles not used in this report
No Reference Reason for exclusion
1 Rakatansky H. Review article: gastroenterology and the pharmaceutical industry.
Aliment Pharmacol Ther 2002;16:1859–66.
Too specific
2 Chaudhry F, Ashish K, Brant S. Saturday surgeries—do patients feel their needs can
be met by alternative out-of-hours care? A questionnaire study. Br J Gen Practice
2003;54:46–9.
Too specific
3 Franks A. General practitioner with a special interest in dermatology—the
dermatologist’s perspective. Clin Med 2004;4:87–8.
Too brief, not
gastroenterology
4 Gonsalkorale WM, Toner BB, Whorwell PJ. Cognitive change in patients undergoing
hypnotherapy for irritable bowel syndrome. J Psychosom Res 2004;56:271–8.
Too specific
5 Yacavone RF, Locke III GR, Provenzale D, et al. Quality of life measurement in
gastroenterology: what is available? Am J Gastroenterol 2001;96:285–97.
Too specific
6 Morris JS. Laennec’s stethoscope—the Welsh connection.; J Roy Soc Med
2004;97:137–41.
Too specific
7 D’Costa H, Taylor EW. Patient management following uncomplicated elective
gastrointestinal operations. Br J Clin Pract 1990;44: 552–6.
Too treatment
focused
8 Woolfson RG, Jennings K,Whalen GF. Management of bowel obstruction in patients
with abdominal cancer. Arch Surg 1997;132:1093–7.
Too treatment
focused
9 Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel
obstruction in advanced gynaecological and gastrointestinal cancer (Cochrane
review). In: The Cochrane Library 2004, Issue 3.
Too treatment
focused
10 Soares-Weiser K, Brezis M, Tur-Kaspa R, et al. Antibiotic prophylaxis for cirrhotic
patients with gastrointestinal bleeding (Cochrane review). In: The Cochrane Library
2004, Issue 3.
Too treatment
focused
11 Selective Decontamination of the Digestive Tract Trialists’ Collaborative Group.
Meta-analysis of randomized controlled trials of selective decontamination of the
digestive tract. BMJ 1993;307:525–32.
Too treatment
focused
12 Guenaga KF, Matos D, Castro AA, et al. Mechanical bowel preparation for elective
colorectal surgery (Cochrane review). In: The Cochrane Library 2004, Issue 3.
Too treatment
focused
13 Lewis SJ, Egger M, Sylvester PA, et al. Early enteral feeding versus ‘‘nil by mouth’’
after gastrointestinal surgery: systematic review and meta-analysis of controlled
trials. BMJ 2001;323:1–5.
Too treatment
focused
14 Logan AJ, Morris-Stiff GJ, Bowrey DJ, et al. Upper gastrointestinal complications after
renal transplantation: a 3-yr sequential study. Clin Transplant 2002;16:163–7.
Too treatment
focused
15 Henry DA, O’Connell DL. Effects of fibrinolytic inhibitors on mortality from upper
gastrointestinal haemorrhage. BMJ 1989;298:1142–6.
Too treatment
focused
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Table A.15 Articles not used for economic analysis
No Reference
Reason for
exclusion
1 Sonnenberg A. Personal view: cost and benefit of medical rituals in gastroenterology.
Aliment Pharmacol Ther 2004;20:939–42.
Too specific
2 Ladas SD, Malfertheiner P, Axon A. An introductory course for training in endoscopy.
Dig Dis 2002;20:242–5.
Too specific
3 Dick A, Keady S, Mohamed F, et al. Use of unlicensed and off-label medication in
paediatric gastroenterology with a review of the commonly used formularies in the UK.
Aliment Pharmacol Ther 2003;17:571–5.
Too specific
4 Cooper DL, Smith GE, O’Brien SJ, et al. What can analysis of calls to NHS direct tell us
about the epidemiology of gastrointestinal infections in the community? J Infect
2003;46:101–5.
Too specific
5 Keys J, Beardon PHG, Lau C, et al. General practitioners’ use of non-steroidal
anti-inflammatory drugs in Tayside and Fife regions. J R Soc Med 1992;85:442–5.
No economics
6 Rembacken B, Fujii T, Kondo H. The recognition and endoscopic treatment of early
gastric and colonic cancer. Best Pract Res Clin Gastroenterol 2001;15:317–36.
No economics
7 Dube MG, Lobo DN, Rowlands BJet al. Audit of acute pancreatitis management: a tale
of two hospitals. J R Coll Surg Edinb 2001;46:292–6.
No economics
8 Langman M, Kahler KH, Kong SX, et al. Drug switching patterns among patients taking
non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general
practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf
2001;10:517–24.
No economics
9 Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow-up
after curative resection for colorectal cancer:systematic review and meta-analysis of
randomized trials. BMJ 2002;324:813.
No economics
10 Pathmakanthan S, Murray I, Smith K, et al. Nurse endoscopists in United Kingdom
health care: a survey of prevalence skills and attitudes. J Adv Nurs 2001;36:705–10.
No economics
11 O’ Hanrahan T, Irving MH. The role of home parenteral nutrition in the management
of intestinal failure—report of 400 cases. Clin Nutr 1992;11:331–6.
No economics
12 Thompson WG, Heaton KW, Symth GT, et al. Irritable bowel syndrome in general
practice: prevalence, characteristics, and referral. Gut 2000;46:78–82.
No economics
13 Thomas-Gibson S, Thapar C, Shah SG, et al. Colonoscopy at a combined district
general hospital and specialist endoscopy unit:lessons from 505 consecutive
examinations. J Roy Soc Med 2002;95:194–7.
Not relevant
14 Stanghellini V, Armstrong D, Monnikes H, et al. Systematic review: do we need a new
gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther
2004;19:463–79.
Non-UK article
15 Spiegel BMR, Vakil NB, Ofman JJ. Dyspepsia management in primary care:a decision
analysis of competing strategies. Gastroenterology 2002;122:1270–85.
Non-UK article
16 Lin OS, Mannava S, Hwang KL, et al. Reasons for current practices in managing Barrett’s
esophagus. Dis Esophagus 2002;15:39–45.
Non-UK article
17 Abuksis G, Mor M, Segal N, et al. Patient education program is cost effective for
preventing failure of endoscopic procedures in a Gastroenterology department.
Am J Gastroenterol 2001;96:1786–90.
Non-UK article
18 Van Kouwen MC, Drenth JP, Verhoeven HM, et al. Upper gastrointestinal endoscopy
in patients aged 85 years or more. Results of a feasibility study in a district general
hospital. Arch Gerontol Geriatr 2003;37:45–50.
Non-UK article
19 Lapane KL, Spooner JJ, Mucha L, et al. Effect of nonsteroidal anti-inflammatory drug use
on the rate of gastrointestinal hospitalizations among people living in long term care.
J Am Geriatr Soc 2001;49:577–84.
Non-UK article
20 Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel
disease in Canada:results from a National Population Health Survey.
Am J Gastroenterol 2003;98:844–9.
Non-UK article
21 Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome
patients in a health maintenance organization; Am J Gastroenterol 2001;96:3122–9.
Non-UK article
22 Yim HB, Jacobson BC, Saltzman JR, et al. Clinical outcome of the use of enteral stents
for palliation of patients with malignant upper GI obstruction; Gastrointest Endosc
2001;53:329–32.
Non-UK article
23 Bini EJ, Weinshel EH, Generoso R, et al. Impact of gastroenterology consultation on the
outcomes of patients admitted to the hospital with decompensated cirrhosis. Hepatology
2001;34:1089–95.
Non-UK article
24 Pardo A, Durandez R, Hernandez M, et al. Impact of physician specialty on the cost of
nonvariceal upper GI bleeding care; Am J Gastroenterol 2002;97:1535–42.
Non-UK article
25 Fletcher DR. Peptic disease: can we afford current management? Aust N Z J Surg
1997;67:75–80.
Non-UK article
26 Callahan CM, Buchanan NN, Stump TE. Healthcare costs associated with percutaneous
endoscopic gastrostomy among older adults in a defined community. J Am Geriatr Soc
2001;49:1525–9.
Non-UK article
27 Lang M, Niskanen M, Miettinen P, et al. Outcome and resource utilization in
gastroenterological surgery. Br J Surg 2001;88:1006–14.
Non-UK article
28 Richter JM, Wang TC, Fawaz K, et al. Practice patterns and costs of hospitalization for
upper gastrointestinal hemorrhage; J Clin Gastroenterol 1991;13:268–73.
Non-UK article
29 Parente F, Bargiggia S, Bianchi Porro G. Prospective audit of gastroscopy under the
‘three-day rule’: a regional initiative in Italy to reduce waiting time for suspected
malignancy. Aliment Pharmacol Ther 2002;16:1011–14.
Non-UK article
30 Quirk DM, Barry MJ, Aserkoff B, et al. Physician specialty and variations in the cost of
treating patients with acute upper gastrointestinal bleeding; Gastroenterology
1997;113:1443–8.
Non-UK article
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No Reference
Reason for
exclusion
31 The Burden of Gastrointestinal Diseases, The American Gastroenterological Association.
Available at http://www.gastro.org/wmspage.cfm?parm1 = 669 (accessed 3 January
2006).
Non-UK article
32 Delvaux M. Digestive health in the elderly: faecal incontinence in adults. Aliment
Pharmacol Ther 2003;8(Suppl 3):84–9.
Non-UK article
33 Marshall JK, Cawdron R, Yamamura DL, et al. Use and misuse of cost effectiveness
terminology in the gastroenterology literature:a systematic review. Am J Gastroenterol
2002;97:172–9.
Non-UK article
34 Provenzale D, Lipscomb J. A reader’s guide to economic analysis in the GI literature.
Am J Gastroenterol 1996;91:2461–70.
Non-UK article
35 Gross CP, Canto MI, Hixson J, et al. Management of Barrett’s esophagus: a national
study of practice patterns and their cost implications. Am J Gastroenterol
1999;94:3440–7.
Non-UK article
36 Froehlich F, Burnand B, Pache I, et al. Overuse of upper gastrointestinal endoscopy in a
country with open access endoscopy: a prospective study in primary care. Gastrointest
Endosc 1997;45:13–19.
Non-UK article
37 Norum J, Olsen JA. A cost effectiveness approach to the Norwegian follow-up
programme in colorectal cancer. Ann Oncol 1997;8:1081–7.
Non-UK article
38 Spiegel BMR, Targownik LE, DeRosa V, et al. The quality of published health economic
analyses in digestive diseases:a systematic review and quantitative appraisal.
Gastroenterology 2004;127:403–11.
Non-UK article
39 Provenzale D, Wong JB, Onken JE, et al. Performing a cost effectiveness
analysis:surveillance of patients with ulcerative colitis. Am J Gastroenterol
1998;93:872–80.
Non-UK article
40 Maroun J, Ng E, Berthelot JM, et al. Lifetime costs of colon and rectal cancer
management in Canada. Chronic Dis Can 2003;24:91–101.
Non-UK article
41 Sonnenberg A, Inadomi JM, Becker LA. Economic analysis of step-wise treatment of
gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1003–13.
Non-UK article
42 Loeve F, Brown ML, Boer R, et al. Endoscopic colorectal cancer screening:a cost-saving
analysis. J Natl Cancer Inst 2000;92:557–63.
Non-UK article
43 Nietert PJ, Silverstein MD, Mokhashi MS, et al. Cost effectiveness of screening a
population with chronic gastroesophageal reflux. Gastrointest Endosc 2003;57:311–18.
Non-UK article
44 Sonnenberg A, Delco F, Inadomi JM. Cost effectiveness of colonoscopy in screening for
colorectal cancer. Ann Intern Med 2000;133:573–84.
Non-UK article
45 Baxter YC, Dias MCG, Maculevicius J, et al. Economc study in surgical patients of a
new model of nutrition therapy integrating hospital and home vs the conventional
hospital model. JPEN J Parenter Enteral Nutr 2005;29(Suppl):S96–105.
Non-UK article
46 Chen SC, Rex DK. Review article:registered nurse-administered propofol sedation for
endoscopy. Aliment Pharmacol Ther 2004;19:147–55.
Non-UK article
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Appendix 5: Glossary
Appendix 6: Specialists who provided comments and
feedback
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